<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#" class="js weava-extension-context" data-weava-installed="1" data-qb-installed="true"><head><style type="text/css">:root, :host {
  --fa-font-solid: normal 900 1em/1 "Font Awesome 6 Solid";
  --fa-font-regular: normal 400 1em/1 "Font Awesome 6 Regular";
  --fa-font-light: normal 300 1em/1 "Font Awesome 6 Light";
  --fa-font-thin: normal 100 1em/1 "Font Awesome 6 Thin";
  --fa-font-duotone: normal 900 1em/1 "Font Awesome 6 Duotone";
  --fa-font-sharp-solid: normal 900 1em/1 "Font Awesome 6 Sharp";
  --fa-font-brands: normal 400 1em/1 "Font Awesome 6 Brands";
}

svg:not(:root).svg-inline--fa, svg:not(:host).svg-inline--fa {
  overflow: visible;
  box-sizing: content-box;
}

.svg-inline--fa {
  display: var(--fa-display, inline-block);
  height: 1em;
  overflow: visible;
  vertical-align: -0.125em;
}
.svg-inline--fa.fa-2xs {
  vertical-align: 0.1em;
}
.svg-inline--fa.fa-xs {
  vertical-align: 0em;
}
.svg-inline--fa.fa-sm {
  vertical-align: -0.0714285705em;
}
.svg-inline--fa.fa-lg {
  vertical-align: -0.2em;
}
.svg-inline--fa.fa-xl {
  vertical-align: -0.25em;
}
.svg-inline--fa.fa-2xl {
  vertical-align: -0.3125em;
}
.svg-inline--fa.fa-pull-left {
  margin-right: var(--fa-pull-margin, 0.3em);
  width: auto;
}
.svg-inline--fa.fa-pull-right {
  margin-left: var(--fa-pull-margin, 0.3em);
  width: auto;
}
.svg-inline--fa.fa-li {
  width: var(--fa-li-width, 2em);
  top: 0.25em;
}
.svg-inline--fa.fa-fw {
  width: var(--fa-fw-width, 1.25em);
}

.fa-layers svg.svg-inline--fa {
  bottom: 0;
  left: 0;
  margin: auto;
  position: absolute;
  right: 0;
  top: 0;
}

.fa-layers-counter, .fa-layers-text {
  display: inline-block;
  position: absolute;
  text-align: center;
}

.fa-layers {
  display: inline-block;
  height: 1em;
  position: relative;
  text-align: center;
  vertical-align: -0.125em;
  width: 1em;
}
.fa-layers svg.svg-inline--fa {
  -webkit-transform-origin: center center;
          transform-origin: center center;
}

.fa-layers-text {
  left: 50%;
  top: 50%;
  -webkit-transform: translate(-50%, -50%);
          transform: translate(-50%, -50%);
  -webkit-transform-origin: center center;
          transform-origin: center center;
}

.fa-layers-counter {
  background-color: var(--fa-counter-background-color, #ff253a);
  border-radius: var(--fa-counter-border-radius, 1em);
  box-sizing: border-box;
  color: var(--fa-inverse, #fff);
  line-height: var(--fa-counter-line-height, 1);
  max-width: var(--fa-counter-max-width, 5em);
  min-width: var(--fa-counter-min-width, 1.5em);
  overflow: hidden;
  padding: var(--fa-counter-padding, 0.25em 0.5em);
  right: var(--fa-right, 0);
  text-overflow: ellipsis;
  top: var(--fa-top, 0);
  -webkit-transform: scale(var(--fa-counter-scale, 0.25));
          transform: scale(var(--fa-counter-scale, 0.25));
  -webkit-transform-origin: top right;
          transform-origin: top right;
}

.fa-layers-bottom-right {
  bottom: var(--fa-bottom, 0);
  right: var(--fa-right, 0);
  top: auto;
  -webkit-transform: scale(var(--fa-layers-scale, 0.25));
          transform: scale(var(--fa-layers-scale, 0.25));
  -webkit-transform-origin: bottom right;
          transform-origin: bottom right;
}

.fa-layers-bottom-left {
  bottom: var(--fa-bottom, 0);
  left: var(--fa-left, 0);
  right: auto;
  top: auto;
  -webkit-transform: scale(var(--fa-layers-scale, 0.25));
          transform: scale(var(--fa-layers-scale, 0.25));
  -webkit-transform-origin: bottom left;
          transform-origin: bottom left;
}

.fa-layers-top-right {
  top: var(--fa-top, 0);
  right: var(--fa-right, 0);
  -webkit-transform: scale(var(--fa-layers-scale, 0.25));
          transform: scale(var(--fa-layers-scale, 0.25));
  -webkit-transform-origin: top right;
          transform-origin: top right;
}

.fa-layers-top-left {
  left: var(--fa-left, 0);
  right: auto;
  top: var(--fa-top, 0);
  -webkit-transform: scale(var(--fa-layers-scale, 0.25));
          transform: scale(var(--fa-layers-scale, 0.25));
  -webkit-transform-origin: top left;
          transform-origin: top left;
}

.fa-1x {
  font-size: 1em;
}

.fa-2x {
  font-size: 2em;
}

.fa-3x {
  font-size: 3em;
}

.fa-4x {
  font-size: 4em;
}

.fa-5x {
  font-size: 5em;
}

.fa-6x {
  font-size: 6em;
}

.fa-7x {
  font-size: 7em;
}

.fa-8x {
  font-size: 8em;
}

.fa-9x {
  font-size: 9em;
}

.fa-10x {
  font-size: 10em;
}

.fa-2xs {
  font-size: 0.625em;
  line-height: 0.1em;
  vertical-align: 0.225em;
}

.fa-xs {
  font-size: 0.75em;
  line-height: 0.0833333337em;
  vertical-align: 0.125em;
}

.fa-sm {
  font-size: 0.875em;
  line-height: 0.0714285718em;
  vertical-align: 0.0535714295em;
}

.fa-lg {
  font-size: 1.25em;
  line-height: 0.05em;
  vertical-align: -0.075em;
}

.fa-xl {
  font-size: 1.5em;
  line-height: 0.0416666682em;
  vertical-align: -0.125em;
}

.fa-2xl {
  font-size: 2em;
  line-height: 0.03125em;
  vertical-align: -0.1875em;
}

.fa-fw {
  text-align: center;
  width: 1.25em;
}

.fa-ul {
  list-style-type: none;
  margin-left: var(--fa-li-margin, 2.5em);
  padding-left: 0;
}
.fa-ul > li {
  position: relative;
}

.fa-li {
  left: calc(var(--fa-li-width, 2em) * -1);
  position: absolute;
  text-align: center;
  width: var(--fa-li-width, 2em);
  line-height: inherit;
}

.fa-border {
  border-color: var(--fa-border-color, #eee);
  border-radius: var(--fa-border-radius, 0.1em);
  border-style: var(--fa-border-style, solid);
  border-width: var(--fa-border-width, 0.08em);
  padding: var(--fa-border-padding, 0.2em 0.25em 0.15em);
}

.fa-pull-left {
  float: left;
  margin-right: var(--fa-pull-margin, 0.3em);
}

.fa-pull-right {
  float: right;
  margin-left: var(--fa-pull-margin, 0.3em);
}

.fa-beat {
  -webkit-animation-name: fa-beat;
          animation-name: fa-beat;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, ease-in-out);
          animation-timing-function: var(--fa-animation-timing, ease-in-out);
}

.fa-bounce {
  -webkit-animation-name: fa-bounce;
          animation-name: fa-bounce;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.28, 0.84, 0.42, 1));
          animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.28, 0.84, 0.42, 1));
}

.fa-fade {
  -webkit-animation-name: fa-fade;
          animation-name: fa-fade;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1));
          animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1));
}

.fa-beat-fade {
  -webkit-animation-name: fa-beat-fade;
          animation-name: fa-beat-fade;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1));
          animation-timing-function: var(--fa-animation-timing, cubic-bezier(0.4, 0, 0.6, 1));
}

.fa-flip {
  -webkit-animation-name: fa-flip;
          animation-name: fa-flip;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, ease-in-out);
          animation-timing-function: var(--fa-animation-timing, ease-in-out);
}

.fa-shake {
  -webkit-animation-name: fa-shake;
          animation-name: fa-shake;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, linear);
          animation-timing-function: var(--fa-animation-timing, linear);
}

.fa-spin {
  -webkit-animation-name: fa-spin;
          animation-name: fa-spin;
  -webkit-animation-delay: var(--fa-animation-delay, 0s);
          animation-delay: var(--fa-animation-delay, 0s);
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 2s);
          animation-duration: var(--fa-animation-duration, 2s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, linear);
          animation-timing-function: var(--fa-animation-timing, linear);
}

.fa-spin-reverse {
  --fa-animation-direction: reverse;
}

.fa-pulse,
.fa-spin-pulse {
  -webkit-animation-name: fa-spin;
          animation-name: fa-spin;
  -webkit-animation-direction: var(--fa-animation-direction, normal);
          animation-direction: var(--fa-animation-direction, normal);
  -webkit-animation-duration: var(--fa-animation-duration, 1s);
          animation-duration: var(--fa-animation-duration, 1s);
  -webkit-animation-iteration-count: var(--fa-animation-iteration-count, infinite);
          animation-iteration-count: var(--fa-animation-iteration-count, infinite);
  -webkit-animation-timing-function: var(--fa-animation-timing, steps(8));
          animation-timing-function: var(--fa-animation-timing, steps(8));
}

@media (prefers-reduced-motion: reduce) {
  .fa-beat,
.fa-bounce,
.fa-fade,
.fa-beat-fade,
.fa-flip,
.fa-pulse,
.fa-shake,
.fa-spin,
.fa-spin-pulse {
    -webkit-animation-delay: -1ms;
            animation-delay: -1ms;
    -webkit-animation-duration: 1ms;
            animation-duration: 1ms;
    -webkit-animation-iteration-count: 1;
            animation-iteration-count: 1;
    transition-delay: 0s;
    transition-duration: 0s;
  }
}
@-webkit-keyframes fa-beat {
  0%, 90% {
    -webkit-transform: scale(1);
            transform: scale(1);
  }
  45% {
    -webkit-transform: scale(var(--fa-beat-scale, 1.25));
            transform: scale(var(--fa-beat-scale, 1.25));
  }
}
@keyframes fa-beat {
  0%, 90% {
    -webkit-transform: scale(1);
            transform: scale(1);
  }
  45% {
    -webkit-transform: scale(var(--fa-beat-scale, 1.25));
            transform: scale(var(--fa-beat-scale, 1.25));
  }
}
@-webkit-keyframes fa-bounce {
  0% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
  10% {
    -webkit-transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0);
            transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0);
  }
  30% {
    -webkit-transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em));
            transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em));
  }
  50% {
    -webkit-transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0);
            transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0);
  }
  57% {
    -webkit-transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em));
            transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em));
  }
  64% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
  100% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
}
@keyframes fa-bounce {
  0% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
  10% {
    -webkit-transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0);
            transform: scale(var(--fa-bounce-start-scale-x, 1.1), var(--fa-bounce-start-scale-y, 0.9)) translateY(0);
  }
  30% {
    -webkit-transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em));
            transform: scale(var(--fa-bounce-jump-scale-x, 0.9), var(--fa-bounce-jump-scale-y, 1.1)) translateY(var(--fa-bounce-height, -0.5em));
  }
  50% {
    -webkit-transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0);
            transform: scale(var(--fa-bounce-land-scale-x, 1.05), var(--fa-bounce-land-scale-y, 0.95)) translateY(0);
  }
  57% {
    -webkit-transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em));
            transform: scale(1, 1) translateY(var(--fa-bounce-rebound, -0.125em));
  }
  64% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
  100% {
    -webkit-transform: scale(1, 1) translateY(0);
            transform: scale(1, 1) translateY(0);
  }
}
@-webkit-keyframes fa-fade {
  50% {
    opacity: var(--fa-fade-opacity, 0.4);
  }
}
@keyframes fa-fade {
  50% {
    opacity: var(--fa-fade-opacity, 0.4);
  }
}
@-webkit-keyframes fa-beat-fade {
  0%, 100% {
    opacity: var(--fa-beat-fade-opacity, 0.4);
    -webkit-transform: scale(1);
            transform: scale(1);
  }
  50% {
    opacity: 1;
    -webkit-transform: scale(var(--fa-beat-fade-scale, 1.125));
            transform: scale(var(--fa-beat-fade-scale, 1.125));
  }
}
@keyframes fa-beat-fade {
  0%, 100% {
    opacity: var(--fa-beat-fade-opacity, 0.4);
    -webkit-transform: scale(1);
            transform: scale(1);
  }
  50% {
    opacity: 1;
    -webkit-transform: scale(var(--fa-beat-fade-scale, 1.125));
            transform: scale(var(--fa-beat-fade-scale, 1.125));
  }
}
@-webkit-keyframes fa-flip {
  50% {
    -webkit-transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg));
            transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg));
  }
}
@keyframes fa-flip {
  50% {
    -webkit-transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg));
            transform: rotate3d(var(--fa-flip-x, 0), var(--fa-flip-y, 1), var(--fa-flip-z, 0), var(--fa-flip-angle, -180deg));
  }
}
@-webkit-keyframes fa-shake {
  0% {
    -webkit-transform: rotate(-15deg);
            transform: rotate(-15deg);
  }
  4% {
    -webkit-transform: rotate(15deg);
            transform: rotate(15deg);
  }
  8%, 24% {
    -webkit-transform: rotate(-18deg);
            transform: rotate(-18deg);
  }
  12%, 28% {
    -webkit-transform: rotate(18deg);
            transform: rotate(18deg);
  }
  16% {
    -webkit-transform: rotate(-22deg);
            transform: rotate(-22deg);
  }
  20% {
    -webkit-transform: rotate(22deg);
            transform: rotate(22deg);
  }
  32% {
    -webkit-transform: rotate(-12deg);
            transform: rotate(-12deg);
  }
  36% {
    -webkit-transform: rotate(12deg);
            transform: rotate(12deg);
  }
  40%, 100% {
    -webkit-transform: rotate(0deg);
            transform: rotate(0deg);
  }
}
@keyframes fa-shake {
  0% {
    -webkit-transform: rotate(-15deg);
            transform: rotate(-15deg);
  }
  4% {
    -webkit-transform: rotate(15deg);
            transform: rotate(15deg);
  }
  8%, 24% {
    -webkit-transform: rotate(-18deg);
            transform: rotate(-18deg);
  }
  12%, 28% {
    -webkit-transform: rotate(18deg);
            transform: rotate(18deg);
  }
  16% {
    -webkit-transform: rotate(-22deg);
            transform: rotate(-22deg);
  }
  20% {
    -webkit-transform: rotate(22deg);
            transform: rotate(22deg);
  }
  32% {
    -webkit-transform: rotate(-12deg);
            transform: rotate(-12deg);
  }
  36% {
    -webkit-transform: rotate(12deg);
            transform: rotate(12deg);
  }
  40%, 100% {
    -webkit-transform: rotate(0deg);
            transform: rotate(0deg);
  }
}
@-webkit-keyframes fa-spin {
  0% {
    -webkit-transform: rotate(0deg);
            transform: rotate(0deg);
  }
  100% {
    -webkit-transform: rotate(360deg);
            transform: rotate(360deg);
  }
}
@keyframes fa-spin {
  0% {
    -webkit-transform: rotate(0deg);
            transform: rotate(0deg);
  }
  100% {
    -webkit-transform: rotate(360deg);
            transform: rotate(360deg);
  }
}
.fa-rotate-90 {
  -webkit-transform: rotate(90deg);
          transform: rotate(90deg);
}

.fa-rotate-180 {
  -webkit-transform: rotate(180deg);
          transform: rotate(180deg);
}

.fa-rotate-270 {
  -webkit-transform: rotate(270deg);
          transform: rotate(270deg);
}

.fa-flip-horizontal {
  -webkit-transform: scale(-1, 1);
          transform: scale(-1, 1);
}

.fa-flip-vertical {
  -webkit-transform: scale(1, -1);
          transform: scale(1, -1);
}

.fa-flip-both,
.fa-flip-horizontal.fa-flip-vertical {
  -webkit-transform: scale(-1, -1);
          transform: scale(-1, -1);
}

.fa-rotate-by {
  -webkit-transform: rotate(var(--fa-rotate-angle, none));
          transform: rotate(var(--fa-rotate-angle, none));
}

.fa-stack {
  display: inline-block;
  vertical-align: middle;
  height: 2em;
  position: relative;
  width: 2.5em;
}

.fa-stack-1x,
.fa-stack-2x {
  bottom: 0;
  left: 0;
  margin: auto;
  position: absolute;
  right: 0;
  top: 0;
  z-index: var(--fa-stack-z-index, auto);
}

.svg-inline--fa.fa-stack-1x {
  height: 1em;
  width: 1.25em;
}
.svg-inline--fa.fa-stack-2x {
  height: 2em;
  width: 2.5em;
}

.fa-inverse {
  color: var(--fa-inverse, #fff);
}

.sr-only,
.fa-sr-only {
  position: absolute;
  width: 1px;
  height: 1px;
  padding: 0;
  margin: -1px;
  overflow: hidden;
  clip: rect(0, 0, 0, 0);
  white-space: nowrap;
  border-width: 0;
}

.sr-only-focusable:not(:focus),
.fa-sr-only-focusable:not(:focus) {
  position: absolute;
  width: 1px;
  height: 1px;
  padding: 0;
  margin: -1px;
  overflow: hidden;
  clip: rect(0, 0, 0, 0);
  white-space: nowrap;
  border-width: 0;
}

.svg-inline--fa .fa-primary {
  fill: var(--fa-primary-color, currentColor);
  opacity: var(--fa-primary-opacity, 1);
}

.svg-inline--fa .fa-secondary {
  fill: var(--fa-secondary-color, currentColor);
  opacity: var(--fa-secondary-opacity, 0.4);
}

.svg-inline--fa.fa-swap-opacity .fa-primary {
  opacity: var(--fa-secondary-opacity, 0.4);
}

.svg-inline--fa.fa-swap-opacity .fa-secondary {
  opacity: var(--fa-primary-opacity, 1);
}

.svg-inline--fa mask .fa-primary,
.svg-inline--fa mask .fa-secondary {
  fill: black;
}

.fad.fa-inverse,
.fa-duotone.fa-inverse {
  color: var(--fa-inverse, #fff);
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>

    <meta charset="utf-8">
<link rel="canonical" href="https://www.anticancerfund.org/en/database-repurposing-trials-oncology">
<meta property="og:site_name" content="Anticancer Fund">
<meta property="og:url" content="https://www.anticancerfund.org/en/database-repurposing-trials-oncology">
<meta property="og:title" content="Database repurposing trials in oncology">
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)">
<meta name="MobileOptimized" content="width">
<meta name="HandheldFriendly" content="true">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<style>div#sliding-popup, div#sliding-popup .eu-cookie-withdraw-banner, .eu-cookie-withdraw-tab {background: #0779bf} div#sliding-popup.eu-cookie-withdraw-wrapper { background: transparent; } #sliding-popup h1, #sliding-popup h2, #sliding-popup h3, #sliding-popup p, #sliding-popup label, #sliding-popup div, .eu-cookie-compliance-more-button, .eu-cookie-compliance-secondary-button, .eu-cookie-withdraw-tab { color: #ffffff;} .eu-cookie-withdraw-tab { border-color: #ffffff;}</style>
<link rel="icon" href="/themes/custom/entityone/favicon.ico" type="image/vnd.microsoft.icon">
<link rel="alternate" hreflang="en" href="https://www.anticancerfund.org/en/database-repurposing-trials-oncology">
<script src="/sites/default/files/eu_cookie_compliance/eu_cookie_compliance.script.js?ss1cfp" defer=""></script>

    <title>Database repurposing trials in oncology | Anticancer Fund</title>
    <link rel="stylesheet" media="all" href="/sites/default/files/css/css_Gv22-gHbRrO2ZdED_wi_9ZFGqnxK3ZgpmfbsTCHZjrU.css?delta=0&amp;language=en&amp;theme=entityone&amp;include=eJxtUltuxCAMvFC8HCkyxkmtOHbEY7Xp6YuU3Qo1_UDAjJnxgwUpLEiPvqZylsp7iFh4IsVSzvfZMwfzvKPKN09sVerpxmFVj6gTv6qKbSHldqA-3teJ20zum3Df9kMFjTj8B86JF2xaB-WoThtAcRJU2DkJ3tnFvXIGscUnxdNbnZMU8ifnM_Q4ch0eifWsGD7KJNytIXPxlonLEHlp3QCITTR1w4sAxcijgXninpTyS6IyHLiOvYqZMVFuexzAHcV6ddbuxSna2rrEmNjSZwDSZzTPf81_qZtSYcz0NZp2P4DqBxg-ZcUqbgN9_QKIGS2JrVfDfgA9xNXd">
<link rel="stylesheet" media="all" href="/sites/default/files/css/css_kLZZDSJvi0jIrQAVYTTSvlNNrCkSNsdE3a5PUKQTa5g.css?delta=1&amp;language=en&amp;theme=entityone&amp;include=eJxtUltuxCAMvFC8HCkyxkmtOHbEY7Xp6YuU3Qo1_UDAjJnxgwUpLEiPvqZylsp7iFh4IsVSzvfZMwfzvKPKN09sVerpxmFVj6gTv6qKbSHldqA-3teJ20zum3Df9kMFjTj8B86JF2xaB-WoThtAcRJU2DkJ3tnFvXIGscUnxdNbnZMU8ifnM_Q4ch0eifWsGD7KJNytIXPxlonLEHlp3QCITTR1w4sAxcijgXninpTyS6IyHLiOvYqZMVFuexzAHcV6ddbuxSna2rrEmNjSZwDSZzTPf81_qZtSYcz0NZp2P4DqBxg-ZcUqbgN9_QKIGS2JrVfDfgA9xNXd">

    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"en\/","currentPath":"node\/373","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxtkmuOwyAMhC8E5UiRAYf1xtgRj6rZ0y9qdiXa9AdgfyPBjEVgqPVwHiqacNYZa4WE1QQt6ERLBqYfNCiN2qGCzrOGzdpVtWGxJKteRQZJ_XnNRaoaCNhmjAQXtSKU8DXjghBD6dlPcB2uLDXMn9iyMHjkSUqsHmZAwiRo_w0FQgloC1btJbx4Zji0twuwvhPHkf4U7PuLGUhGQukzG621TXcrcKcEjVQmWTTiGCrjgzyj3cfwJrUedUSzvoBEknRaN9iXoLoRjiPvTDBiuE9wibhC5xHk0Ub0zcXSd-DbX2tWCG6s21hzvezcE4lJqolxaZBcGtt7f4NveLzCbM5BLZFq0DuWw40YQdmcSZ5f7hc1ofbN","theme":"entityone","theme_token":null},"ajaxTrustedUrl":{"\/en\/search":true},"gtm":{"tagId":null,"settings":{"data_layer":"dataLayer","include_classes":false,"allowlist_classes":"","blocklist_classes":"","include_environment":false,"environment_id":"","environment_token":""},"tagIds":["GTM-N9CXCWTS"]},"gtag":{"tagId":"","consentMode":false,"otherIds":[],"events":[],"additionalConfigInfo":[]},"fac":{"search":{"id":"search","jsonFilesPath":"\/sites\/default\/files\/fac-json\/search\/en\/YvYd97gmGl3omWJxkv0m9Wjhy99k1gTfveHVypnlX-0\/","inputSelectors":"input.search-page--input","keyMinLength":1,"keyMaxLength":10,"breakpoint":0,"emptyResult":"","allResultsLink":true,"allResultsLinkThreshold":1,"highlightingEnabled":false,"resultLocation":""}},"data":{"extlink":{"extTarget":false,"extTargetAppendNewWindowLabel":"(opens in a new window)","extTargetNoOverride":false,"extNofollow":false,"extTitleNoOverride":false,"extNoreferrer":true,"extFollowNoOverride":false,"extClass":"0","extLabel":"(link is external)","extImgClass":false,"extSubdomains":true,"extExclude":"","extInclude":"","extCssExclude":"","extCssInclude":"","extCssExplicit":"","extAlert":false,"extAlertText":"This link will take you to an external web site. We are not responsible for their content.","extHideIcons":false,"mailtoClass":"0","telClass":"","mailtoLabel":"(link sends email)","telLabel":"(link is a phone number)","extUseFontAwesome":false,"extIconPlacement":"append","extPreventOrphan":false,"extFaLinkClasses":"fa fa-external-link","extFaMailtoClasses":"fa fa-envelope-o","extAdditionalLinkClasses":"","extAdditionalMailtoClasses":"","extAdditionalTelClasses":"","extFaTelClasses":"fa fa-phone","whitelistedDomains":[],"extExcludeNoreferrer":""}},"eu_cookie_compliance":{"cookie_policy_version":"1.0.0","popup_enabled":true,"popup_agreed_enabled":false,"popup_hide_agreed":false,"popup_clicking_confirmation":false,"popup_scrolling_confirmation":false,"popup_html_info":"\u003Cdiv class=\u0022eu-cookie-compliance-banner eu-cookie-compliance-banner-info\u0022\u003E\n  \u003Cdiv class =\u0022popup-content info eu-cookie-compliance-content\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022 class=\u0022eu-cookie-compliance-message\u0022\u003E\n      \u003Ch2\u003E\u003Cspan\u003EWe use cookies on this site to enhance your user experience.\u003C\/span\u003E\u003C\/h2\u003E\u003Cp\u003E\u003Cspan\u003EBy clicking \u2018Accept\u2019, you agree to us doing so.\u003C\/span\u003E\u003C\/p\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003E\u003Cspan\u003EMore info\u003C\/span\u003E\u003C\/button\u003E\n            \u003Ca href=\u0022https:\/\/anticancerfund.org\/disclaimer\u0022 class=\u0022eu-cookie-compliance-disclaimer\u0022\u003Edisclaimer\u003C\/a\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022 class=\u0022eu-cookie-compliance-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-secondary-button button button--small\u0022\u003E\u003Cspan\u003EAccept\u003Csvg xmlns=\u0022http:\/\/www.w3.org\/2000\/svg\u0022 width=\u002217\u0022 height=\u002212\u0022 viewBox=\u00220 0 17 12\u0022\u003E\n        \u003Cpolyline fill=\u0022none\u0022 stroke=\u0022#3F474C\u0022 stroke-linecap=\u0022round\u0022 stroke-linejoin=\u0022round\u0022 stroke-width=\u00222\u0022 points=\u0022584 61.762 588.837 66.6 598.437 57\u0022 transform=\u0022translate(-583 -56)\u0022\/\u003E\n      \u003C\/svg\u003E\u003C\/span\u003E\n\u003C\/button\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022decline-button eu-cookie-compliance-default-button button button--small button--primary\u0022 \u003E\u003Cspan\u003ENo, thanks\u003C\/span\u003E\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","use_mobile_message":false,"mobile_popup_html_info":"\u003Cdiv class=\u0022eu-cookie-compliance-banner eu-cookie-compliance-banner-info\u0022\u003E\n  \u003Cdiv class =\u0022popup-content info eu-cookie-compliance-content\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022 class=\u0022eu-cookie-compliance-message\u0022\u003E\n      \n              \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003E\u003Cspan\u003EMore info\u003C\/span\u003E\u003C\/button\u003E\n            \u003Ca href=\u0022https:\/\/anticancerfund.org\/disclaimer\u0022 class=\u0022eu-cookie-compliance-disclaimer\u0022\u003Edisclaimer\u003C\/a\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022 class=\u0022eu-cookie-compliance-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-secondary-button button button--small\u0022\u003E\u003Cspan\u003EAccept\u003Csvg xmlns=\u0022http:\/\/www.w3.org\/2000\/svg\u0022 width=\u002217\u0022 height=\u002212\u0022 viewBox=\u00220 0 17 12\u0022\u003E\n        \u003Cpolyline fill=\u0022none\u0022 stroke=\u0022#3F474C\u0022 stroke-linecap=\u0022round\u0022 stroke-linejoin=\u0022round\u0022 stroke-width=\u00222\u0022 points=\u0022584 61.762 588.837 66.6 598.437 57\u0022 transform=\u0022translate(-583 -56)\u0022\/\u003E\n      \u003C\/svg\u003E\u003C\/span\u003E\n\u003C\/button\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022decline-button eu-cookie-compliance-default-button button button--small button--primary\u0022 \u003E\u003Cspan\u003ENo, thanks\u003C\/span\u003E\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","mobile_breakpoint":768,"popup_html_agreed":false,"popup_use_bare_css":false,"popup_height":"auto","popup_width":"100%","popup_delay":1000,"popup_link":"\/en\/privacy-and-liability-policy","popup_link_new_window":true,"popup_position":false,"fixed_top_position":true,"popup_language":"en","store_consent":false,"better_support_for_screen_readers":false,"cookie_name":"","reload_page":false,"domain":"","domain_all_sites":false,"popup_eu_only":false,"popup_eu_only_js":false,"cookie_lifetime":100,"cookie_session":0,"set_cookie_session_zero_on_disagree":0,"disagree_do_not_show_popup":false,"method":"opt_in","automatic_cookies_removal":false,"allowed_cookies":"","withdraw_markup":"\u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-tab\u0022\u003EPrivacy settings\u003C\/button\u003E\n\u003Cdiv aria-labelledby=\u0022popup-text\u0022 class=\u0022eu-cookie-withdraw-banner\u0022\u003E\n  \u003Cdiv class=\u0022popup-content info eu-cookie-compliance-content\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022 class=\u0022eu-cookie-compliance-message\u0022 role=\u0022document\u0022\u003E\n      \u003Ch2\u003EWe use cookies on this site to enhance your user experience\u003C\/h2\u003E\u003Cp\u003EYou have given your consent for us to set cookies.\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022 class=\u0022eu-cookie-compliance-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-button  button button--small button--primary\u0022\u003EWithdraw consent\u003C\/button\u003E\n    \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","withdraw_enabled":false,"reload_options":0,"reload_routes_list":"","withdraw_button_on_info_popup":false,"cookie_categories":[],"cookie_categories_details":[],"enable_save_preferences_button":true,"cookie_value_disagreed":"0","cookie_value_agreed_show_thank_you":"1","cookie_value_agreed":"2","containing_element":"body","settings_tab_enabled":false,"olivero_primary_button_classes":" button button--small button--primary","olivero_secondary_button_classes":" button button--small","close_button_action":"close_banner","open_by_default":true,"modules_allow_popup":true,"hide_the_banner":false,"geoip_match":true},"user":{"uid":0,"permissionsHash":"47f4934959a6724636db4d476d24638b2f85cf5fbe333108c551f89af58fa8e8"}}</script>
<script src="/sites/default/files/js/js_uvL9Tj82H-DlxB5EbcrwMRuzBTMCuQEuqUOIntbW0dU.js?scope=header&amp;delta=0&amp;language=en&amp;theme=entityone&amp;include=eJxtjksOwyAMRC9EwpHQxDUuxbFRAlJ6-2ZRqd_FaPTebCaDYgbNZ1LTIcVCfqnA1ku_u3EU9QUa-OharMbLNhp0fmLgkci9Fj5rbVpgxPGfDOIuyqlDovT1EyHfPOOG4-3Fok51mhQmA8L7z7QzNro-AF8uUjc"></script>


    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin="">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;500;700&amp;family=Poppins:wght@400;500;700&amp;display=swap" rel="stylesheet">
    <link rel="apple-touch-icon" sizes="76x76" href="/themes/custom/entityone/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="/themes/custom/entityone/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="/themes/custom/entityone/favicon-16x16.png">
    <link rel="manifest" href="/themes/custom/entityone/site.webmanifest">
    <link rel="mask-icon" href="/themes/custom/entityone/safari-pinned-tab.svg" color="#008aa9">
    <link rel="shortcut icon" href="/themes/custom/entityone/favicon.ico">
    <meta name="msapplication-TileColor" content="#008aa9">
    <meta name="msapplication-config" content="/themes/custom/entityone/browserconfig.xml">
    <meta name="theme-color" content="#ffffff">  
  <style type="text/css">.lf-progress {
  -webkit-appearance: none;
  -moz-apperance: none;
  width: 100%;
  /* margin: 0 10px; */
  height: 4px;
  border-radius: 3px;
  cursor: pointer;
}
.lf-progress:focus {
  outline: none;
  border: none;
}
.lf-progress::-moz-range-track {
  cursor: pointer;
  background: none;
  border: none;
  outline: none;
}
.lf-progress::-webkit-slider-thumb {
  -webkit-appearance: none !important;
  height: 13px;
  width: 13px;
  border: 0;
  border-radius: 50%;
  background: #0fccce;
  cursor: pointer;
}
.lf-progress::-moz-range-thumb {
  -moz-appearance: none !important;
  height: 13px;
  width: 13px;
  border: 0;
  border-radius: 50%;
  background: #0fccce;
  cursor: pointer;
}
.lf-progress::-ms-track {
  width: 100%;
  height: 3px;
  cursor: pointer;
  background: transparent;
  border-color: transparent;
  color: transparent;
}
.lf-progress::-ms-fill-lower {
  background: #ccc;
  border-radius: 3px;
}
.lf-progress::-ms-fill-upper {
  background: #ccc;
  border-radius: 3px;
}
.lf-progress::-ms-thumb {
  border: 0;
  height: 15px;
  width: 15px;
  border-radius: 50%;
  background: #0fccce;
  cursor: pointer;
}
.lf-progress:focus::-ms-fill-lower {
  background: #ccc;
}
.lf-progress:focus::-ms-fill-upper {
  background: #ccc;
}
.lf-player-container :focus {
  outline: 0;
}
.lf-popover {
  position: relative;
}

.lf-popover-content {
  display: inline-block;
  position: absolute;
  opacity: 1;
  visibility: visible;
  transform: translate(0, -10px);
  box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
  transition: all 0.3s cubic-bezier(0.75, -0.02, 0.2, 0.97);
}

.lf-popover-content.hidden {
  opacity: 0;
  visibility: hidden;
  transform: translate(0, 0px);
}

.lf-player-btn-container {
  display: flex;
  align-items: center;
}
.lf-player-btn {
  cursor: pointer;
  fill: #999;
  width: 14px;
}

.lf-player-btn.active {
  fill: #555;
}

.lf-popover {
  position: relative;
}

.lf-popover-content {
  display: inline-block;
  position: absolute;
  background-color: #ffffff;
  opacity: 1;

  transform: translate(0, -10px);
  box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
  transition: all 0.3s cubic-bezier(0.75, -0.02, 0.2, 0.97);
  padding: 10px;
}

.lf-popover-content.hidden {
  opacity: 0;
  visibility: hidden;
  transform: translate(0, 0px);
}

.lf-arrow {
  position: absolute;
  z-index: -1;
  content: '';
  bottom: -9px;
  border-style: solid;
  border-width: 10px 10px 0px 10px;
}

.lf-left-align,
.lf-left-align .lfarrow {
  left: 0;
  right: unset;
}

.lf-right-align,
.lf-right-align .lf-arrow {
  right: 0;
  left: unset;
}

.lf-text-input {
  border: 1px #ccc solid;
  border-radius: 5px;
  padding: 3px;
  width: 60px;
  margin: 0;
}

.lf-color-picker {
  display: flex;
  flex-direction: row;
  justify-content: space-between;
  height: 90px;
}

.lf-color-selectors {
  display: flex;
  flex-direction: column;
  justify-content: space-between;
}

.lf-color-component {
  display: flex;
  flex-direction: row;
  font-size: 12px;
  align-items: center;
  justify-content: center;
}

.lf-color-component strong {
  width: 40px;
}

.lf-color-component input[type='range'] {
  margin: 0 0 0 10px;
}

.lf-color-component input[type='number'] {
  width: 50px;
  margin: 0 0 0 10px;
}

.lf-color-preview {
  font-size: 12px;
  display: flex;
  flex-direction: column;
  align-items: center;
  justify-content: space-between;
  padding-left: 5px;
}

.lf-preview {
  height: 60px;
  width: 60px;
}

.lf-popover-snapshot {
  width: 150px;
}
.lf-popover-snapshot h5 {
  margin: 5px 0 10px 0;
  font-size: 0.75rem;
}
.lf-popover-snapshot a {
  display: block;
  text-decoration: none;
}
.lf-popover-snapshot a:before {
  content: 'â¥¼';
  margin-right: 5px;
}
.lf-popover-snapshot .lf-note {
  display: block;
  margin-top: 10px;
  color: #999;
}
.lf-player-controls > div {
  margin-right: 5px;
  margin-left: 5px;
}
.lf-player-controls > div:first-child {
  margin-left: 0px;
}
.lf-player-controls > div:last-child {
  margin-right: 0px;
}
</style><style>[_nghost-rnq-c106]{height:100vh}.weava-ui-wrapper-new[_ngcontent-rnq-c106]{box-shadow:#0006 -1px 3px 60px;position:fixed;top:0;opacity:.99;left:initial;right:-580px;display:block;width:340px;min-width:auto;height:100vh;z-index:9999999999996!important;background:white;border:none;box-sizing:border-box;transition:1s}.weava-ui-wrapper-new[_ngcontent-rnq-c106] > *[_ngcontent-rnq-c106]{display:flex}.weava-ui-wrapper-new.show[_ngcontent-rnq-c106]{right:0;transition:1s}.weava-ui-wrapper-new.show.folder-show[_ngcontent-rnq-c106]{width:580px!important}ngb-toast.weava-notification-frame[_ngcontent-rnq-c106]{box-shadow:#0006 -1px 3px 45px!important;position:fixed!important;left:initial!important;top:20px!important;right:20px!important;width:300px!important;border-radius:4px!important;background-color:#142733!important;transition:all .3s ease!important;z-index:999}</style><style>#clipperButton[_ngcontent-rnq-c108]{font-size:30px!important;line-height:30px!important;width:30px!important;height:30px!important;text-align:center!important;z-index:2147483647!important;position:absolute!important;top:5px!important;right:5px!important;padding:0!important;background:midnightblue!important;color:#fff!important;border:none!important;outline:none!important;border-radius:50%!important}.weava-drop-area-wrapper[_ngcontent-rnq-c108]{position:fixed!important;z-index:2147483647!important;top:50%!important;width:70px!important;padding-left:10px;left:-10px;background-color:#142733!important;transition:left .2s!important;opacity:0;display:none;flex-direction:column;justify-content:center}.weava-drop-area-wrapper.weava-drop-area-wrapper-show[_ngcontent-rnq-c108]{opacity:1;display:flex}.weava-drop-area-wrapper.weava-drop-area-wrapper-drag-over[_ngcontent-rnq-c108]{left:0}.weava-drop-area[_ngcontent-rnq-c108]{display:inline-flex;justify-content:center;height:50px!important;background-color:#142733!important}.weava-drop-area[_ngcontent-rnq-c108] > img[_ngcontent-rnq-c108]{max-width:80%;margin:3px}.weava-drop-area-text[_ngcontent-rnq-c108]{font-weight:700!important;padding:7px 0!important;text-align:center!important;background-color:#142733!important;color:#cbcbcb!important;font-size:10px!important}</style><style>[_nghost-rnq-c76]{width:340px;height:100vh}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .logo[_ngcontent-rnq-c76]{width:60%;margin-top:40px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .title[_ngcontent-rnq-c76]{max-width:250px;color:#848484;font-family:Lato,Helvetica Neue,Helvetica,sans-serif;font-size:18px;font-weight:400;line-height:24px;text-align:center;margin-top:24px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .login-btn[_ngcontent-rnq-c76]{width:60%;padding:10px 15px;border-radius:2px;border:1px solid #00b8c2;background:#00bfd2;color:#fff;font-size:14px;text-align:center;transition:all .1s ease-in;cursor:pointer;margin-top:58px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .login-btn[_ngcontent-rnq-c76]:hover{background:#01dccf;color:#fff}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .login-btn[_ngcontent-rnq-c76]:active, [_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-main[_ngcontent-rnq-c76]   .login-btn.active[_ngcontent-rnq-c76]{background:#617186;border-color:#617186}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-loader[_ngcontent-rnq-c76]   .logo-wrap[_ngcontent-rnq-c76]{height:50%;max-height:200px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-loader[_ngcontent-rnq-c76]   .logo-wrap[_ngcontent-rnq-c76]   .logo[_ngcontent-rnq-c76]{width:50%}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-loader[_ngcontent-rnq-c76]   .logo-wrap[_ngcontent-rnq-c76]   .loader[_ngcontent-rnq-c76]{width:40px;height:40px;margin-top:14px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-loader[_ngcontent-rnq-c76]   .login-actions[_ngcontent-rnq-c76]{height:50%;max-height:280px}[_nghost-rnq-c76]   .login-c[_ngcontent-rnq-c76]   .login-loader[_ngcontent-rnq-c76]   .login-actions[_ngcontent-rnq-c76]   .space[_ngcontent-rnq-c76]{margin:20px}[_nghost-rnq-c76]   .login-text-sm[_ngcontent-rnq-c76]{font-size:12px;color:#9f9f9f;line-height:23px;text-align:center}[_nghost-rnq-c76]   .login-text-link-sm[_ngcontent-rnq-c76]{vertical-align:middle;display:inline-block;color:#0fa0a3;text-decoration:none;font-size:14px;cursor:pointer}</style><style>.dashboard-overall-container[_ngcontent-rnq-c97]{display:flex;background:#f7f7f7;flex-direction:row;justify-content:flex-start;overflow:hidden}.dashboard-overall-container[_ngcontent-rnq-c97]   .app-dashboard-menu-outer-container[_ngcontent-rnq-c97]{left:0;width:240px;margin-left:0;transition:all 1s ease}.dashboard-overall-container[_ngcontent-rnq-c97]   .app-dashboard-menu-outer-container.sidebar-hidden[_ngcontent-rnq-c97]{margin-left:-240px!important}.dashboard-overall-container[_ngcontent-rnq-c97]   .main-panel-larger-outer-container[_ngcontent-rnq-c97]{flex-grow:1;min-width:calc(100% - 240px);transition:all 1s ease;display:flex;flex-direction:column;justify-content:flex-start}.dashboard-overall-container[_ngcontent-rnq-c97]   .main-panel-larger-outer-container.sidebar-show[_ngcontent-rnq-c97]{margin-left:240px}.dashboard-overall-container[_ngcontent-rnq-c97]   .main-panel-larger-outer-container[_ngcontent-rnq-c97]   .main-dashboard-content[_ngcontent-rnq-c97], .dashboard-overall-container[_ngcontent-rnq-c97]   .main-panel-larger-outer-container[_ngcontent-rnq-c97]   .main-dashboard-content[_ngcontent-rnq-c97]   .app-main-panel-outer-container[_ngcontent-rnq-c97]{display:flex;flex-direction:column;flex:1}.dashboard-overall-container[_ngcontent-rnq-c97]   .main-panel-larger-outer-container[_ngcontent-rnq-c97]   .main-dashboard-content[_ngcontent-rnq-c97]   .app-main-panel-outer-container[_ngcontent-rnq-c97]   app-main-panel[_ngcontent-rnq-c97]{display:flex;flex-direction:column;flex:1}</style><style>.menu-panel[_ngcontent-rnq-c88]{display:flex;flex-direction:column;overflow-x:hidden;overflow-y:hidden;width:240px;height:100%;height:100vh;border:none;border:0;margin:0;padding-top:0;padding-bottom:0;background:#142733}.menu-header[_ngcontent-rnq-c88]{height:41px;background:rgba(0,0,0,.05);color:#fff;text-align:left}.menu-body[_ngcontent-rnq-c88]{display:flex;flex-direction:column;flex:1;min-height:140px;overflow-y:auto}.menu-body[_ngcontent-rnq-c88]::-webkit-scrollbar-track{display:initial;box-shadow:inset 0 0 6px #0000004d;border-radius:10px;background-color:#1e3c4e}.menu-body[_ngcontent-rnq-c88]::-webkit-scrollbar{display:initial;background-color:#142733;width:.7em;border-radius:10px}.menu-body[_ngcontent-rnq-c88]::-webkit-scrollbar-thumb{display:initial;border-radius:10px;box-shadow:inset 0 0 6px #0000004d;background-color:#01dccf}.menu-footer[_ngcontent-rnq-c88]{bottom:0;border-top:1px;border-top-color:#00b8c2}.menu-panel-dim-background[_ngcontent-rnq-c88]{position:fixed;z-index:500;inset:0;display:none;background:#000;opacity:.5}.menu-panel-dim-background.active[_ngcontent-rnq-c88]{display:block}.gistnote-header-wrapper[_ngcontent-rnq-c88]{display:flex;align-items:center;padding:14px;height:inherit;color:#fff;font-weight:400;font-weight:500;font-size:18px;text-align:left}.gistnote-header-logo[_ngcontent-rnq-c88]{width:28px}.gistnote-header-logo-wrapper[_ngcontent-rnq-c88]{display:flex;padding:0 12px}.gistnote-header-title-wrapper[_ngcontent-rnq-c88]{padding-right:75px}.gistnote-header-icons-wrapper[_ngcontent-rnq-c88]{height:41px;padding-left:40px}.gistnote-header-icons-wrapper[_ngcontent-rnq-c88]:hover{background:rgba(0,0,0,.4)}.gistnote-header-icons-wrapper[_ngcontent-rnq-c88]:active{background:rgba(0,0,0,.6)}</style><style>.dashboard-nav-header[_ngcontent-rnq-c96]{position:absolute;z-index:51;top:0;display:block;width:340px;height:47px;min-height:28px;margin:0 auto;background:white;text-align:center}.dashboard-nav-header[_ngcontent-rnq-c96]   .dashboard-main[_ngcontent-rnq-c96]{height:inherit}.dashboard-nav-header[_ngcontent-rnq-c96]   .dashboard-folder-colors[_ngcontent-rnq-c96]{padding:5px 5px 5px 18px}.dashboard-nav-header[_ngcontent-rnq-c96]   .dashboard-folder-colors[_ngcontent-rnq-c96]   app-color-item[_ngcontent-rnq-c96]{opacity:.4}.dashboard-nav-header[_ngcontent-rnq-c96]   .dashboard-folder-colors[_ngcontent-rnq-c96]   app-color-item.color-selected[_ngcontent-rnq-c96]{opacity:1!important}.dashboard-nav-header[_ngcontent-rnq-c96]   .dashboard-search-filter-text[_ngcontent-rnq-c96]{background:#fffbe6;color:#5b3b08;text-align:left;padding:5px 5px 5px 18px;font-size:13px}.dashboard-nav-header[_ngcontent-rnq-c96]   .menu-button[_ngcontent-rnq-c96]{border:0;background:transparent;opacity:.55;padding:10px;height:100%}.dashboard-nav-header[_ngcontent-rnq-c96]   .menu-button[_ngcontent-rnq-c96]   .menu-icon[_ngcontent-rnq-c96]{width:15px;height:15px;vertical-align:middle}.dashboard-nav-header[_ngcontent-rnq-c96]   .collection-title[_ngcontent-rnq-c96]{opacity:1;font-size:18px;font-weight:400;overflow:hidden;line-height:16px;text-overflow:ellipsis;width:max-content;max-width:186px;cursor:pointer;transition:all .2s ease}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-collection-title-wrapper[_ngcontent-rnq-c96]{width:100%;flex:1;flex-basis:100%;display:flex;align-items:center;justify-content:flex-end}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-collection-title-wrapper[_ngcontent-rnq-c96]   .search-form[_ngcontent-rnq-c96]{flex:1}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-collection-title-wrapper[_ngcontent-rnq-c96]   .search-form[_ngcontent-rnq-c96]   input[_ngcontent-rnq-c96]{width:100%;outline:none;overflow:hidden;margin-left:2px;border:0;box-shadow:none;background-color:transparent;font-size:14px;color:#d3d3d3;font-weight:lighter;font-weight:300;line-height:23px;text-overflow:ellipsis;white-space:nowrap}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-menu-wrapper[_ngcontent-rnq-c96]{display:flex;justify-content:space-between;align-items:center;width:100%}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-menu-active-folder[_ngcontent-rnq-c96]{max-width:270px}.dashboard-nav-header[_ngcontent-rnq-c96]   .nav-menu-action-buttons[_ngcontent-rnq-c96]{margin-left:auto;padding:0 10px}.dashboard-nav-search-mode[_ngcontent-rnq-c96]{background:#0c1f29}.dashboard-folder-colors-wrapper[_ngcontent-rnq-c96]{background:#142733}.dashboard-folder-colors[_ngcontent-rnq-c96]{display:flex}.dashboard-folder-colors[_ngcontent-rnq-c96]   app-color-item[_ngcontent-rnq-c96]{padding:0 2px}  .nav-menu-action-buttons app-button button{padding:6px!important}  .nav-menu-action-buttons .nav-menu-home-button.button{background:#727272!important}  .nav-menu-action-buttons .nav-menu-home-button.button:hover{background:#595959!important}  .nav-menu-action-buttons .nav-menu-home-button.button img{opacity:1}  .nav-menu-action-buttons .nav-menu-home-button.button .icon-button-badge{position:absolute;top:-5px;right:-5px;border-radius:50%;font-size:10px;font-weight:700;background:#fa3e3e;color:#fff;padding:9px 3px;width:18px;height:18px;text-align:center}  .nav-menu-action-buttons .nav-menu-home-button.button .icon-button-badge.loading{background:none!important;color:#000!important;font-size:12px;padding:3px;animation:_ngcontent-rnq-c96_loading 2s linear infinite}@keyframes _ngcontent-rnq-c96_loading{0%{transform:rotate(0)}to{transform:rotate(360deg)}}  .dashboard-nav-search-mode .nav-menu-action-buttons .button,   .dashboard-nav-search-mode .nav-menu-action-buttons app-button{background:transparent!important}  .dashboard-nav-search-mode .nav-menu-action-buttons .button:hover,   .dashboard-nav-search-mode .nav-menu-action-buttons app-button:hover{background:transparent!important}  .dashboard-nav-search-mode .nav-menu-action-buttons .button:hover img,   .dashboard-nav-search-mode .nav-menu-action-buttons app-button:hover img{opacity:1}</style><style>[_nghost-rnq-c95]{width:100%;position:relative}div.main-panel-body[_ngcontent-rnq-c95]{display:flex;flex-direction:column;flex-grow:1;padding:50px 0 150px;position:absolute;overflow-x:hidden;overflow-y:auto;max-height:100%;width:100%}.main-panel-footer[_ngcontent-rnq-c95]{display:flex;justify-content:space-between;align-items:center;padding:3px 12px;border-top:1px solid #efefef;background:#fdfdfd;position:absolute;left:0;right:0;bottom:0;width:100%}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95]{padding:6px;background:white;border:#efefef;border-radius:50%;box-shadow:0 2px 3px #000c;transition:all .3s ease;cursor:pointer!important}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95]:hover{opacity:1;box-shadow:0 2px 6px #00000080}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95]:active{transform:rotate(45deg);background:#525252}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image.nav-icon-pinned[_ngcontent-rnq-c95]{transform:rotate(45deg);background:#00b8c2;box-shadow:none}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95] > img[_ngcontent-rnq-c95]{opacity:0;transition:.3s all ease}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95] > img.pin-icon[_ngcontent-rnq-c95]{position:absolute;width:20px;height:20px}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95] > img.pin-border[_ngcontent-rnq-c95]{width:20px;height:20px}.main-panel-footer[_ngcontent-rnq-c95]   .pin-image[_ngcontent-rnq-c95] > img.opacity-show[_ngcontent-rnq-c95]{opacity:.9}.main-panel-footer[_ngcontent-rnq-c95]   .highlight-toggle[_ngcontent-rnq-c95]{margin-left:auto}.main-panel-action-buttons[_ngcontent-rnq-c95]{display:flex;justify-content:center;align-items:center;padding:30px 15px}.main-panel-action-buttons-column[_ngcontent-rnq-c95]{padding:0 7px;text-align:center;display:inline-flex;flex-direction:column;justify-content:stretch}.main-panel-action-button-description[_ngcontent-rnq-c95]{font-size:10px;text-transform:uppercase;margin-bottom:10px;line-height:14px;color:#9f9f9f}  .main-panel-action-buttons-column app-button .button{width:100%;font-size:12px;padding:9px;justify-content:unset}.main-panel-upgrade-button[_ngcontent-rnq-c95]{text-align:left;font-size:13px;text-decoration:underline;cursor:pointer;color:#00b8c2}</style><style>.folder-list[_ngcontent-rnq-c79]   ul[_ngcontent-rnq-c79]{list-style:none!important;margin:0;padding:0}.folder-list[_ngcontent-rnq-c79]   ul[_ngcontent-rnq-c79]   li[_ngcontent-rnq-c79] > div.spacer[_ngcontent-rnq-c79]{padding-bottom:3px}.folder-list[_ngcontent-rnq-c79]   ul[_ngcontent-rnq-c79]   li[_ngcontent-rnq-c79] > div.spacer.droppable[_ngcontent-rnq-c79]{border-bottom:3px dotted rgba(0,184,194,.5019607843);padding-bottom:0}.folder-list[_ngcontent-rnq-c79]   ul[_ngcontent-rnq-c79]   li[_ngcontent-rnq-c79] > div.spacer.dragged[_ngcontent-rnq-c79]{border-bottom:3px solid #00b8c2;padding-bottom:0}</style><style>[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]{display:flex;padding:7px 0}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .folder-icons[_ngcontent-rnq-c84]{opacity:.7;color:#fff;transition:all .12s ease}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .folder-icons.folder-action-icon[_ngcontent-rnq-c84]{font-size:14px;padding:3.5px;margin:0 2px;cursor:pointer}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .folder-icons.folder-action-icon[_ngcontent-rnq-c84]:disabled{cursor:no-drop;background-color:#9f9f9f;opacity:.7}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .folder-icons.folder-action-icon[_ngcontent-rnq-c84]:hover{opacity:1}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .create-folder-input[_ngcontent-rnq-c84]{flex-grow:1;margin-right:10px;font-size:13px;font-weight:300;border-radius:2px;line-height:20px}[_nghost-rnq-c84]   .create-folder-wrapper[_ngcontent-rnq-c84]   .create-folder-input[_ngcontent-rnq-c84]:focus{outline:0;border:1px solid #01dccf}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]{padding:0 10px!important}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .folder-icon-folder[_ngcontent-rnq-c84]{margin-right:5px;color:#88a7cd;font-size:34px;opacity:1!important}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]{display:flex;flex-direction:column}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]{display:flex;align-content:space-evenly;justify-content:flex-start}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .action-button[_ngcontent-rnq-c84]{margin-top:5px;border:1px solid #00b8c2;background:#00bfd2;color:#fff;font-size:12px;transition:all .12s ease-in;cursor:pointer}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .action-button[_ngcontent-rnq-c84]:hover{background:#01dccf;border-color:#01dccf;color:#fff}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .action-button[_ngcontent-rnq-c84]:active{background:#617186;border-color:#617186;color:#fff}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .action-button[_ngcontent-rnq-c84]:disabled{background:#e4e4e4;border-color:#e4e4e4;cursor:not-allowed}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .cancel-button[_ngcontent-rnq-c84]{margin-top:5px;margin-left:5px;font-size:12px;cursor:pointer}[_nghost-rnq-c84]   .create-folder-wrapper.main-panel[_ngcontent-rnq-c84]   .input-wrapper[_ngcontent-rnq-c84]   .button-wrapper[_ngcontent-rnq-c84]   .cancel-button[_ngcontent-rnq-c84]:disabled{cursor:not-allowed}</style><style>[_nghost-rnq-c87]{margin-top:auto}.rating-link-wrapper[_ngcontent-rnq-c87]{display:flex;justify-content:space-between;align-items:center;font-size:13px;padding:7px;text-align:left;background:rgba(0,0,0,.19);color:#fff}.rating-link[_ngcontent-rnq-c87]{cursor:pointer;color:#fff}.rating-close-button[_ngcontent-rnq-c87]{cursor:pointer}.rating-close-button[_ngcontent-rnq-c87]   img[_ngcontent-rnq-c87]{padding:5px}.rating-link-wrapper[_ngcontent-rnq-c87] > a[_ngcontent-rnq-c87]{font-size:13px;color:#01dccf;text-decoration:underline;cursor:pointer}.rating-close-button[_ngcontent-rnq-c87]{padding:0}.rating-close-button[_ngcontent-rnq-c87]   img[_ngcontent-rnq-c87]{opacity:.7;width:30px;height:30px}.rating-close-button[_ngcontent-rnq-c87]   img[_ngcontent-rnq-c87]:hover{opacity:1}</style><style>.menu-panel-footer[_ngcontent-rnq-c86]{z-index:100;width:240px;background:rgb(16,32,41)}.menu-panel-footer[_ngcontent-rnq-c86]   .link[_ngcontent-rnq-c86], .menu-panel-footer[_ngcontent-rnq-c86]   .link-storage-upgrade[_ngcontent-rnq-c86]{color:#fff;font-size:14px;opacity:.7;transition:all .2s ease;text-decoration:none}.menu-panel-footer[_ngcontent-rnq-c86]   .link-storage-upgrade[_ngcontent-rnq-c86]{color:#00b8c2}.menu-panel-footer[_ngcontent-rnq-c86]   .link[_ngcontent-rnq-c86]:hover, .menu-panel-footer[_ngcontent-rnq-c86]   .link-storage-upgrade[_ngcontent-rnq-c86]:hover, .menu-panel-footer[_ngcontent-rnq-c86]   .link[_ngcontent-rnq-c86]:active, .menu-panel-footer[_ngcontent-rnq-c86]   .link-storage-upgrade[_ngcontent-rnq-c86]:active{opacity:1}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]{display:flex;justify-content:space-between;align-items:center;padding:10px;background:rgba(0,0,0,.19);opacity:.7;cursor:pointer}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]:hover, .menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]:active{opacity:1}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]   .menu-footer-text[_ngcontent-rnq-c86]{color:#fff;cursor:pointer;text-decoration:none;display:inline-block;vertical-align:middle;font-size:14px}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]   .menu-footer-text[_ngcontent-rnq-c86]:hover{opacity:1}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]   .menu-footer-icon-wrapper[_ngcontent-rnq-c86]{width:40px;opacity:.4;text-align:right;cursor:pointer}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]   .menu-footer-icon-wrapper[_ngcontent-rnq-c86]:hover{opacity:1}.menu-panel-footer[_ngcontent-rnq-c86]   .menu-item[_ngcontent-rnq-c86]   .menu-footer-icon-wrapper[_ngcontent-rnq-c86]   .my-account-icon[_ngcontent-rnq-c86]{vertical-align:middle;width:23px;height:23px}.storage[_ngcontent-rnq-c86]{padding-top:10px;border-top:1px solid #00b8c2;margin:0 15px 25px}.storage[_ngcontent-rnq-c86] > h6[_ngcontent-rnq-c86]{color:#fff;margin:10px 0 15px}.storage[_ngcontent-rnq-c86] > div.storage-value[_ngcontent-rnq-c86]{color:#fff;font-size:10px;margin:10px 0 20px}.storage[_ngcontent-rnq-c86] > div.storage-value[_ngcontent-rnq-c86] > span[_ngcontent-rnq-c86]{opacity:.7}.storage[_ngcontent-rnq-c86] > div.storage-value[_ngcontent-rnq-c86] > span.text-danger[_ngcontent-rnq-c86]{opacity:1}</style><style>.button[_ngcontent-rnq-c92]{font-size:14px;display:inline-flex;justify-content:space-between;align-items:center;position:relative!important;border:0;border-radius:3px;cursor:pointer;transition:.25s;color:#303030;padding:.57em;background:#fff!important;box-shadow:inset 0 0 0 .5px #0000003d,inset 0 -.5px #0000002b}.button[_ngcontent-rnq-c92]:hover{background:linear-gradient(to bottom,rgba(255,255,255,.4),rgba(0,0,0,.03))!important;color:#363636;opacity:1}.button-icon[_ngcontent-rnq-c92]{display:inline-block;line-height:0}.button.button-rounded[_ngcontent-rnq-c92]{border-radius:50%}.button.button-transparent[_ngcontent-rnq-c92]{background-color:transparent;box-shadow:none}.button.button-transparent[_ngcontent-rnq-c92]:hover{background-color:#0000001a!important}.button-title[_ngcontent-rnq-c92]{flex:auto}  .button-icon img{width:20px;height:20px;opacity:.6}</style><style>.main-panel-filter[_ngcontent-rnq-c94]{min-height:30px;padding:4px;display:flex;align-items:center}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]{border:1px solid #e1e1e1;padding:3px 6px;background:transparent;margin-right:2px}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]   img[_ngcontent-rnq-c94]{width:11px;height:18px;vertical-align:middle;opacity:.5}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]   img[_ngcontent-rnq-c94]:disabled{cursor:no-drop}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]   .new-folder-icon[_ngcontent-rnq-c94]{width:15px!important}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]   .toggle-highlight-icon[_ngcontent-rnq-c94]{width:8px!important}.main-panel-filter[_ngcontent-rnq-c94]   .header-button[_ngcontent-rnq-c94]   .sort-highlight-icon[_ngcontent-rnq-c94]{width:16px!important}.main-panel-filter[_ngcontent-rnq-c94]   .main-panel-upgrade-button[_ngcontent-rnq-c94]{font-size:13px;text-decoration:underline;cursor:pointer;color:#00b8c2;box-shadow:none;border:0;background:transparent}.main-panel-filter[_ngcontent-rnq-c94]   .spacer[_ngcontent-rnq-c94]{flex:1}.main-panel-filter[_ngcontent-rnq-c94]     app-toggle-icon-button button{padding:0}</style><style>[_nghost-rnq-c89]{display:flex;flex-direction:row;align-self:center}[_nghost-rnq-c89]   .toggle-label[_ngcontent-rnq-c89]{align-self:center;padding-right:10px;color:#303030;font-size:13px;font-weight:lighter;line-height:16px;cursor:default}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]{display:block;position:relative;width:52px;height:25px}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   input[type=checkbox][_ngcontent-rnq-c89]{display:none}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   input[type=checkbox][_ngcontent-rnq-c89]:checked ~ .toggle-button-switch[_ngcontent-rnq-c89]{left:27px}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   input[type=checkbox][_ngcontent-rnq-c89]:checked ~ .toggle-button-text[_ngcontent-rnq-c89]{background-color:#00b8c2}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   .toggle-button-switch[_ngcontent-rnq-c89]{position:absolute;top:1px;left:1px;width:24px;height:24px;background-color:#fff;border-radius:100%;cursor:pointer;z-index:100;transition:left .3s}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   .toggle-button-text[_ngcontent-rnq-c89]{overflow:hidden;background-color:#ccc;border-radius:12.5px;box-shadow:1px 1px 2.5px #323232bf;transition:background-color .3s}[_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   .toggle-button-text-on[_ngcontent-rnq-c89], [_nghost-rnq-c89]   .toggle-component[_ngcontent-rnq-c89]   .toggle-button-text-off[_ngcontent-rnq-c89]{float:left;width:50%;height:100%;line-height:25px;font-size:12px;font-family:Lato,Helvetica Neue,Helvetica,sans-serif;font-weight:700;color:#fff;text-align:center}</style><style>button[_ngcontent-rnq-c93]{background-color:transparent}</style><style>ngb-alert{display:block}
</style><style>[_nghost-rnq-c80]{position:relative;padding:0;display:block;width:100%}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]{color:#fff;cursor:pointer;display:flex;flex-direction:column;align-items:stretch}[_nghost-rnq-c80]   .folder.main-panel[_ngcontent-rnq-c80]{color:#303030}[_nghost-rnq-c80]   .folder.main-panel[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-title[_ngcontent-rnq-c80]{opacity:1!important;padding:2px!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]{width:100%}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]:hover   .folder-action[_ngcontent-rnq-c80]{display:flex!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]{display:flex;align-items:center;height:30px;width:100%;padding:0 10px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper.droppable-content--zone[_ngcontent-rnq-c80]{border-bottom:2px solid #00b8c2}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper.active[_ngcontent-rnq-c80]:after{position:absolute;background:rgba(255,255,255,.15);top:0;right:0;width:240px;height:30px;content:""}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper.active[_ngcontent-rnq-c80]   .folder-icon-folder[_ngcontent-rnq-c80]{opacity:1!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper.active[_ngcontent-rnq-c80]   .folder-title[_ngcontent-rnq-c80]{opacity:1!important;padding:2px!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper.active[_ngcontent-rnq-c80]   .folder-icon-arrow[_ngcontent-rnq-c80]{opacity:.7}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]{display:flex;align-items:center;max-width:calc(100% - 25px)}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents.droppable-content--zone[_ngcontent-rnq-c80]{border-bottom:2px solid #00b8c2}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]{max-width:90%}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80]{display:flex;flex-direction:column}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80], [_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80]:hover{text-decoration:none;color:inherit}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80]:focus{outline:none!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80]   .folder-title[_ngcontent-rnq-c80]{opacity:.5;font-size:14px;font-weight:400;padding:2px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-link[_ngcontent-rnq-c80]   .folder-title[_ngcontent-rnq-c80]:hover{opacity:1}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-contents[_ngcontent-rnq-c80]   .folder-text[_ngcontent-rnq-c80]   .folder-create-date[_ngcontent-rnq-c80]{font-size:10px;color:#9f9f9f}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-action-wrapper[_ngcontent-rnq-c80]{position:absolute;z-index:10;right:10px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-action-wrapper[_ngcontent-rnq-c80]   .folder-action[_ngcontent-rnq-c80]{display:none}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-action-wrapper[_ngcontent-rnq-c80]   .folder-action[_ngcontent-rnq-c80]   .folder-icons[_ngcontent-rnq-c80]{opacity:1;border:1px solid rgba(221,221,221,.15);background-color:#085a90;color:#fff;box-shadow:0 2px 2px #00000073;transition:all .12s ease}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-action-wrapper[_ngcontent-rnq-c80]   .folder-action[_ngcontent-rnq-c80]   .folder-icons.folder-action-icon[_ngcontent-rnq-c80]{font-size:14px;padding:3.5px;margin:0 2px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body[_ngcontent-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]   .folder-action-wrapper[_ngcontent-rnq-c80]   .folder-action[_ngcontent-rnq-c80]   .folder-icons.folder-action-icon[_ngcontent-rnq-c80]:disabled{cursor:no-drop;background-color:#9f9f9f}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body.droppable-content--zone[_ngcontent-rnq-c80]{background:rgba(0,199,209,.7176470588)}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body.droppable-content--zone[_ngcontent-rnq-c80]   .folder-icon-folder[_ngcontent-rnq-c80]{opacity:1}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body.droppable-content--zone[_ngcontent-rnq-c80]   .folder-title[_ngcontent-rnq-c80]{opacity:1;padding:2px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-body.droppable-content--zone[_ngcontent-rnq-c80]   .folder-icon-arrow[_ngcontent-rnq-c80]{opacity:.7}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icons[_ngcontent-rnq-c80]{opacity:.5}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icons.folder-icon-folder[_ngcontent-rnq-c80]{font-size:21px}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icons.folder-icon-folder.main-panel[_ngcontent-rnq-c80]{font-size:34px;opacity:1!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icons.folder-icon-arrow[_ngcontent-rnq-c80]{font-size:16px;opacity:.3}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icon-arrow[_ngcontent-rnq-c80]{margin-right:5px;color:#fff;opacity:.7}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icon-arrow.hidden[_ngcontent-rnq-c80]{opacity:0!important;display:block!important}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-icon-folder[_ngcontent-rnq-c80]{margin-right:5px;color:#88a7cd}[_nghost-rnq-c80]   .folder[_ngcontent-rnq-c80]   .folder-nested[_ngcontent-rnq-c80]{padding-left:32px}app-main-panel-folder-list[_nghost-rnq-c80]   .folder-text[_ngcontent-rnq-c80], app-main-panel-folder-list   [_nghost-rnq-c80]   .folder-text[_ngcontent-rnq-c80]{max-width:80%!important}app-main-panel-folder-list[_nghost-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80], app-main-panel-folder-list   [_nghost-rnq-c80]   .folder-wrapper[_ngcontent-rnq-c80]{height:inherit!important}</style><style>.weava-promo-ads-wrapper[_ngcontent-rnq-c104]{position:relative;text-align:center}.weava-promo-ads-button[_ngcontent-rnq-c104]{margin:5px 0;padding:0 6px}.weava-promo-close-ads-button[_ngcontent-rnq-c104]{color:#929292;font-size:11px;letter-spacing:-1px;width:86px;padding-bottom:2px;padding-top:2px;margin-top:-80px;margin-left:3px}.folder-body[_ngcontent-rnq-c104]{width:100%}.folder-body[_ngcontent-rnq-c104]:hover   .folder-action[_ngcontent-rnq-c104]{display:flex!important}.folder-body[_ngcontent-rnq-c104]   .folder-wrapper[_ngcontent-rnq-c104]{display:flex;align-items:center;height:30px;width:100%;padding:0 10px}.folder-body[_ngcontent-rnq-c104]   .folder-wrapper[_ngcontent-rnq-c104]   .folder-contents[_ngcontent-rnq-c104]{display:flex;align-items:center}.folder-body[_ngcontent-rnq-c104]   .folder-icons[_ngcontent-rnq-c104]{font-size:34px}</style><style>.folder-card-list[_ngcontent-rnq-c103]{font-size:14px}.folder-card-list[_ngcontent-rnq-c103]   .folder-card[_ngcontent-rnq-c103]{padding:5px 0}</style><style>.auth-notification[_ngcontent-rnq-c102]{display:flex;flex-direction:row;align-items:center;padding:12px;font-size:12px}.auth-notification[_ngcontent-rnq-c102]   img[_ngcontent-rnq-c102]{width:32px;height:32px;margin-right:10px}</style><style>.main-panel-website-card[_ngcontent-rnq-c101]{padding:5px;display:flex;align-items:center;justify-content:flex-start;cursor:pointer}.main-panel-website-card[_ngcontent-rnq-c101]:hover   .main-panel-website-card-favicon[_ngcontent-rnq-c101]   fa-icon[_ngcontent-rnq-c101]{opacity:.6}.main-panel-website-card[_ngcontent-rnq-c101]:hover{background:#f2f2f2}.main-panel-website-card[_ngcontent-rnq-c101]:hover   .main-panel-website-card-actions[_ngcontent-rnq-c101]{display:block}.main-panel-website-card-favicon[_ngcontent-rnq-c101]{display:flex;align-items:center;margin-right:5px;font-size:12px}.main-panel-website-card-favicon[_ngcontent-rnq-c101]   fa-icon[_ngcontent-rnq-c101]{opacity:0;transition:all .2s;margin-right:5px;visibility:hidden}.main-panel-website-card-favicon[_ngcontent-rnq-c101]   fa-icon.show[_ngcontent-rnq-c101]{visibility:visible}.main-panel-website-card-favicon[_ngcontent-rnq-c101]   img[_ngcontent-rnq-c101], .main-panel-website-card-favicon[_ngcontent-rnq-c101]   .img-placeholder[_ngcontent-rnq-c101]{width:30px;height:30px}.main-panel-website-card-data[_ngcontent-rnq-c101]{display:inline-flex;flex-direction:column;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;flex:1;margin-left:auto}.main-panel-website-card-data[_ngcontent-rnq-c101]   a[_ngcontent-rnq-c101]{text-decoration:none;color:#303030;font-size:13px;margin-bottom:5px}.main-panel-website-card-data[_ngcontent-rnq-c101]   a[_ngcontent-rnq-c101]:hover{text-decoration:underline}.main-panel-website-stat[_ngcontent-rnq-c101]{font-size:10px;color:#9f9f9f}.main-panel-website-card-actions[_ngcontent-rnq-c101]{margin-left:auto;display:none}.main-panel-website-card-colors[_ngcontent-rnq-c101]{display:inline-block;vertical-align:middle}.main-panel-website-card-color[_ngcontent-rnq-c101]{width:10px;height:10px;border-radius:50%;display:inline-block;margin-right:3px}</style><style>[_nghost-rnq-c99]   img[_ngcontent-rnq-c99]{max-width:100%;cursor:pointer}.highlight-card[_ngcontent-rnq-c99]{position:relative;background:#ffffff;border-bottom:1px solid rgba(0,0,0,.05);font-family:Lato,Helvetica Neue,Helvetica,sans-serif;font-size:13px;line-height:17px;cursor:pointer;border:0;border-left:5px solid}.highlight-card[_ngcontent-rnq-c99]:hover{background-color:#f9f9f9}.highlight-card[_ngcontent-rnq-c99]:hover   .highlight-card-actions[_ngcontent-rnq-c99]{display:block}.highlight-card-text[_ngcontent-rnq-c99]{padding:8px 10px}.highlight-card-image[_ngcontent-rnq-c99] > img[_ngcontent-rnq-c99]{width:100%}.highlight-card-note[_ngcontent-rnq-c99]{margin:10px 10px 10px 0;padding:20px 10px;border-left:3px solid rgba(0,0,0,.05);background:#fff;color:#889da2}.highlight-card-note.disabled[_ngcontent-rnq-c99]{background:#e4e4e4;color:#9f9f9f!important}.highlight-card-note[_ngcontent-rnq-c99]:hover   .highlight-card-note-actions[_ngcontent-rnq-c99]{display:block}.highlight-card-note[_ngcontent-rnq-c99]:hover{box-shadow:0 1px 4px #0000004d;color:#303030}.highlight-card-note-feedback[_ngcontent-rnq-c99]{position:absolute;left:20px;bottom:20px;color:#889da2;font-size:11px}.highlight-card-note-feedback.error[_ngcontent-rnq-c99]{color:#a65757}.highlight-card-note-actions[_ngcontent-rnq-c99]{position:absolute;right:20px;bottom:20px}.highlight-card-note-actions[_ngcontent-rnq-c99]{display:none}.highlight-card-note-actions[_ngcontent-rnq-c99]   button[_ngcontent-rnq-c99]{color:#0fa0a3;background:none!important;font-size:11px}.highlight-card-note-actions[_ngcontent-rnq-c99]   button[disabled][_ngcontent-rnq-c99]{opacity:.5;cursor:not-allowed}.highlight-card-note-actions[_ngcontent-rnq-c99]   button[_ngcontent-rnq-c99]:hover{text-decoration:underline}.highlight-card-actions[_ngcontent-rnq-c99]{position:absolute;display:none;top:3px;right:3px}.highlight-missing-text[_ngcontent-rnq-c99]{color:#fa3e3e;margin-bottom:.5rem}.highlight-missing-text[_ngcontent-rnq-c99]   fa-icon[_ngcontent-rnq-c99]{margin-right:5px}[contenteditable=true][_ngcontent-rnq-c99]{white-space:pre-wrap}[contenteditable=true][_ngcontent-rnq-c99]:focus{outline:none}[contenteditable=true][_ngcontent-rnq-c99]:empty:not(:focus):before{content:attr(data-placeholder)!important}[contenteditable=false][_ngcontent-rnq-c99]{-webkit-user-select:none;user-select:none;cursor:not-allowed!important}  app-button{display:inline-flex;background:#fff;position:relative}  app-button+app-button{margin-left:2px}  .highlight-card-icon-button.button{padding:5px!important}  .highlight-card .search-match{background:yellow}</style><style>p[_ngcontent-rnq-c98]{text-align:justify;text-overflow:ellipsis;white-space:pre-wrap;line-height:17px;font-family:Lato,Helvetica Neue,Helvetica,sans-serif;font-size:13px;margin:0}button[_ngcontent-rnq-c98]{box-shadow:none;border:0;background:transparent;color:#0fa0a3;font-size:12px;cursor:pointer;padding:0}button[_ngcontent-rnq-c98]:hover{text-decoration:underline}.collapsed[_ngcontent-rnq-c98]{overflow:hidden}</style></head>

  <body class="no-sidebars path-node page-node-type-flexible-page eu-cookie-compliance-popup-open eu-cookie-compliance-status-null" data-once="body-click-listeners" data-eu-cookie-compliance-once="true" data-new-gr-c-s-check-loaded="14.1223.0" data-gr-ext-installed=""><svg class="theSprite" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><symbol viewBox="0 0 24 25" id="icon--arrow-right"><path d="M12.293 5.793a1 1 0 011.414 0l6 6a1 1 0 010 1.414l-6 6a1 1 0 01-1.414-1.414l4.293-4.293H5a1 1 0 110-2h11.586l-4.293-4.293a1 1 0 010-1.414z"></path></symbol><symbol viewBox="0 0 15 12" id="icon--check"><path fill-rule="evenodd" d="M5 12L0 7l2-2 3 3 8-8 2 2z"></path></symbol><symbol viewBox="0 0 12 7" id="icon--chevron-down"><path d="M11.707.293a1 1 0 01.083 1.32l-.083.094-5 5a1 1 0 01-1.32.083l-.094-.083-5-5A1 1 0 011.613.21l.094.083L6 4.584 10.293.293a1 1 0 011.32-.083l.094.083z"></path></symbol><symbol viewBox="0 0 16 16" id="icon--error"><path d="M8.002 1a7 7 0 100 14 7 7 0 000-14zm4.025 9.284c.062.063.1.149.1.239a.34.34 0 01-.1.24l-1.262 1.262a.34.34 0 01-.48 0L8.002 9.742l-2.286 2.283a.34.34 0 01-.48 0l-1.261-1.262a.336.336 0 010-.478L6.258 8 3.975 5.716a.34.34 0 010-.48l1.262-1.262a.34.34 0 01.48 0l2.285 2.284 2.283-2.284a.34.34 0 01.48 0l1.262 1.262c.062.063.1.149.1.24a.345.345 0 01-.1.24L9.744 8l2.283 2.284z"></path></symbol><symbol viewBox="0 0 24 24" id="icon--facebook"><path d="M17.737.005L14.625 0c-3.497 0-5.756 2.318-5.756 5.906V8.63h-3.13a.49.49 0 00-.489.49v3.945c0 .27.22.49.49.49h3.129v9.956c0 .27.219.489.489.489h4.083c.27 0 .49-.22.49-.49v-9.956h3.658a.49.49 0 00.49-.489V9.119a.49.49 0 00-.489-.49h-3.66V6.322c0-1.11.264-1.673 1.71-1.673h2.096c.27 0 .49-.22.49-.49V.494a.49.49 0 00-.489-.489z"></path></symbol><symbol viewBox="0 0 21 20" id="icon--heart"><path d="M10.501 3.773a5 5 0 00-6.869 7.263l5.69 5.69c.652.65 1.707.65 2.358 0l5.69-5.69a5 5 0 00-6.869-7.263zm-.976 1.37l.387.387a.833.833 0 001.179 0l.387-.387a3.333 3.333 0 014.714 4.714l-5.69 5.69-5.691-5.69a3.333 3.333 0 114.714-4.714z"></path></symbol><symbol viewBox="0 0 20 20" id="icon--heart_full"><path d="M10 4.885C8.617 1.136 1.665 1.693 1.665 7.363c0 2.825 2.125 6.584 8.333 10.415 6.209-3.83 8.334-7.59 8.334-10.415 0-5.637-6.945-6.249-8.334-2.478z"></path></symbol><symbol viewBox="0 0 24 24" id="icon--instagram"><path d="M16.85 0h-9.7C3.207 0 0 3.207 0 7.15v9.7C0 20.793 3.207 24 7.15 24h9.7c3.943 0 7.15-3.207 7.15-7.15v-9.7C24 3.207 20.793 0 16.85 0zm4.736 16.85a4.735 4.735 0 01-4.736 4.736h-9.7a4.735 4.735 0 01-4.736-4.736v-9.7A4.735 4.735 0 017.15 2.414h9.7a4.735 4.735 0 014.736 4.736v9.7z"></path><path d="M12 5.793a6.214 6.214 0 00-6.207 6.208A6.214 6.214 0 0012 18.208 6.214 6.214 0 0018.207 12 6.214 6.214 0 0012 5.793zm0 10a3.793 3.793 0 110-7.585 3.793 3.793 0 010 7.586zM18.219 7.327a1.487 1.487 0 100-2.975 1.487 1.487 0 000 2.975z"></path></symbol><symbol viewBox="0 0 24 24" id="icon--linkedin"><path d="M23.95 14.063v8.855h-5.133v-8.262c0-2.075-.742-3.492-2.6-3.492-1.419 0-2.263.955-2.634 1.878-.136.33-.17.79-.17 1.252v8.624H8.276s.07-13.993 0-15.443h5.135v2.19c-.01.016-.024.033-.034.05h.034v-.05c.682-1.052 1.9-2.553 4.627-2.553 3.38 0 5.912 2.208 5.912 6.95zM2.907.03C1.149.031 0 1.184 0 2.7c0 1.482 1.116 2.67 2.838 2.67h.034c1.79 0 2.904-1.188 2.904-2.67C5.743 1.184 4.663.03 2.906.03zM.305 22.918h5.133V7.475H.305v15.443z"></path></symbol><symbol viewBox="0 0 488.076 488.076" id="icon--select-arrow"><path d="M0 49.017c0-13.824 11.207-25.03 25.03-25.03h438.017c13.824 0 25.029 11.207 25.029 25.03L262.81 455.745s-18.772 18.773-37.545 0C206.494 436.973 0 49.017 0 49.017z"></path></symbol><symbol viewBox="0 0 16 16" id="icon--status"><path d="M6.464 13.676a.502.502 0 01-.707 0L.797 8.721a.502.502 0 010-.707l1.405-1.407a.5.5 0 01.707 0l2.849 2.848a.504.504 0 00.707 0l6.629-6.626a.502.502 0 01.707 0l1.404 1.404a.504.504 0 010 .707l-8.741 8.736z"></path></symbol><symbol viewBox="0 0 1200 1227" id="icon--twitter"><path d="M714.163 519.284L1160.89 0H1055.03L667.137 450.887L357.328 0H0L468.492 681.821L0 1226.37H105.866L515.491 750.218L842.672 1226.37H1200L714.137 519.284H714.163ZM569.165 687.828L521.697 619.934L144.011 79.6944H306.615L611.412 515.685L658.88 583.579L1055.08 1150.3H892.476L569.165 687.854V687.828Z"></path></symbol><symbol viewBox="0 0 24 24" id="icon--twitter-old"><path d="M24 4.557a9.831 9.831 0 01-2.827.775 4.944 4.944 0 002.164-2.722 9.925 9.925 0 01-3.128 1.195 4.924 4.924 0 00-8.39 4.489A13.978 13.978 0 011.672 3.15a4.886 4.886 0 00-.666 2.474 4.92 4.92 0 002.19 4.098 4.924 4.924 0 01-2.23-.618v.061a4.928 4.928 0 003.949 4.828 4.986 4.986 0 01-1.298.172c-.318 0-.625-.031-.927-.091a4.926 4.926 0 004.599 3.42 9.878 9.878 0 01-6.115 2.103c-.397 0-.789-.024-1.174-.067a13.917 13.917 0 007.547 2.215c9.056 0 14.007-7.502 14.007-14.008l-.016-.637A9.832 9.832 0 0024 4.557z"></path></symbol><symbol viewBox="0 0 16 16" id="icon--warning"><path d="M14.66 12.316L9.344 1.683c-.738-1.476-1.946-1.476-2.685 0L1.342 12.316C.604 13.793 1.35 15 3 15h10.002c1.65 0 2.396-1.207 1.658-2.684zM7 4h2.002v5H7V4zm2.252 8.615a.627.627 0 01-.625.625h-1.25a.627.627 0 01-.626-.625v-1.239c0-.344.281-.625.626-.625h1.25c.344 0 .625.281.625.625v1.239z"></path></symbol><symbol viewBox="0 0 24 24" id="icon--youtube"><path fill-rule="evenodd" clip-rule="evenodd" d="M21.39 4.264a3.007 3.007 0 012.116 2.115c.514 1.878.494 5.793.494 5.793s0 3.894-.494 5.772a3.007 3.007 0 01-2.116 2.116c-1.878.494-9.39.494-9.39.494s-7.493 0-9.39-.514a3.007 3.007 0 01-2.116-2.115C0 16.066 0 12.152 0 12.152s0-3.895.494-5.773A3.069 3.069 0 012.61 4.244C4.488 3.75 12 3.75 12 3.75s7.512 0 9.39.514zM9.608 8.554l6.247 3.598-6.247 3.598V8.554z"></path></symbol></svg>    <a href="#main-content" class="visually-hidden focusable skip-link">
      Skip to main content
    </a>
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N9CXCWTS"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

    

<div role="document" class="page">
  <div class="nav-spacer"></div>
  <div class="site-header--mobile">
    <a href="/en" title="Home" rel="home" class="site-logo">
      <img src="/themes/custom/entityone/logo.png" alt="Home">
    </a>
    <a href="#menu" id="menu-toggle" class="menutoggle" aria-label="Mobile menu toggle">
      <div class="menutoggle-box">
        <span class="bar bar-1"></span>
        <span class="bar bar-2"></span>
        <span class="bar bar-3"></span>
      </div>
    </a>
  </div> 
  <header id="site-header" class="site-header" data-once="mobile-menu">
    <div class="site-header-inner">            <div class="region region--header-top">
    <div class="region__inner">
                
<div id="block-system-branding-block" class="block block--system block--system-branding-block">    <a href="/en" title="Home" rel="home" class="site-logo">
      <img src="/themes/custom/entityone/logo.svg" alt="Home">
    </a>
  </div>


          </div>
  </div>

                    <div class="region region--header">
    <div class="region__inner">          <nav id="menu--top-navigation" aria-label="Top navigation" class="block block-menu navigation menu--top-navigation">
      

              <ul class="menu">
        <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">About us<svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/our-mission" title="Our mission" class="menu-item--link" data-drupal-link-system-path="node/324">Our mission &amp; values</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/meet-team" title="Meet the team" class="menu-item--link" data-drupal-link-system-path="node/325">Meet the team</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/our-story" title="Our story" class="menu-item--link" data-drupal-link-system-path="node/360">Our story</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/our-governance" title="Board of Directors &amp; Governance" class="menu-item--link" data-drupal-link-system-path="node/338">Board of Directors &amp; Governance</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/annual-reports-financial-transparency" title="Annual Report" class="menu-item--link" data-drupal-link-system-path="node/339">Annual Report &amp; Transparency</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/about-us/our-partners-network" title="Partners &amp; Network" class="menu-item--link" data-drupal-link-system-path="node/348">Partners &amp; Network</a></span></li>
        </ul>
  </li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/happy-hear-you" class="menu-item--link" data-drupal-link-system-path="node/347">Contact us</a></span></li>
    <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">Manifesto 2024 <svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="https://www.anticancerfund.org/en/manifesto-2024/urgency-now" class="menu-item--link">Our commitment to innovation</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="https://www.anticancerfund.org/en/manifesto-2024/manifesto-2024-endorsements" class="menu-item--link">Endorsements</a></span></li>
        </ul>
  </li>
        </ul>
  


  </nav>
<div class="views-exposed-form block block--views block--views-exposed-filter-blocksearch-results-page-1 block--views-exposed-filter-block-search-results-page-1" data-drupal-selector="views-exposed-form-search-results-page-1" id="block-views-exposed-filter-block-search-results-page-1" data-once="search-toggle">      
      


<form action="/en/search" method="get" id="views-exposed-form-search-results-page-1" accept-charset="UTF-8" class="form form--views-exposed-form form-fac-result">
      <div class="form--inline clearfix">
  


<div class="js-form-item form-item js-form-type-textfield form-item--textfield js-form-item-search form-item--search">
      





<div class="form-item__label form-item__label--default">
    <label for="edit-search">

              <span class="label-helper"></span>
      
      <span class="label-text">Search</span>

          </label>
  </div>
  
  
      <input placeholder="Search" class="search-page--input form-text" data-drupal-selector="edit-search" type="text" id="edit-search" name="search" value="" size="30" maxlength="128" data-once="fac" autocomplete="off" autocorrect="off" autocapitalize="none" spellcheck="false" aria-autocomplete="list" aria-owns="fac-result-search-0">
  
  
  
  </div>
<div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions">
<button data-drupal-selector="edit-submit-search-results" type="submit" id="edit-submit-search-results" value="Search" class="button js-form-submit form-submit btn btn--default">
  <span>Search</span>
</button></div>

</div>

  <div class="fac-result hidden" id="fac-result-search-0"><div class="announce visually-hidden" id="fac-announce-search-0" role="status" aria-live="polite"></div><ul class="result-list hidden" role="listbox" aria-labelledby="fac-announce-search-0"><li class="see-all-link hidden" id="fac-see-all-link-search-0" role="option" style="cursor: pointer;"><div><a href="#">See all results</a></div></li></ul></div></form>


      <div id="search-icon">
        <svg class="icon-search" width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg">
          <path d="M10 4C6.68629 4 4 6.68629 4 10C4 13.3137 6.68629 16 10 16C13.3137 16 16 13.3137 16 10C16 6.68629 13.3137 4 10 4ZM2 10C2 5.58172 5.58172 2 10 2C14.4183 2 18 5.58172 18 10C18 11.8487 17.3729 13.551 16.3199 14.9056L21.7071 20.2929C22.0976 20.6834 22.0976 21.3166 21.7071 21.7071C21.3166 22.0976 20.6834 22.0976 20.2929 21.7071L14.9056 16.3199C13.551 17.3729 11.8487 18 10 18C5.58172 18 2 14.4183 2 10Z" fill="black"></path>
        </svg>
        <svg class="icon-close" xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none">
          <path d="M5.29289 5.2929C5.68342 4.90237 6.31658 4.90237 6.70711 5.2929L12 10.5858L17.2929 5.2929C17.6834 4.90237 18.3166 4.90237 18.7071 5.2929C19.0976 5.68342 19.0976 6.31659 18.7071 6.70711L13.4142 12L18.7071 17.2929C19.0976 17.6834 19.0976 18.3166 18.7071 18.7071C18.3166 19.0976 17.6834 19.0976 17.2929 18.7071L12 13.4142L6.70711 18.7071C6.31658 19.0976 5.68342 19.0976 5.29289 18.7071C4.90237 18.3166 4.90237 17.6834 5.29289 17.2929L10.5858 12L5.29289 6.70711C4.90237 6.31659 4.90237 5.68342 5.29289 5.2929Z" fill="black"></path>
        </svg>
      </div>

  </div>




<div class="language-switcher-language-url block block--language block--language-blocklanguage-interface block--language-block" id="block-language-block-language-interface" role="navigation" data-once="language-toggle">
  

  <button class="">
    <span>en</span>
    <svg class="icon icon--chevron-down">
      <use xlink:href="#icon--chevron-down"></use>
    </svg>
  </button>
    
  

      <ul class="links language-switcher-language-url"><li hreflang="en" data-drupal-link-system-path="node/373" class="en is-active" aria-current="page"><a href="/en/database-repurposing-trials-oncology" class="language-link is-active" hreflang="en" data-drupal-link-system-path="node/373" aria-current="page">EN</a></li><li hreflang="nl" data-drupal-link-system-path="node/373" class="nl"><a href="/nl/node/373" class="language-link" hreflang="nl" data-drupal-link-system-path="node/373">NL</a></li><li hreflang="fr" data-drupal-link-system-path="node/373" class="fr"><a href="/fr/node/373" class="language-link" hreflang="fr" data-drupal-link-system-path="node/373">FR</a></li></ul>
  </div>

      </div>
  </div>
 

                    <div class="region region--header-bottom">
    <div class="region__inner">
                <nav id="menu--main" aria-label="Hoofdnavigatie" class="block block-menu navigation menu--main">
      

              <ul class="menu main-menu ">
        <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">Clinical research<svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu main-menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/clinical-research/our-research-focus" class="menu-item--link" data-drupal-link-system-path="node/368">Our research focus</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/trials" class="menu-item--link" data-drupal-link-system-path="trials">Our clinical trials</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/clinical-research/science-office" title="Science office" class="menu-item--link" data-drupal-link-system-path="node/327">Science office</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/clinical-research/challenging-decision-makers-put-patients-back-centre" class="menu-item--link" data-drupal-link-system-path="node/364">Policy hub</a></span></li>
        </ul>
  </li>
    <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">Patient support<svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu main-menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="https://www.mycancernavigator.org" target="_blank" class="menu-item--link ext" data-extlink="" rel="noreferrer">My Cancer Navigator</a></span></li>
        </ul>
  </li>
    <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">News<svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu main-menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/news" class="menu-item--link" data-drupal-link-system-path="news">News releases</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/blog" class="menu-item--link" data-drupal-link-system-path="blog">Blogs</a></span></li>
        </ul>
  </li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/thank-you" class="menu-item--link" data-drupal-link-system-path="node/437">Sponsors &amp; donors</a></span></li>
    <li class="menu-item menu-item--expanded">
        <span class="menu-item__inner">
          <span class="menu-item--link">Get involved<svg class="icon icon--chevron-down">
                <use xlink:href="#icon--chevron-down"></use>
              </svg></span></span>
              <ul class="menu main-menu">
        <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/get-involved/together-we-can-do-so-much-more" class="menu-item--link" data-drupal-link-system-path="node/351">Make a donation</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/get-involved/your-donations-can-work-miracles" class="menu-item--link" data-drupal-link-system-path="node/352">Bank account information</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/get-involved/sponsorship-pledged-giving" class="menu-item--link" data-drupal-link-system-path="node/425">Sponsorship &amp; pledged giving</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/get-involved/maximise-your-tax-benefit" class="menu-item--link" data-drupal-link-system-path="node/353">Maximise your tax benefit</a></span></li>
    <li class="menu-item">
        <span class="menu-item__inner">
          <a href="/en/get-involved/leave-lasting-legacy" class="menu-item--link" data-drupal-link-system-path="node/359">Leave a legacy</a></span></li>
        </ul>
  </li>
        </ul>
  


  </nav>
<div id="block-acf-donate-button" class="block block--acf-general block--acf-donate-button">  <div class="donate-button">
    <a class="btn btn--donate" href="https://anticancerfund1.koalect.com/en-GB/p/merci-de-soutenir-le-fonds-anticancer/step-1" target="_blank" rel="noreferrer">
      <svg class="heart-full" width="20" height="20" viewBox="0 0 20 20" fill="none" xmlns="http://www.w3.org/2000/svg">
        <path d="M9.99935 4.88549C8.6181 1.13618 1.66602 1.69313 1.66602 7.36327C1.66602 10.1883 3.79102 13.9473 9.99935 17.7778C16.2077 13.9473 18.3327 10.1883 18.3327 7.36327C18.3327 1.72577 11.3882 1.11396 9.99935 4.88549Z" fill="white"></path>
      </svg>
      <svg class="heart" width="21" height="20" viewBox="0 0 21 20" fill="none" xmlns="http://www.w3.org/2000/svg">
        <path d="M10.5013 3.77304C8.53812 2.01408 5.51901 2.07789 3.63243 3.96447C1.67981 5.91709 1.67981 9.08291 3.63243 11.0355L9.32279 16.7259C9.97367 17.3768 11.0289 17.3768 11.6798 16.7259L17.3702 11.0355C19.3228 9.08291 19.3228 5.91709 17.3702 3.96447C15.4836 2.07789 12.4645 2.01408 10.5013 3.77304ZM9.52499 5.14298L9.91205 5.53003C10.2375 5.85547 10.7651 5.85547 11.0906 5.53003L11.4776 5.14298C12.7794 3.84123 14.8899 3.84123 16.1917 5.14298C17.4934 6.44473 17.4934 8.55527 16.1917 9.85702L10.5013 15.5474L4.81095 9.85702C3.5092 8.55527 3.5092 6.44473 4.81095 5.14298C6.11269 3.84123 8.22324 3.84123 9.52499 5.14298Z" fill="white"></path>
      </svg>
      Donate
    </a>
  </div>
</div>


          </div>
  </div>

        </div>
  </header>      <section class="content-top" data-once="content-top">
         <div class="region region--content-top">
    <div class="region__inner">
              <div id="block-system-breadcrumb-block" class="block block--system block--system-breadcrumb-block">
  <div>
    <ol class="breadcrumb">
              <li class="breadcrumb-item">            <a href="/en">Home</a>
          </li>
              <li class="breadcrumb-item">            Database Repurposing Trials In Oncology
          </li>
          </ol>
  </div>
</div>

<div data-drupal-messages-fallback="" class="hidden"></div>

          </div>
  </div>

      </section>
    <a id="main-content" class="main-content" tabindex="-1"></a>
      <main role="main">
      <div class="inner">          <section id="content" class="main ">
              <div class="region region--content">
    <div class="region__inner">
              <div id="block-system-main-block" class="block block--system block--system-main-block"><article class="node node--type-flexible-page node--view-mode-full">
        <div class="node__content">


  <div class="layout--layout-onecol tocbotized">
    <div class="layout__region layout__region--content">
  


<div class="block block--entity-label block--page-title">
  
  
              <h1 class="page-title">Database repurposing trials in oncology</h1>
  </div>

<div class="block block--layout-builder block--inline-block--science-resources">
    
          

      <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/floatthead/2.1.2/jquery.floatThead.js"></script>
<script src="https://sciencedata.anticancerfund.org/pages/jquery.tablesorter.min.js"></script>
<script src="https://sciencedata.anticancerfund.org/pages/redo_filter.js"></script>
<script src="https://sciencedata.anticancerfund.org/pages/fetch_table.js"></script>		
<link rel="stylesheet" type="text/css" href="https://sciencedata.anticancerfund.org/pages/ReDO_DBs.css">
<link rel="stylesheet" type="text/css" href="https://sciencedata.anticancerfund.org/pages/NCT_record.css">
<style>
body {font-family: Arial, Helvetica, sans-serif;}
* {box-sizing: border-box;}

.form-inline {  
  display: flex;
  flex-flow: row wrap;
  align-items: center;
}

.form-inline label {
  margin: 5px 10px 5px 0;
}

.form-inline input, select {
  vertical-align: middle;
  margin: 5px 10px 5px 0;
  padding: 10px;
  background-color: #fff;
  border: 1px solid #ddd;
}

@media (max-width: 800px) {
  .form-inline input {
    margin: 10px 0;
  }
  
  .form-inline {
    flex-direction: column;
    align-items: stretch;
  }
}
</style>

		<div style="margin:auto;margin-top:50px;width:80%;" class="container">
		
		<p>The ReDO_Trials_DB is a curated database of active clinical trials investigating the use of non-cancer drugs as potential cancer treatments. All trials in this database
		include one or more licensed non-cancer drugs in an intervention arm as an anticancer agent rather than for symptom control or supportive care. Primary cancer prevention trials
		are not included. Active trials are those which are recruiting, not yet recruiting, have temporarily paused recruitment or are following up on recruited patients. Trials which have 
		completed, been terminated, withdrawn or with unknown status are not included. </p>

		<p>Cite as: Pantziarka, P., Vandeborne, L., &amp; Bouche, G. (2021). <a href="https://www.frontiersin.org/articles/10.3389/fphar.2021.790952/full" class="ext" data-extlink="" rel="noreferrer">
		<b>A Database of Drug Repurposing Clinical Trials in Oncology.</b> Frontiers in Pharmacology, 10 November 2021, DOI: /10.3389/fphar.2021.790952</a></p>
		
		<p>A machine-readable version of this database can be downloaded here: <a href="https://sciencedata.anticancerfund.org/pages/ReDO_Trials_DB.txt"><strong>ReDO_Trials_DB.txt</strong></a>. 
		The ReDO database of repurposing candidates in oncology can be accessed here: <a href="https://www.anticancerfund.org/database-repurposing-drugs-oncology">ReDO_DB</a>.</p>

		<hr>
		<p>Important note for patients! This list identifies drugs that, based on their scientific properties, warrant further scientific investigation. 
		In most cases the existing scientific evidence for their effects on cancer is very limited. Further scientific and clinical research is needed before 
		any statements regarding their anti-cancer activity can be made. This list is not intended to be used as a source for possible treatment options for patients.</p>

		<p>If you need help exploring further treatment options for your situation, please take a look at our <a href="https://www.anticancerfund.org/patient-support/we-help-patients">My Cancer Navigator</a> service.</p>
		<hr>
		<div class="form-inline"><table class="redo" style="margin-left: auto;margin-right:auto;"><tbody><tr><td colspan="3">Summary results as of last data import on: <span id="Last_Import">09/12/2024</span></td></tr><tr><td colspan="2">Number of included repurposing trials</td><td>911</td></tr><tr><td colspan="2">Number of ReDO drugs included in trials</td><td>186</td></tr><tr><td colspan="2">Number of patients planned for inclusion in trials</td><td>161601</td></tr><tr><td colspan="2">Number of countries with Principal Investigator of trial</td><td>44</td></tr><tr><td colspan="3">&nbsp;</td></tr><tr><td>&nbsp;</td><td>Number</td><td>Percentage</td></tr><tr><td>Include pediatric patients</td><td>39</td><td>4.3%</td></tr><tr><td>At Phase 3 or 4</td><td>142</td><td>15.6%</td></tr><tr><td>Include control arm</td><td>408</td><td>44.8%</td></tr></tbody></table><table class="redo" style="margin-left: auto;margin-right:auto;"><tbody><tr><td colspan="4">Most popular drugs in trials as of last data import on: 09/12/2024</td></tr><tr><td>Metformin</td><td>128</td><td>Celecoxib</td><td>56</td></tr><tr><td>Hydroxychloroquine</td><td>40</td><td>Acetylsalicylic Acid</td><td>37</td></tr><tr><td>Ascorbic acid</td><td>35</td><td>Propofol</td><td>32</td></tr><tr><td>Propranolol</td><td>29</td><td>Valproic Acid</td><td>28</td></tr><tr><td>Zoledronic Acid</td><td>26</td><td>Atorvastatin</td><td>24</td></tr><tr><td>Selumetinib</td><td>24</td><td>Simvastatin</td><td>23</td></tr></tbody></table></div><hr>		<div><form class="form-inline"><label for="Cancer_Group">Select cancer group: </label><select id="Cancer_Group" name="Cancer_Group" style="width:400px;" onchange="fetchTable(this.value,controlled.value,pediatric.value)"><option value="" disabled="" selected="">--select--</option><option value="%">All</option><option value="Breast">Breast</option><option value="Bone Sarcoma">Bone Sarcoma</option><option value="Urological">Urological</option><option value="CNS">CNS</option><option value="Endocrine">Endocrine</option><option value="GI">GI</option><option value="Gynaecological">Gynaecological</option><option value="Head and Neck">Head and Neck</option><option value="Leukemia">Leukemia</option><option value="Lung">Lung</option><option value="Lymphoma">Lymphoma</option><option value="Ocular">Ocular</option><option value="Other">Other</option><option value="Other Haem-onc">Other Haem-onc</option><option value="Skin">Skin</option><option value="Soft Tissue Sarcoma">Soft Tissue Sarcoma</option><option value="Multiple cancer types">Multiple cancer types</option><option value="AIDS-related">AIDS-related</option></select><input type="checkbox" id="controlled" name="controlled" value="%" onclick="setCheckbox(this)"><label for="controlled">Controlled trials only</label><input type="checkbox" id="pediatric" name="pediatric" value="%" onclick="setCheckbox(this)"><label for="pediatric">Includes pediatric patients</label></form></div><p>

<select id="inc_exc" onchange="ReDO_Filter('redo',1,2,3, 4)"><option value="1">Include text:</option><option value="0">Exclude text:</option></select>
<input type="text" id="filterTerm" onkeyup="ReDO_Filter('redo',1,2,3, 4)" placeholder="Filter by NCT, Title, Cancer Group or Drug." title="Type in NCT, title, cancer group or drug">
<br>
<em>Click in header cell to sort table by that column. Hover over header cell for additional text. Click on trial row to view record.</em>
<br>

</p><p>Database build date: <span id="lastUpdate">09/12/2024</span> </p>
<p>Number of trials selected from database: <span id="records">911</span>  <span id="filter">(Filter not active)</span></p>		
		
		
				<div class="floatThead-wrapper" style="position: relative; clear: both;"><div aria-hidden="true" class="floatThead-container" style="overflow-x: hidden; padding-left: 0px; padding-right: 0px; position: absolute; margin-top: 0px; top: 0px; z-index: 1; will-change: transform; transform: translateX(0px) translateY(0px); left: 0px; width: 895.196px;"><table class="redo floatThead-table" style="border-collapse: collapse; border: 0px none rgb(128, 128, 128); display: table; width: 895.196px; margin: 0px; table-layout: auto;"><colgroup><col style="width: 47.9167px;"><col style="width: 179.975px;"><col style="width: 282.377px;"><col style="width: 116.385px;"><col style="width: 144.387px;"><col style="width: 123.37px;"></colgroup></table></div><table class="redo" id="redo" style="table-layout: auto; min-width: 895.196px;"><thead>
						<tr><th title="Rank" class="header">id</th>
						<th title="Trial registration id" class="header">NCT Number</th>
						<th title="Trail title" class="header">Title</th>
						<th title="Group of cancers included" class="header">Cancer Group</th>
						<th title="ReDO drug included in trial" class="header">Drug</th>
						<th title="Phase of trial" class="header">Phase</th>
					</tr></thead><colgroup><col style="width: 47.9167px;"><col style="width: 179.975px;"><col style="width: 282.377px;"><col style="width: 116.385px;"><col style="width: 144.387px;"><col style="width: 123.37px;"></colgroup>
					
					<tbody class="tbody" id="redo_body"><tr>
						<td>2</td>
						<td>NCT03047837</td>
						<td>A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>3</td>
						<td>NCT02969681</td>
						<td>Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>8</td>
						<td>NCT02748707</td>
						<td>Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>9</td>
						<td>NCT03664115</td>
						<td>Itraconazole in Non Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>10</td>
						<td>NCT01529593</td>
						<td>Temsirolimus in Combination with Metformin in Patients with Advanced Cancers</td>
						<td>Multiple cancer types</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>13</td>
						<td>NCT02678975</td>
						<td>Disulfiram in Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Disulfiram</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>20</td>
						<td>NCT03273231</td>
						<td>The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection</td>
						<td>GI</td>
						<td>Ketamine</td>
						<td>Other</td>
					</tr><tr>
						<td>21</td>
						<td>NCT03253289</td>
						<td>Meclizine for Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Meclizine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>24</td>
						<td>NCT01844076</td>
						<td>Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma</td>
						<td>GI</td>
						<td>Mepacrine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>25</td>
						<td>NCT01930864</td>
						<td>Metformin Plus Irinotecan for Refractory Colorectal Cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>27</td>
						<td>NCT02978547</td>
						<td>The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>28</td>
						<td>NCT02437812</td>
						<td>Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>29</td>
						<td>NCT03833466</td>
						<td>Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>34</td>
						<td>NCT02451774</td>
						<td>Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction</td>
						<td>Leukemia</td>
						<td>Pentoxifylline</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>35</td>
						<td>NCT02897986</td>
						<td>Study of a Propranolol (HEMANGIOL ) and Oral Metronomic Vinorelbine (NAVELBINE ) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Propranolol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>41</td>
						<td>NCT01342692</td>
						<td>Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes</td>
						<td>Other Haem-onc</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>48</td>
						<td>NCT03184493</td>
						<td>Celebrex and Metformin for Postoperative Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Celecoxib; Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>51</td>
						<td>NCT01562626</td>
						<td>Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Flucytosine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>52</td>
						<td>NCT03972748</td>
						<td>Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.</td>
						<td>Skin</td>
						<td>Itraconazole</td>
						<td>Other</td>
					</tr><tr>
						<td>54</td>
						<td>NCT03777930</td>
						<td>The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol</td>
						<td>Multiple cancer types</td>
						<td>Megestrol Acetate</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>55</td>
						<td>NCT02122185</td>
						<td>Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>59</td>
						<td>NCT04657237</td>
						<td>Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer</td>
						<td>Breast</td>
						<td>Acetaminophen</td>
						<td>Other</td>
					</tr><tr>
						<td>60</td>
						<td>NCT03467360</td>
						<td>Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Acetazolamide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>62</td>
						<td>NCT02607072</td>
						<td>Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>63</td>
						<td>NCT00565708</td>
						<td>Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>64</td>
						<td>NCT02467582</td>
						<td>Adjuvant Aspirin Treatment for Colon Cancer Patients</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>65</td>
						<td>NCT03491410</td>
						<td>Breast Cancer Active Surveillance, Alternative Option, Aspirin Included</td>
						<td>Breast</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>66</td>
						<td>NCT02647099</td>
						<td>Adjuvant Low Dose Aspirin in Colorectal Cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>67</td>
						<td>NCT04188119</td>
						<td>A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>68</td>
						<td>NCT02945033</td>
						<td>Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>69</td>
						<td>NCT04534218</td>
						<td>Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>70</td>
						<td>NCT02301286</td>
						<td>A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>71</td>
						<td>NCT03819101</td>
						<td>Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Acetylsalicylic Acid; Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>73</td>
						<td>NCT03326791</td>
						<td>Aspirin in Colorectal Cancer Liver Metastases</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>74</td>
						<td>NCT03464305</td>
						<td>ASPIRIN Trial Belgium</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>78</td>
						<td>NCT03899987</td>
						<td>Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery</td>
						<td>Urological</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>79</td>
						<td>NCT01936233</td>
						<td>Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>81</td>
						<td>NCT02804815</td>
						<td>Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours</td>
						<td>Breast; Urological; GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>82</td>
						<td>NCT03638297</td>
						<td>PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>83</td>
						<td>NCT03245489</td>
						<td>Anti-platelet + Pembro for H N Tumors</td>
						<td>Head and Neck</td>
						<td>Acetylsalicylic Acid; Clopidogrel</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>85</td>
						<td>NCT04812808</td>
						<td>Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma</td>
						<td>GI</td>
						<td>Bazedoxifene</td>
						<td>Other</td>
					</tr><tr>
						<td>86</td>
						<td>NCT03900871</td>
						<td>Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>87</td>
						<td>NCT03290820</td>
						<td>Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients</td>
						<td>Head and Neck</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>88</td>
						<td>NCT02366884</td>
						<td>Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)</td>
						<td>Multiple cancer types</td>
						<td>Albendazole; Chloroquine; Clarithromycin; Clotrimazole; Dapsone; Doxycycline; Itraconazole; Ivermectin; Levamisole; Mebendazole; Metronidazole; Miconazole; Miltefosine; Nitazoxanide; Terbinafine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>89</td>
						<td>NCT04691765</td>
						<td>Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients</td>
						<td>Leukemia</td>
						<td>Anakinra</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>90</td>
						<td>NCT04840004</td>
						<td>Efficacy and Safety of High Dose Aprepitant Treatment in Patients With Advanced Non-Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Aprepitant</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>92</td>
						<td>NCT02633098</td>
						<td>A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer</td>
						<td>GI</td>
						<td>Artesunate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>93</td>
						<td>NCT03093129</td>
						<td>Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)</td>
						<td>GI</td>
						<td>Artesunate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>94</td>
						<td>NCT04801511</td>
						<td>Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>95</td>
						<td>NCT04463459</td>
						<td>Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy</td>
						<td>Breast</td>
						<td>Ascorbic acid</td>
						<td>Other</td>
					</tr><tr>
						<td>96</td>
						<td>NCT04035096</td>
						<td>The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>97</td>
						<td>NCT01852890</td>
						<td>Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>98</td>
						<td>NCT04516681</td>
						<td>IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>100</td>
						<td>NCT03541486</td>
						<td>A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>101</td>
						<td>NCT04033107</td>
						<td>High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors</td>
						<td>GI</td>
						<td>Ascorbic acid; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>102</td>
						<td>NCT02905578</td>
						<td>A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>103</td>
						<td>NCT03146962</td>
						<td>High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies</td>
						<td>Multiple cancer types</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>104</td>
						<td>NCT02420314</td>
						<td>Pharmacological Ascorbate for Lung Cancer</td>
						<td>Lung</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>105</td>
						<td>NCT02905591</td>
						<td>A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC</td>
						<td>Lung</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>106</td>
						<td>NCT04488783</td>
						<td>Potentiation of Chemotherapy in Brain Tumors by Zinc</td>
						<td>CNS</td>
						<td>Ascorbic acid</td>
						<td>Other</td>
					</tr><tr>
						<td>107</td>
						<td>NCT03799094</td>
						<td>Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations</td>
						<td>Lung</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>109</td>
						<td>NCT04634227</td>
						<td>Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)</td>
						<td>Soft Tissue Sarcoma; Bone Sarcoma</td>
						<td>Ascorbic acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>110</td>
						<td>NCT03508726</td>
						<td>High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>112</td>
						<td>NCT04687176</td>
						<td>Frontline Oral Arsenic Trioxide for APL</td>
						<td>Leukemia</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>113</td>
						<td>NCT03999723</td>
						<td>Combining Active and Passive DNA Hypomethylation</td>
						<td>Leukemia</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>114</td>
						<td>NCT02344355</td>
						<td>A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme</td>
						<td>CNS</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>116</td>
						<td>NCT03602235</td>
						<td>High Dose Ascorbic Acid for Plasma Cell Disorders</td>
						<td>Other Haem-onc</td>
						<td>Ascorbic acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>117</td>
						<td>NCT01752491</td>
						<td>A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme</td>
						<td>CNS</td>
						<td>Ascorbic acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>119</td>
						<td>NCT04026230</td>
						<td>Impact of Atorvastatin on Prostate Cancer Progression During ADT</td>
						<td>Urological</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>121</td>
						<td>NCT04601116</td>
						<td>The MASTER Study (MAmmary Cancer STatin ER Positive Study)</td>
						<td>Breast</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>122</td>
						<td>NCT02958852</td>
						<td>A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer</td>
						<td>Breast</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>124</td>
						<td>NCT03560882</td>
						<td>A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies</td>
						<td>Multiple cancer types; Leukemia</td>
						<td>Atorvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>126</td>
						<td>NCT03971019</td>
						<td>Survival Benefits of Statins in Breast Cancer Patients</td>
						<td>Breast</td>
						<td>Atorvastatin; Simvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>127</td>
						<td>NCT04862260</td>
						<td>Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma</td>
						<td>GI</td>
						<td>Atorvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>129</td>
						<td>NCT03024684</td>
						<td>Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment</td>
						<td>GI</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>131</td>
						<td>NCT03568994</td>
						<td>Atovaquone (Mepron ) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)</td>
						<td>Leukemia</td>
						<td>Atovaquone</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>132</td>
						<td>NCT03456700</td>
						<td>Auranofin and Sirolimus in Treating Participants With Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Auranofin; Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>135</td>
						<td>NCT04158635</td>
						<td>Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Bosentan</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>136</td>
						<td>NCT03596073</td>
						<td>Topical Calcipotriene Treatment for Breast Cancer Immunoprevention</td>
						<td>Breast</td>
						<td>Calcipotriol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>138</td>
						<td>NCT04094688</td>
						<td>Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>139</td>
						<td>NCT03986268</td>
						<td>Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy</td>
						<td>Breast</td>
						<td>Cholecalciferol</td>
						<td>Other</td>
					</tr><tr>
						<td>140</td>
						<td>NCT01787409</td>
						<td>Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency</td>
						<td>Lymphoma</td>
						<td>Cholecalciferol</td>
						<td>Other</td>
					</tr><tr>
						<td>142</td>
						<td>NCT03389659</td>
						<td>XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC</td>
						<td>GI</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>143</td>
						<td>NCT02786875</td>
						<td>Diet, Exercise and Vitamin D in Breast Cancer Recurrence</td>
						<td>Breast</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>144</td>
						<td>NCT03078855</td>
						<td>A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma</td>
						<td>Lymphoma</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>147</td>
						<td>NCT04839731</td>
						<td>Combination 5-FU / Calcipotriene Cream for SCCIS/SCC</td>
						<td>Skin</td>
						<td>Calcipotriol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>148</td>
						<td>NCT02553447</td>
						<td>Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency</td>
						<td>Lymphoma; Leukemia</td>
						<td>Cholecalciferol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>149</td>
						<td>NCT03467789</td>
						<td>Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma</td>
						<td>Skin</td>
						<td>Calcipotriol; Calcitriol; Cholecalciferol; Paricalcitol</td>
						<td>Other</td>
					</tr><tr>
						<td>150</td>
						<td>NCT04442412</td>
						<td>Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy</td>
						<td>Lymphoma</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>151</td>
						<td>NCT04073680</td>
						<td>A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Canagliflozin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>152</td>
						<td>NCT02944201</td>
						<td>Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate</td>
						<td>Urological</td>
						<td>Carvedilol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>154</td>
						<td>NCT02885974</td>
						<td>Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer</td>
						<td>Urological</td>
						<td>Celecoxib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>155</td>
						<td>NCT03645187</td>
						<td>Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>156</td>
						<td>NCT03498326</td>
						<td>Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>157</td>
						<td>NCT03864575</td>
						<td>An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced    Cold    Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>158</td>
						<td>NCT01150045</td>
						<td>Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>159</td>
						<td>NCT03896113</td>
						<td>Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma</td>
						<td>Gynaecological</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>161</td>
						<td>NCT03926338</td>
						<td>Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>162</td>
						<td>NCT02574728</td>
						<td>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</td>
						<td>Multiple cancer types</td>
						<td>Celecoxib; Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>164</td>
						<td>NCT04162873</td>
						<td>Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>165</td>
						<td>NCT01881048</td>
						<td>Window of Opportunity Study Targeting the Inflammatory Milieu</td>
						<td>Breast</td>
						<td>Celecoxib; Omega 3</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>166</td>
						<td>NCT03026140</td>
						<td>Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>167</td>
						<td>NCT04469530</td>
						<td>Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Celecoxib; Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>168</td>
						<td>NCT04348747</td>
						<td>Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer</td>
						<td>Breast</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>170</td>
						<td>NCT00268476</td>
						<td>Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy</td>
						<td>Urological</td>
						<td>Celecoxib; Metformin; Zoledronic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>172</td>
						<td>NCT04093323</td>
						<td>Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma</td>
						<td>Skin</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>175</td>
						<td>NCT02030964</td>
						<td>N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan</td>
						<td>Other</td>
						<td>Celecoxib; Eflornithine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>178</td>
						<td>NCT01356290</td>
						<td>Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT</td>
						<td>CNS</td>
						<td>Celecoxib; Fenofibrate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>179</td>
						<td>NCT04397679</td>
						<td>Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma</td>
						<td>CNS</td>
						<td>Chloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>181</td>
						<td>NCT04772846</td>
						<td>Chloroquine for Glioblastoma.</td>
						<td>CNS</td>
						<td>Chloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>182</td>
						<td>NCT04224441</td>
						<td>Repurposing Chlorpromazine in the Treatment of Glioblastoma</td>
						<td>CNS</td>
						<td>Chlorpromazine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>184</td>
						<td>NCT04523987</td>
						<td>A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.</td>
						<td>GI</td>
						<td>Ciprofloxacin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>185</td>
						<td>NCT02387203</td>
						<td>Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin</td>
						<td>GI</td>
						<td>Clarithromycin; Lansoprazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>186</td>
						<td>NCT04063189</td>
						<td>Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>188</td>
						<td>NCT01745588</td>
						<td>Autologous Stem Cell Transplant With Pomalidomide (CC-4047 ) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>189</td>
						<td>NCT02542657</td>
						<td>Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>190</td>
						<td>NCT04287660</td>
						<td>Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>192</td>
						<td>NCT01559935</td>
						<td>Carfilzomib, Clarithromycin (Biaxin ), Lenalidomide (Revlimid ), and Dexamethasone (Decadron ) [Car-BiRD] Therapy for Subjects With Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>193</td>
						<td>NCT02575144</td>
						<td>GEM-CLARIDEX: Ld vs BiRd</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>194</td>
						<td>NCT02343042</td>
						<td>Selinexor and Backbone Treatments of Multiple Myeloma Patients</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>196</td>
						<td>NCT03031483</td>
						<td>Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma</td>
						<td>Lymphoma</td>
						<td>Clarithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>199</td>
						<td>NCT03294486</td>
						<td>Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients</td>
						<td>CNS</td>
						<td>Flucytosine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>201</td>
						<td>NCT04736589</td>
						<td>Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway</td>
						<td>Breast</td>
						<td>Sirolimus</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>202</td>
						<td>NCT02749513</td>
						<td>Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients</td>
						<td>GI</td>
						<td>Itraconazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>203</td>
						<td>NCT00859781</td>
						<td>177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer</td>
						<td>Urological</td>
						<td>Ketoconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>204</td>
						<td>NCT03662412</td>
						<td>Study of Sirolimus in Patients With Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Sirolimus</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>205</td>
						<td>NCT03099356</td>
						<td>Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer</td>
						<td>Endocrine</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>206</td>
						<td>NCT03458221</td>
						<td>Signal TrAnsduction Pathway Activity Analysis in OVarian cancER</td>
						<td>Gynaecological</td>
						<td>Itraconazole</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>208</td>
						<td>NCT04481100</td>
						<td>CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer</td>
						<td>GI</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>210</td>
						<td>NCT03217669</td>
						<td>Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy</td>
						<td>Multiple cancer types; Lung</td>
						<td>Sirolimus</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>211</td>
						<td>NCT02584647</td>
						<td>PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Sirolimus</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>213</td>
						<td>NCT02446431</td>
						<td>Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence</td>
						<td>Bone Sarcoma; Soft Tissue Sarcoma</td>
						<td>Valproic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>215</td>
						<td>NCT04018872</td>
						<td>Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer</td>
						<td>GI</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>216</td>
						<td>NCT01552434</td>
						<td>Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease</td>
						<td>Multiple cancer types</td>
						<td>Valproic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>217</td>
						<td>NCT03763396</td>
						<td>Azoles Targeting Recurrent High Grade Gliomas</td>
						<td>CNS</td>
						<td>Ketoconazole; Posaconazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>218</td>
						<td>NCT04771130</td>
						<td>A Study of BGB-11417 in Participants With Myeloid Malignancies</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Posaconazole</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>220</td>
						<td>NCT04813653</td>
						<td>Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells</td>
						<td>Other Haem-onc</td>
						<td>Cyclosporine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>221</td>
						<td>NCT03778996</td>
						<td>SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma</td>
						<td>Bone Sarcoma; Soft Tissue Sarcoma</td>
						<td>Phenytoin; Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>226</td>
						<td>NCT01869114</td>
						<td>Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy</td>
						<td>Leukemia</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>227</td>
						<td>NCT04264260</td>
						<td>Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment</td>
						<td>GI</td>
						<td>Colchicine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>228</td>
						<td>NCT03652467</td>
						<td>The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Deferoxamine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>229</td>
						<td>NCT04113005</td>
						<td>Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Desmopressin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>230</td>
						<td>NCT03889795</td>
						<td>Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Digoxin; Metformin; Simvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>231</td>
						<td>NCT04141995</td>
						<td>FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Digoxin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>233</td>
						<td>NCT03323346</td>
						<td>Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer</td>
						<td>Breast</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>234</td>
						<td>NCT04265274</td>
						<td>Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.</td>
						<td>Breast</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>235</td>
						<td>NCT02671890</td>
						<td>Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer</td>
						<td>Multiple cancer types; GI</td>
						<td>Disulfiram</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>237</td>
						<td>NCT03950830</td>
						<td>Disulfiram and Cisplatin in Refractory TGCTs.</td>
						<td>Urological</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>238</td>
						<td>NCT03363659</td>
						<td>Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme</td>
						<td>CNS</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>239</td>
						<td>NCT02715609</td>
						<td>Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma</td>
						<td>CNS</td>
						<td>Disulfiram</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>240</td>
						<td>NCT02874430</td>
						<td>Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer</td>
						<td>Breast; Gynaecological</td>
						<td>Doxycycline; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>241</td>
						<td>NCT03076281</td>
						<td>Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery</td>
						<td>Head and Neck</td>
						<td>Doxycycline; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>242</td>
						<td>NCT01820910</td>
						<td>Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment</td>
						<td>Lymphoma</td>
						<td>Doxycycline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>243</td>
						<td>NCT03116659</td>
						<td>CTCL Directed Therapy</td>
						<td>Lymphoma</td>
						<td>Doxycycline</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>244</td>
						<td>NCT01653925</td>
						<td>Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression</td>
						<td>Urological</td>
						<td>Dutasteride</td>
						<td>Other</td>
					</tr><tr>
						<td>246</td>
						<td>NCT01342367</td>
						<td>Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer</td>
						<td>Urological</td>
						<td>Dutasteride; Finasteride</td>
						<td>Other</td>
					</tr><tr>
						<td>251</td>
						<td>NCT02679144</td>
						<td>Neuroblastoma Maintenance Therapy Trial</td>
						<td>Other</td>
						<td>Eflornithine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>256</td>
						<td>NCT03603795</td>
						<td>Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy</td>
						<td>Leukemia</td>
						<td>Eltrombopag</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>257</td>
						<td>NCT03838029</td>
						<td>Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery</td>
						<td>GI</td>
						<td>Etodolac; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>258</td>
						<td>NCT03919461</td>
						<td>Colorectal Metastasis Prevention International Trial 2</td>
						<td>GI</td>
						<td>Etodolac; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>259</td>
						<td>NCT03647072</td>
						<td>PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy</td>
						<td>Lymphoma</td>
						<td>Famotidine; Lansoprazole</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>260</td>
						<td>NCT04049747</td>
						<td>Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer</td>
						<td>Urological</td>
						<td>Finasteride</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>261</td>
						<td>NCT04226066</td>
						<td>Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Flucytosine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>263</td>
						<td>NCT04011410</td>
						<td>Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer</td>
						<td>Urological</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>264</td>
						<td>NCT01494155</td>
						<td>Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>265</td>
						<td>NCT03037437</td>
						<td>Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>266</td>
						<td>NCT04523857</td>
						<td>ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer</td>
						<td>Breast</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>267</td>
						<td>NCT04735068</td>
						<td>Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>268</td>
						<td>NCT04132505</td>
						<td>Binimetinib and Hydroxychloroquine in Treating Patients with KRAS Mutant Metastatic Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>271</td>
						<td>NCT04841148</td>
						<td>Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer</td>
						<td>Breast</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>273</td>
						<td>NCT04214418</td>
						<td>Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies</td>
						<td>Multiple cancer types; GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>276</td>
						<td>NCT04524702</td>
						<td>Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine; Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>277</td>
						<td>NCT03825289</td>
						<td>Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>278</td>
						<td>NCT01480154</td>
						<td>Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer</td>
						<td>Multiple cancer types; Urological; Skin</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>284</td>
						<td>NCT00977470</td>
						<td>Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations</td>
						<td>Lung</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>288</td>
						<td>NCT04669197</td>
						<td>Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>290</td>
						<td>NCT04787991</td>
						<td>Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>291</td>
						<td>NCT03598595</td>
						<td>Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>292</td>
						<td>NCT04464759</td>
						<td>A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma</td>
						<td>Skin</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>293</td>
						<td>NCT03754179</td>
						<td>Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma</td>
						<td>Skin</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>295</td>
						<td>NCT04201457</td>
						<td>A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration</td>
						<td>CNS</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>296</td>
						<td>NCT03979651</td>
						<td>MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma</td>
						<td>Skin</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>298</td>
						<td>NCT04863950</td>
						<td>Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Imipramine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>299</td>
						<td>NCT02935205</td>
						<td>Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Indomethacin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>300</td>
						<td>NCT02950259</td>
						<td>Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)</td>
						<td>Breast</td>
						<td>Indomethacin; Omeprazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>304</td>
						<td>NCT04495894</td>
						<td>Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma</td>
						<td>Urological; Lung</td>
						<td>Ketorolac</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>307</td>
						<td>NCT03709446</td>
						<td>Leflunomide in Previously Treated Metastatic Triple Negative Cancers</td>
						<td>Breast</td>
						<td>Leflunomide</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>309</td>
						<td>NCT04508790</td>
						<td>Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Leflunomide</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>310</td>
						<td>NCT03940378</td>
						<td>Treatment of Advanced Intrahepatic Cholangiocarcinoma</td>
						<td>GI</td>
						<td>Levamisole</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>311</td>
						<td>NCT02815410</td>
						<td>Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients</td>
						<td>CNS</td>
						<td>Levetiracetam</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>313</td>
						<td>NCT01686126</td>
						<td>Improving the Treatment for Women With Early Stage Cancer of the Uterus</td>
						<td>Gynaecological</td>
						<td>Levonorgestrel; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>314</td>
						<td>NCT04634539</td>
						<td>Trial of First-line L-glutamine with Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>L-Glutamine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>315</td>
						<td>NCT04710290</td>
						<td>A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers</td>
						<td>Multiple cancer types</td>
						<td>L-Glutamine</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>316</td>
						<td>NCT04449289</td>
						<td>Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>317</td>
						<td>NCT04162535</td>
						<td>Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>318</td>
						<td>NCT04316013</td>
						<td>Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial</td>
						<td>GI; Lung</td>
						<td>Lidocaine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>319</td>
						<td>NCT03134430</td>
						<td>Effects of Regional Nerve Block on Cancer Recurrence</td>
						<td>Multiple cancer types</td>
						<td>Lidocaine</td>
						<td>Other</td>
					</tr><tr>
						<td>321</td>
						<td>NCT01042379</td>
						<td>I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>322</td>
						<td>NCT03153280</td>
						<td>Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer</td>
						<td>GI</td>
						<td>Lithium</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>323</td>
						<td>NCT01669369</td>
						<td>Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Lithium</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>324</td>
						<td>NCT03563248</td>
						<td>Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>325</td>
						<td>NCT01821729</td>
						<td>Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>326</td>
						<td>NCT04106856</td>
						<td>Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>327</td>
						<td>NCT03900793</td>
						<td>Losartan + Sunitinib in Treatment of Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Losartan</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>329</td>
						<td>NCT03925662</td>
						<td>Mebendazole as Adjuvant Treatment for Colon Cancer</td>
						<td>GI</td>
						<td>Mebendazole</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>331</td>
						<td>NCT04443049</td>
						<td>To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.</td>
						<td>GI</td>
						<td>Mebendazole</td>
						<td>Other</td>
					</tr><tr>
						<td>333</td>
						<td>NCT02429570</td>
						<td>Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary</td>
						<td>CNS</td>
						<td>Meclofenamate</td>
						<td>Other</td>
					</tr><tr>
						<td>334</td>
						<td>NCT01430351</td>
						<td>Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy</td>
						<td>CNS</td>
						<td>Mefloquine; Memantine; Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>336</td>
						<td>NCT03024580</td>
						<td>A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer</td>
						<td>Breast</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>337</td>
						<td>NCT04046185</td>
						<td>Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>338</td>
						<td>NCT04491643</td>
						<td>Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate; Rosuvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>339</td>
						<td>NCT02506777</td>
						<td>Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.</td>
						<td>Breast</td>
						<td>Melatonin; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>340</td>
						<td>NCT02506790</td>
						<td>Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer</td>
						<td>Breast</td>
						<td>Melatonin; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>341</td>
						<td>NCT04530097</td>
						<td>Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC</td>
						<td>Lung</td>
						<td>Melatonin</td>
						<td>Other</td>
					</tr><tr>
						<td>342</td>
						<td>NCT04387630</td>
						<td>Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>343</td>
						<td>NCT04559308</td>
						<td>The Effect of Metformin on Breast Cancer Patients</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>346</td>
						<td>NCT03379909</td>
						<td>Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>348</td>
						<td>NCT02339168</td>
						<td>Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>352</td>
						<td>NCT03238495</td>
						<td>Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>353</td>
						<td>NCT04248998</td>
						<td>Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>355</td>
						<td>NCT04275713</td>
						<td>Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>356</td>
						<td>NCT02614339</td>
						<td>Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>358</td>
						<td>NCT01864096</td>
						<td>The Metformin Active Surveillance Trial (MAST) Study</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>360</td>
						<td>NCT03874000</td>
						<td>Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>364</td>
						<td>NCT03048500</td>
						<td>Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>365</td>
						<td>NCT02336087</td>
						<td>Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>366</td>
						<td>NCT04536805</td>
						<td>Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>367</td>
						<td>NCT03994744</td>
						<td>Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>368</td>
						<td>NCT04414540</td>
						<td>Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>370</td>
						<td>NCT01797523</td>
						<td>A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>371</td>
						<td>NCT02365597</td>
						<td>An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer</td>
						<td>Urological</td>
						<td>Metformin; Midazolam</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>373</td>
						<td>NCT02065687</td>
						<td>Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>375</td>
						<td>NCT02186847</td>
						<td>Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>376</td>
						<td>NCT04114136</td>
						<td>Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies</td>
						<td>Multiple cancer types</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>377</td>
						<td>NCT03311308</td>
						<td>A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma</td>
						<td>Skin</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>380</td>
						<td>NCT04758000</td>
						<td>Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse</td>
						<td>Bone Sarcoma</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>381</td>
						<td>NCT02780024</td>
						<td>Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>383</td>
						<td>NCT04691960</td>
						<td>A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>384</td>
						<td>NCT01750567</td>
						<td>A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL</td>
						<td>Leukemia</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>385</td>
						<td>NCT03600363</td>
						<td>A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients</td>
						<td>Lymphoma</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>386</td>
						<td>NCT04264676</td>
						<td>Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>389</td>
						<td>NCT03225547</td>
						<td>Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer</td>
						<td>Breast</td>
						<td>Mifepristone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>390</td>
						<td>NCT02788981</td>
						<td>Abraxane  With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Miltefosine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>392</td>
						<td>NCT04477200</td>
						<td>Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma</td>
						<td>CNS</td>
						<td>Mycophenolate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>393</td>
						<td>NCT04169763</td>
						<td>Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery</td>
						<td>Gynaecological</td>
						<td>Nelfinavir</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>395</td>
						<td>NCT03256916</td>
						<td>Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix</td>
						<td>Gynaecological</td>
						<td>Nelfinavir</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>400</td>
						<td>NCT02807805</td>
						<td>Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Niclosamide</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>401</td>
						<td>NCT02416739</td>
						<td>Anticancer Activity of Nicotinamide on Lung Cancer</td>
						<td>Lung</td>
						<td>Nicotinamide</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>402</td>
						<td>NCT04844528</td>
						<td>Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)</td>
						<td>Leukemia</td>
						<td>Nicotinamide</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>403</td>
						<td>NCT04677049</td>
						<td>Study of Niacin in Glioblastoma</td>
						<td>CNS</td>
						<td>Nicotinamide</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>405</td>
						<td>NCT04564521</td>
						<td>Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.</td>
						<td>Ocular</td>
						<td>Nitroglycerin</td>
						<td>Other</td>
					</tr><tr>
						<td>406</td>
						<td>NCT02295059</td>
						<td>Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention</td>
						<td>Breast</td>
						<td>Omega 3</td>
						<td>Other</td>
					</tr><tr>
						<td>407</td>
						<td>NCT03831178</td>
						<td>Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting</td>
						<td>Breast</td>
						<td>Omega 3</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>408</td>
						<td>NCT03516253</td>
						<td>Fish Oil and EPO in Breast Cancer</td>
						<td>Breast</td>
						<td>Omega 3</td>
						<td>Other</td>
					</tr><tr>
						<td>409</td>
						<td>NCT04664816</td>
						<td>Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer</td>
						<td>Urological</td>
						<td>Omega 3</td>
						<td>Other</td>
					</tr><tr>
						<td>410</td>
						<td>NCT04175769</td>
						<td>EPA+DHA for Non-small Cell Lung Cancer Patients.</td>
						<td>Lung</td>
						<td>Omega 3</td>
						<td>Other</td>
					</tr><tr>
						<td>411</td>
						<td>NCT02176902</td>
						<td>Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer</td>
						<td>Urological</td>
						<td>Omega 3</td>
						<td>Other</td>
					</tr><tr>
						<td>412</td>
						<td>NCT03428477</td>
						<td>EPA for Metastasis Trial 2</td>
						<td>GI</td>
						<td>Omega 3</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>413</td>
						<td>NCT03753334</td>
						<td>Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.</td>
						<td>Urological</td>
						<td>Omega 3</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>414</td>
						<td>NCT02333435</td>
						<td>Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life</td>
						<td>Urological</td>
						<td>Omega 3</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>416</td>
						<td>NCT04337580</td>
						<td>Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer</td>
						<td>Urological</td>
						<td>Omeprazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>417</td>
						<td>NCT03520790</td>
						<td>Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>419</td>
						<td>NCT04617067</td>
						<td>Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>422</td>
						<td>NCT04054362</td>
						<td>Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>423</td>
						<td>NCT03415854</td>
						<td>Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>424</td>
						<td>NCT01871454</td>
						<td>Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers</td>
						<td>Lung</td>
						<td>Pentoxifylline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>426</td>
						<td>NCT04794127</td>
						<td>Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Pioglitazone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>427</td>
						<td>NCT02889003</td>
						<td>Second STOP After Pioglitazone Priming in CML Patients</td>
						<td>Leukemia</td>
						<td>Pioglitazone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>428</td>
						<td>NCT03177291</td>
						<td>Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC</td>
						<td>Lung</td>
						<td>Pirfenidone</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>429</td>
						<td>NCT04467723</td>
						<td>Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC</td>
						<td>Lung</td>
						<td>Pirfenidone</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>431</td>
						<td>NCT03746080</td>
						<td>Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma</td>
						<td>CNS</td>
						<td>Plerixafor</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>435</td>
						<td>NCT04475705</td>
						<td>Propofol vs Sevo for Paediatric Tumor Surgery</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>436</td>
						<td>NCT03447691</td>
						<td>Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>437</td>
						<td>NCT04259398</td>
						<td>Anesthesia and Cancer Study: Colon Cancer</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>438</td>
						<td>NCT03034096</td>
						<td>General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>439</td>
						<td>NCT04800393</td>
						<td>The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.</td>
						<td>Breast</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>441</td>
						<td>NCT04513808</td>
						<td>Total Intravenous Anesthesia and Recurrence Free Survival</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>442</td>
						<td>NCT04601961</td>
						<td>Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>444</td>
						<td>NCT04503148</td>
						<td>Anesthesia and Cancer Study: Renal Cell Carcinoma</td>
						<td>Urological</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>445</td>
						<td>NCT04005365</td>
						<td>Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>446</td>
						<td>NCT04493489</td>
						<td>Propranolol Adjuvant Treatment of Bladder Cancer</td>
						<td>Urological</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>448</td>
						<td>NCT03384836</td>
						<td>Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery</td>
						<td>Skin</td>
						<td>Propranolol</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>449</td>
						<td>NCT04682158</td>
						<td>Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>450</td>
						<td>NCT03108300</td>
						<td>Use of Propranolol Hydrochloride in the Treatment of Metastatic STS</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>452</td>
						<td>NCT02962947</td>
						<td>MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients</td>
						<td>Skin</td>
						<td>Propranolol</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>460</td>
						<td>NCT04761614</td>
						<td>Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Riluzole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>461</td>
						<td>NCT01303341</td>
						<td>Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma</td>
						<td>Skin; Multiple cancer types</td>
						<td>Riluzole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>465</td>
						<td>NCT03324425</td>
						<td>Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer</td>
						<td>Breast</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>466</td>
						<td>NCT03086291</td>
						<td>A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>467</td>
						<td>NCT04457089</td>
						<td>Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Simvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>468</td>
						<td>NCT04698941</td>
						<td>Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy</td>
						<td>Lung</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>469</td>
						<td>NCT02161822</td>
						<td>Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>471</td>
						<td>NCT01441349</td>
						<td>Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>474</td>
						<td>NCT03993353</td>
						<td>Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer</td>
						<td>Head and Neck</td>
						<td>Tadalafil</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>476</td>
						<td>NCT03962920</td>
						<td>Personalized Treatment of Urogenital Cancers Depends on the Microbiome</td>
						<td>Multiple cancer types</td>
						<td>Tigecycline</td>
						<td>Other</td>
					</tr><tr>
						<td>477</td>
						<td>NCT04691817</td>
						<td>Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy</td>
						<td>Lung</td>
						<td>Tocilizumab</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>481</td>
						<td>NCT03821246</td>
						<td>Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy</td>
						<td>Urological</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>482</td>
						<td>NCT04524871</td>
						<td>A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)</td>
						<td>GI</td>
						<td>Tocilizumab</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>483</td>
						<td>NCT03708224</td>
						<td>Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck</td>
						<td>Multiple cancer types</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>484</td>
						<td>NCT04554771</td>
						<td>Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy</td>
						<td>GI</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>485</td>
						<td>NCT03193190</td>
						<td>A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)</td>
						<td>GI</td>
						<td>Tocilizumab</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>486</td>
						<td>NCT03869190</td>
						<td>Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)</td>
						<td>Urological</td>
						<td>Tocilizumab</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>488</td>
						<td>NCT03999749</td>
						<td>A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma</td>
						<td>Skin</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>489</td>
						<td>NCT03598959</td>
						<td>Tofacitinib Combined With Chidamide in R/R ENKTCL</td>
						<td>Lymphoma</td>
						<td>Tofacitinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>490</td>
						<td>NCT02717884</td>
						<td>Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Tranylcypromine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>491</td>
						<td>NCT00873275</td>
						<td>Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer</td>
						<td>GI</td>
						<td>Ursodeoxycholic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>493</td>
						<td>NCT04116411</td>
						<td>A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients</td>
						<td>CNS</td>
						<td>Valganciclovir</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>494</td>
						<td>NCT04310176</td>
						<td>Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>495</td>
						<td>NCT01898104</td>
						<td>Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer</td>
						<td>GI</td>
						<td>Valproic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>496</td>
						<td>NCT03919292</td>
						<td>Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca</td>
						<td>Multiple cancer types</td>
						<td>Valproic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>497</td>
						<td>NCT03357757</td>
						<td>Avelumab With Valproic Acid in Virus-associated Cancer</td>
						<td>Multiple cancer types</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>498</td>
						<td>NCT04729543</td>
						<td>MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer</td>
						<td>Skin; Head and Neck</td>
						<td>Valproic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>499</td>
						<td>NCT02068586</td>
						<td>Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma</td>
						<td>Skin</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>500</td>
						<td>NCT03243461</td>
						<td>International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)</td>
						<td>CNS</td>
						<td>Valproic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>501</td>
						<td>NCT02124174</td>
						<td>Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>502</td>
						<td>NCT02265770</td>
						<td>An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma</td>
						<td>CNS</td>
						<td>Valproic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>504</td>
						<td>NCT04590664</td>
						<td>Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma</td>
						<td>CNS</td>
						<td>Verteporfin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>505</td>
						<td>NCT03664687</td>
						<td>Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>506</td>
						<td>NCT02595138</td>
						<td>Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>507</td>
						<td>NCT03073785</td>
						<td>Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer</td>
						<td>Urological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>508</td>
						<td>NCT03932071</td>
						<td>Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Zoledronic Acid</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>509</td>
						<td>NCT03173976</td>
						<td>Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial</td>
						<td>Bone Sarcoma</td>
						<td>Zoledronic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>510</td>
						<td>NCT00470223</td>
						<td>Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>514</td>
						<td>2017-003028-59</td>
						<td>Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study</td>
						<td>Endocrine</td>
						<td>Anakinra</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>515</td>
						<td>2019-004074-25</td>
						<td>A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer</td>
						<td>Breast</td>
						<td>Ascorbic acid; Azithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>517</td>
						<td>2020-003152-33</td>
						<td>A phase II trial of long-term intravenous treatment with bi-weekly Azithromycin in patients with gastric lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma)</td>
						<td>Lymphoma</td>
						<td>Azithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>518</td>
						<td>2009-017137-22</td>
						<td>Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study.</td>
						<td>Lung; GI</td>
						<td>Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>519</td>
						<td>2017-000695-28</td>
						<td>Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.</td>
						<td>Urological</td>
						<td>Cholecalciferol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>520</td>
						<td>2019-000572-41</td>
						<td>An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced  laquo; cold  raquo; solid tumors</td>
						<td>Skin; Lung; Urological; Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>524</td>
						<td>2005-000717-35</td>
						<td>COX-2-h auml;mmare och kemoterapi vid avancerad icke sm aring;cellig lungcancer.  En prospektiv randomiserad dubbel-blind studie.  Key elements: CYclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival (CYCLUS-studien)</td>
						<td>Lung</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>525</td>
						<td>2006-004478-29</td>
						<td>DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PHARMACOGENETIC EVALUATIONS</td>
						<td>Urological</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>526</td>
						<td>2009-014772-22</td>
						<td>Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.</td>
						<td>Lung</td>
						<td>Chloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>527</td>
						<td>2013-004705-59</td>
						<td>Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed by temozolomide) for newly diagnosed glioblastoma patients compared to the standard of care published in the literature</td>
						<td>CNS</td>
						<td>Citalopram</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>529</td>
						<td>2019-002748-25</td>
						<td>Repurposing disulfiram as treatment for metastatic colorectal cancer  An investigator initiated clinical phase II trial</td>
						<td>GI</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>530</td>
						<td>2019-001972-12</td>
						<td>A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer</td>
						<td>Multiple cancer types; Breast</td>
						<td>Disulfiram</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>531</td>
						<td>2019-000558-68</td>
						<td>Phase II study of disulfiram and cisplatin in refractory testicular germ cell cancer.</td>
						<td>Urological</td>
						<td>Disulfiram</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>532</td>
						<td>2019-004259-35</td>
						<td>Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancer</td>
						<td>Urological</td>
						<td>Ebastine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>534</td>
						<td>2018-004091-35</td>
						<td>Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients</td>
						<td>Endocrine</td>
						<td>Hydralazine; Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>535</td>
						<td>2011-004903-20</td>
						<td>Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial</td>
						<td>Lung</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>536</td>
						<td>2011-006350-87</td>
						<td>HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>538</td>
						<td>2010-021962-31</td>
						<td>KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC)</td>
						<td>Urological</td>
						<td>Ketoconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>540</td>
						<td>2014-001523-69</td>
						<td>Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck</td>
						<td>Head and Neck</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>541</td>
						<td>2014-004194-16</td>
						<td>A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>542</td>
						<td>2009-016932-11</td>
						<td>Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer.</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>543</td>
						<td>2011-003154-12</td>
						<td>Circulating Tumor Cells in Patients with Castration Resistant Metastatic Prostate Cancer Undergoing Zoledronate Therapy</td>
						<td>Urological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>544</td>
						<td>2006-000426-31</td>
						<td>STUDIO DI FASE I DELLA COMBINAZIONE FARMACOLOGICA TRA ACIDO ZOLEDRONICO E DOCETAXEL IN PAZIENTI CON CARCINOMA PROSTATICO METASTATICO ORMONO - REFRATTARIO</td>
						<td>Urological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>545</td>
						<td>2013-001188-22</td>
						<td>Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant</td>
						<td>Other Haem-onc</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>546</td>
						<td>2019-004207-13</td>
						<td>Tocotrienol and Bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial</td>
						<td>GI</td>
						<td>Acetaminophen</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>547</td>
						<td>2012-002107-17</td>
						<td>International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours</td>
						<td>Bone Sarcoma</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>550</td>
						<td>2018-004119-36</td>
						<td>Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>552</td>
						<td>2014-000349-59</td>
						<td>METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>554</td>
						<td>2014-005193-11</td>
						<td>METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>556</td>
						<td>2006-006236-22</td>
						<td>Use of Metformin to reduce serum level of Testosterone and improve the metabolic picture in women treated for breast cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>557</td>
						<td>2009-017716-32</td>
						<td>A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>559</td>
						<td>2009-014662-26</td>
						<td>Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients.</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>560</td>
						<td>2014-002602-20</td>
						<td>CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER.</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>561</td>
						<td>2011-004683-30</td>
						<td>A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>562</td>
						<td>2011-000490-30</td>
						<td>Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary breast cancer.</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>563</td>
						<td>2018-004385-34</td>
						<td>Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD) randomised clinical trial.</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid; Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>564</td>
						<td>2007-002608-16</td>
						<td>A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVALT-8B</td>
						<td>Lung</td>
						<td>Nadroparin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>565</td>
						<td>2010-022104-50</td>
						<td>A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT12</td>
						<td>Lung</td>
						<td>Nitroglycerin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>566</td>
						<td>2009-009114-40</td>
						<td>Impact de la technique anesth eacute;sique et analg eacute;sique sur le risque de r eacute;cidive biologique de cancer de la prostate</td>
						<td>Urological</td>
						<td>Propofol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>567</td>
						<td>2013-001096-20</td>
						<td>ASSOCIATION BETWEEN PROTON-PUMP INHIBITORS (PPI) and METRONOMIC CAPECITABINE (mCAP) AS SALVAGE TREATMENT FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL TUMOURS: A RANDOMIZED PHASE II STUDY</td>
						<td>GI</td>
						<td>Rabeprazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>568</td>
						<td>2007-001179-13</td>
						<td>Neo-adjuvant Simvastatin therapy in colorectal cancer</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>569</td>
						<td>2009-014452-30</td>
						<td>Safety and efficacy of the addition of simvastatin to panitumumab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage design.</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>570</td>
						<td>2010-018491-24</td>
						<td>Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells</td>
						<td>Multiple cancer types</td>
						<td>Simvastatin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>571</td>
						<td>2012-001106-26</td>
						<td>PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA</td>
						<td>Bone Sarcoma</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>572</td>
						<td>2011-004062-15</td>
						<td>Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma</td>
						<td>Other</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>576</td>
						<td>2017-004634-28</td>
						<td>A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC)</td>
						<td>Urological</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>578</td>
						<td>CTRI/2020/06/026240</td>
						<td>Effects of Mebendazole to Lenvatinib (drug) in liver cancer</td>
						<td>GI</td>
						<td>Mebendazole</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>579</td>
						<td>JPRN-jRCT2031190065</td>
						<td>Investigator initiated registrational trial of Metformin for atypical endometrial hyperplasia and endometrial carcinoma</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>580</td>
						<td>TCTR20190701001</td>
						<td>Phase II, Multi-Center, Open-Label, Single-Arm Study Evaluating the Efficacy and Safety of Mycophenolate Mofetil in Patients with High-Grade Locally Advanced or Metastatic Osteosarcoma (ESMMO)</td>
						<td>Bone Sarcoma</td>
						<td>Mycophenolate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>581</td>
						<td>JPRN-jRCTs051190076</td>
						<td>Neo-adjuvant combination  chemotherapy of Tranilast in esophageal carcinoma</td>
						<td>GI</td>
						<td>Tranilast</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>582</td>
						<td>DRKS00014054</td>
						<td>Pancreatic resection with perioperative off-Label study of Propranolol and Etodolac - A Phase II randomized Trial</td>
						<td>GI</td>
						<td>Etodolac; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>583</td>
						<td>CTRI/2018/11/016459</td>
						<td>Role of lipid lowering drug in the treatment of rectal cancers</td>
						<td>GI</td>
						<td>Rosuvastatin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>584</td>
						<td>CTRI/2020/09/028095</td>
						<td>Increasing the local pH during  chemoembolization  for hepatocellular carcinoma</td>
						<td>GI</td>
						<td>Sodium Bicarbonate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>585</td>
						<td>CTRI/2016/09/007315</td>
						<td>The study of oral chemotherapy in locally advanced head and neck cancer post radical chemoradiation</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>587</td>
						<td>ACTRN12619000310167</td>
						<td>Vitamin C for endometrial cancer</td>
						<td>Gynaecological</td>
						<td>Ascorbic acid</td>
						<td>Other</td>
					</tr><tr>
						<td>589</td>
						<td>CTRI/2017/11/010651</td>
						<td>standard chemotherapy plus aspirin vs standard chemotherapy alone in locally advanced and metastatic stomach cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>591</td>
						<td>CTRI/2020/02/023616</td>
						<td>To study the combination of oral (Metronomic)chemotherapy along with Intravenous chemotherapy (Paclitaxel) in advanced stage head and neck cancer patients</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>592</td>
						<td>JPRN-UMIN000025398</td>
						<td>A phase 2 trial of nab-paclitaxel, oxaliplatin, S1 and itraconazole for unresectable pancreatic cancer</td>
						<td>GI</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>593</td>
						<td>NL9017</td>
						<td>Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-concept study</td>
						<td>GI</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>594</td>
						<td>ACTRN12616001350415</td>
						<td>the efficacy of histone deacetylase inhibitor valproic acid in the treatment of gliomas</td>
						<td>CNS</td>
						<td>Valproic Acid</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>595</td>
						<td>ACTRN12615000778583</td>
						<td>Investigating the effects of metformin on growth factors involved in prostate cancer progression in prostate cancer patients</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>596</td>
						<td>CTRI/2018/06/014620</td>
						<td>Safety and effectiveness study of ormeloxifene in breast cancer patients.</td>
						<td>Breast</td>
						<td>Ormeloxifene</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>597</td>
						<td>CTRI/2016/04/006872</td>
						<td>The study of small dose chemotherapy after surgery not fit for radiotherapy in recurrent head and neck cancers patients.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>599</td>
						<td>NTR3632</td>
						<td>Development and clinical activity of low dose metronomic chemotherapy with oral paclitaxel.</td>
						<td>Leukemia; Lymphoma</td>
						<td>Ritonavir</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>600</td>
						<td>ACTRN12617001087347</td>
						<td>A clinical trial comparing Simvastatin to placebo, in addition to standard chemotherapy and radiotherapy, in preoperative treatment for patients with rectal cancer.</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>601</td>
						<td>CTRI/2012/07/002828</td>
						<td>Effect of Celecoxib and Erlotinib in Oral Cancers</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>602</td>
						<td>CTRI/2019/02/017815</td>
						<td>A study of Metformin plus chemotherapy in Lung cancer</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>603</td>
						<td>NTR1456</td>
						<td>Antiviral therapy (cidofovir, an acyclic nucleoside phosphate) in combination with radiotherapy in HPV-positive tumors of the oropharynx</td>
						<td>Head and Neck</td>
						<td>Cidofovir</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>604</td>
						<td>CTRI/2018/01/011542</td>
						<td>Mebendazole in brain tumor</td>
						<td>CNS</td>
						<td>Mebendazole</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>605</td>
						<td>NTR988</td>
						<td>High dose simvastatin combined with standard chemotherapy in patients with refractory Multiple Myeloma: a phase II study.</td>
						<td>Other Haem-onc</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>606</td>
						<td>PACTR201602001488346</td>
						<td>Effect of sodium bicarbonate 8.4  on bronchial carcinoma</td>
						<td>Lung</td>
						<td>Sodium Bicarbonate</td>
						<td>Other</td>
					</tr><tr>
						<td>607</td>
						<td>ACTRN12607000082404</td>
						<td>A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomy</td>
						<td>Urological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>608</td>
						<td>CTRI/2018/03/012810</td>
						<td>Advantages of adding Metformin to Chemotherapy in Breast Cancer Patients</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 3/4</td>
					</tr><tr>
						<td>609</td>
						<td>JPRN-jRCTs031190167</td>
						<td>Periopertive administration of flurbiprofen axetil for prevention of postoperative recurrence in patients with non-small cell lung cancer</td>
						<td>Lung</td>
						<td>Flurbiprofen</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>610</td>
						<td>ACTRN12606000079549</td>
						<td>The LoPeZ study</td>
						<td>Lung</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>611</td>
						<td>CTRI/2015/12/006454</td>
						<td>Study of effect of metformin in patients with relapsed epithelial ovarian cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>612</td>
						<td>CTRI/2015/09/006204</td>
						<td>A study of Oral chemotherapy after completion of radiation  and chemotherapy vs observation in Carcinoma esophagus.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>613</td>
						<td>ACTRN12611000301965</td>
						<td>Immunomodulatory effect of anaesthetic technique in breast cancer surgery</td>
						<td>Breast</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>614</td>
						<td>JPRN-UMIN000020681</td>
						<td>Randomized open-label phase II study of adjuvant chemotherapy of S-1 plus metformin vs. S-1 alone in patients with resected pancreatic cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>616</td>
						<td>DRKS00012360</td>
						<td>Pharmacokinetic Enhancement of Crizotinib plasmaconcentrations with Cobicistat or Itraconazole in AnaplasticLymphoma Kinase positive advanced Non-Small Cell LungCancer Patients</td>
						<td>Lung</td>
						<td>Itraconazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>617</td>
						<td>ChiCTR2000038589</td>
						<td>A multicenter, randomized, controlled clinical study of abiraterone combined with dutasteride in the treatment of castration-resistant prostate cancer</td>
						<td>Urological</td>
						<td>Dutasteride</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>618</td>
						<td>ChiCTR2000037943</td>
						<td>Metformin combined with FOLFIRI+bevacizumab in the second-line treatment of non-diabetic RAS mutant metastatic colorectal cancer: a multi-center, single-arm phase II clinical study</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>619</td>
						<td>ChiCTR2000037740</td>
						<td>A prospective study of dextromethorphan and metformin in treating patients with esophageal squamous cell carcinoma sufferering the failure of radiography and chemotherapy</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>620</td>
						<td>ChiCTR2000036618</td>
						<td>Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study</td>
						<td>Bone Sarcoma</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>621</td>
						<td>ChiCTR2000036467</td>
						<td>A prospective single center study on the safety and efficacy of TACE + lovastatinib + PD1 monoclonal antibody in trans transplantation of hepatocellular carcinoma beyond Hangzhou standard</td>
						<td>GI</td>
						<td>Lovastatin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>622</td>
						<td>ChiCTR2000035935</td>
						<td>The effect of local radical treatment on the breast cancer with bone oligometastasis</td>
						<td>Breast</td>
						<td>Ibandronic Acid</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>623</td>
						<td>ChiCTR2000035469</td>
						<td>Effect of continuous intravenous infusion of lidocaine on postoperative recovery and long-term outcomes of patients with pancreatic cancer: A prospective, randomized controlled trial</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>624</td>
						<td>IRCT20120922010901N7</td>
						<td>The effect of metformin in patients with ovarian cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>625</td>
						<td>ChiCTR2000034678</td>
						<td>Ascorbic acid (vitamin C tablets) enhances the efficacy of targeted drugs in advanced renal cell carcinoma: a multicenter randomized controlled trial</td>
						<td>Urological</td>
						<td>Ascorbic acid</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>626</td>
						<td>ChiCTR2000034398</td>
						<td>Gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody for locally advanced pancreatic cancer: a phase II, single center, single arm study</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>627</td>
						<td>ChiCTR2000034397</td>
						<td>Gemcitabine, plus nab-paclitaxel, pirfenidone for pancreatic cancer with liver metastasis: a phase II, single center, single arm study</td>
						<td>GI</td>
						<td>Pirfenidone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>628</td>
						<td>KCT0005192</td>
						<td>Identification of anti-tumor effect of propofol using microRNA profile analysis in patients undergoing lung cancer surgery</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>629</td>
						<td>ChiCTR2000034140</td>
						<td>Study on Metformin Plus Temozolomide in Patient With Recurrent Glioblastoma Multiforme</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>630</td>
						<td>ChiCTR2000034035</td>
						<td>Five-year prognosis of postmenopausal patients with hormone receptor-positive early breast cancer treated with different stains and aromatase inhibitors: a prospective, randomized controlled trial</td>
						<td>Breast</td>
						<td>Pravastatin; Simvastatin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>631</td>
						<td>IRCT20200313046756N1</td>
						<td>Vitamin D, Probiotics and Breast Cancer</td>
						<td>Breast</td>
						<td>Calcipotriol; Calcitriol; Cholecalciferol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>633</td>
						<td>KCT0004674</td>
						<td>Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>634</td>
						<td>ChiCTR2000029245</td>
						<td>The efficacy and safety of the combination of transcatheter arterial chemoembolisation with metronidazole in hepatocellular carcinoma</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Other</td>
					</tr><tr>
						<td>635</td>
						<td>ChiCTR2000028905</td>
						<td>Metformin for chemoradiotherapy prevention in advanced nasopharyngeal carcinoma patients: a double-blind, placebo-controlled, randomized clinical trial</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>636</td>
						<td>KCT0004571</td>
						<td>Phase II trial evaluating the efficacy and safety of physician chosen chemotherapy with hormonal therapy in patients with heavily pretreated advanced ovarian cancer: A multicenter pilot study</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>637</td>
						<td>IRCT20191203045594N1</td>
						<td>The effect of metformin on treatment of squamous cell carcinoma of neck</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>638</td>
						<td>ChiCTR1900026213</td>
						<td>Effect of optimized thoracic paravertebral nerve block on early and rapid recovery and long-term clinical outcome of radical lung cancer patients</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>639</td>
						<td>KCT0004236</td>
						<td>Effect of adjunctive metformin on recurrence of non-DM colorectal cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>640</td>
						<td>IRCT20190726044335N1</td>
						<td>Therapeutic effect of metformin in rectal cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>641</td>
						<td>KCT0003946</td>
						<td>The Identification of the Safety and Efficacy of Tadalafil for the Suppression of Recurrence of Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Tadalafil</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>642</td>
						<td>ChiCTR1900021896</td>
						<td>Prospective study for pd-1 inhibitor combined with liquid biopsy ctDNA detection combined with targeted drugs in the treatment of advanced unresectable liver cancer patients</td>
						<td>GI</td>
						<td>Sirolimus</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>643</td>
						<td>ChiCTR1900021641</td>
						<td>A randomized controlled trial for the effect of metformin on prognosis in patients with oral cancer</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>644</td>
						<td>ChiCTR1900021426</td>
						<td>Effects of flurbiprofen on immune function in patients under radical operation for colon carcinoma</td>
						<td>GI</td>
						<td>Flurbiprofen</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>645</td>
						<td>ChiCTR1900020701</td>
						<td>A randomized controlled trial for intra-arterial infusion chemotherapy combined with sodium bicarbonate and systemic chemotherapy for unresectable gastric cancer</td>
						<td>GI</td>
						<td>Sodium Bicarbonate</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>646</td>
						<td>ChiCTR1800020425</td>
						<td>Effects of total intravenous anesthesia and inhalation anesthesia on the prognosis of patients with endoscopic lung cancer</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>647</td>
						<td>ChiCTR1800017822</td>
						<td>A Prospective clinical trial of the efficacy and safety of zolledronic acid in the adjuvant treatment of breast malignant phyllodes tumors Adjuvant zoledronic acid in patients with breast malignant phyllodes tumors</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>648</td>
						<td>ChiCTR1800016053</td>
						<td>Effect of Ultrasound-guided thoracic paravertebral block on perioperative analgesia and tumor immune function in patients of video-assisted lung cancer surgery</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>649</td>
						<td>ChiCTR1800015808</td>
						<td>Pilot Clinical Study of Chemo-Cocktail (TTF) for Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Fasudil; Tranilast</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>650</td>
						<td>ChiCTR1800015510</td>
						<td>A single-arm exploratory trail of combination of abiraterone with dutasteride in the treatment of abiraterone resistant CRPC</td>
						<td>Urological</td>
						<td>Dutasteride</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>651</td>
						<td>IRCT20170314033080N2</td>
						<td>Effect of losartan with whole bain radiotherapy in brain metastasis</td>
						<td>Multiple cancer types</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>652</td>
						<td>ChiCTR1800014946</td>
						<td>Thalidomide, Clarithromycin and Dexamethasone Regimen for Patients With Newly Diagnosed Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Other</td>
					</tr><tr>
						<td>654</td>
						<td>ChiCTR-IPR-17013973</td>
						<td>The effect of Metformin combine with FOLFOX + Bevacizumab as the first-line therapy in metastatic colorectal cancer, a randomized, open, prospective  clinical study (BeFoLMe study)</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>655</td>
						<td>ChiCTR-IOR-17011859</td>
						<td>The Exploration of the Efficacy of Metformin Combined with First-line Chemotherapy for the Treatment of Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Other</td>
					</tr><tr>
						<td>656</td>
						<td>ChiCTR-IOR-17010695</td>
						<td>The significance of minimal residual disease exmination on the multiple myeloma maintain treatment</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Other</td>
					</tr><tr>
						<td>657</td>
						<td>IRCT2015112725256N1</td>
						<td>Effect of Metformin on Glioblastoma Multiform</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>659</td>
						<td>ChiCTR-IPR-16008553</td>
						<td>Clinical study on the anti-cancer effect of metformin in the breast cancer patients with prediabetes during neoadjuvant chemotherapy.</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>660</td>
						<td>ChiCTR-IPR-16008128</td>
						<td>Effects of two types of anesthesia maintenance on body immunity and malignant behaviours of patients after cancer surgery</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>661</td>
						<td>ChiCTR-IPR-16008078</td>
						<td>Effect of ulinastatin on clinical outcomes of patients with advanced lung cancer resection via thoracotomy</td>
						<td>Lung</td>
						<td>Ulinastatin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>662</td>
						<td>ChiCTR-IIR-16007908</td>
						<td>Zoledronate combinate with gefitinib in advanced non-small cell lung cancer with EGFR activation mutation: a multicenter, randomised controlled, phase II trial.</td>
						<td>Lung</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>663</td>
						<td>ChiCTR-IIR-16007801</td>
						<td>Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>664</td>
						<td>ChiCTR-IPR-15006066</td>
						<td>Clinical research of chemotherapy consisted of temozolomide with concomitant sodium valproate and nicardipine for Glioma</td>
						<td>CNS</td>
						<td>Nicardipine; Valproic Acid</td>
						<td>Other</td>
					</tr><tr>
						<td>665</td>
						<td>CTRI/2010/091/000441</td>
						<td>Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>666</td>
						<td>NTR1250</td>
						<td>A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small-cell lung cancer patients with high-risk for recurrence: NVALT 8B</td>
						<td>Lung</td>
						<td>Nadroparin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>669</td>
						<td>CTRI/2019/09/021263</td>
						<td>Role of affordable oral cancer drugs in advanced mouth cancer - Feasibility study.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>670</td>
						<td>CTRI/2012/07/002802</td>
						<td>Metformin in Triple Negative Operable or Locally Advanced Breast cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>671</td>
						<td>NTR2655</td>
						<td>Potential role of vitamin D treatment in breast cancer.</td>
						<td>Breast</td>
						<td>Cholecalciferol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>676</td>
						<td>JPRN-UMIN000004525</td>
						<td>The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancer</td>
						<td>GI</td>
						<td>Valproic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>677</td>
						<td>ACTRN12614000513617</td>
						<td>ASCOLT Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers.</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>679</td>
						<td>JPRN-UMIN000003493</td>
						<td>Phase II study of neoadjuvant zoledronic acid therapy for early breast cancer patients</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>680</td>
						<td>CTRI/2015/01/005405</td>
						<td>Study evaluating survival benefit of use of low dose continuous chemotherapy drugs along with surgery and radiation in treatment of advanced stage cancers of the oral cavity</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>681</td>
						<td>ACTRN12620000815965</td>
						<td>Phase II Trial of Doxycycline with Radiotherapy for Rectal Cancer</td>
						<td>GI</td>
						<td>Doxycycline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>682</td>
						<td>ACTRN12612000852853</td>
						<td>Preventing Colorectal Cancer Metastases following Surgical Removal of a Primary Tumor</td>
						<td>GI</td>
						<td>Etodolac; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>683</td>
						<td>CTRI/2018/07/014865</td>
						<td>Sorafenib and supportive medication in advanced Hepatocelluar cancer</td>
						<td>GI</td>
						<td>Atorvastatin; Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>684</td>
						<td>NL7726</td>
						<td>Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients</td>
						<td>Endocrine</td>
						<td>Hydralazine; Valproic Acid</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>685</td>
						<td>ACTRN12614000507684</td>
						<td>Pre-surgical aromatase inhibitor combined with non-steroidal anti inflammatory drug treatment in breast cancer</td>
						<td>Breast</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>686</td>
						<td>ACTRN12612000416897</td>
						<td>Sequential evaluation of tumours undergoing pre-operative therapy with aromatase inhibitors and metformin (setup-aim) a neo-adjuvant pilot study in operable hormone sensitive breast cancer in post menopausal women</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Other</td>
					</tr><tr>
						<td>688</td>
						<td>ACTRN12620000156987</td>
						<td>Trial of propranolol to assess the spread of melanoma</td>
						<td>Skin</td>
						<td>Propranolol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>689</td>
						<td>CTRI/2019/09/021213</td>
						<td>A study to evaluate the role of modified regular interval based combined oral chemotherapy that regresses tumor cell development of various forms which is indicated for the treatment of High-Risk Medulloblastoma (a type of brain tumor)</td>
						<td>CNS</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>690</td>
						<td>JPRN-UMIN000000813</td>
						<td>Phase II Study of Amrubicin and Nitroglycerin in Third-Line Chemotherapy in Previously Treated Patients with Non-Small-Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Nitroglycerin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>691</td>
						<td>JPRN-jRCTs011180011</td>
						<td>Neoadjuvant chemoradiotherapy with Metformin for locally advanced pancreatic cancer</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>693</td>
						<td>CTRI/2020/06/025818</td>
						<td>Effect of Vitamin D and turmeric  in lymphoma patients.</td>
						<td>Lymphoma</td>
						<td>Cholecalciferol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>694</td>
						<td>CTRI/2013/06/003734</td>
						<td>Low dose chemotherapy  versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies</td>
						<td>Multiple cancer types</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>695</td>
						<td>JPRN-UMIN000004852</td>
						<td>The exploratory study for the biological  effects of metformin on endometrial cancer: effect to cell cycle,  MAPK, and AMPK/mTOR signal pathway</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>697</td>
						<td>JPRN-UMIN000029402</td>
						<td>Pilot clinical study of boron neutron capture therapy on choroidal malignant melanoma</td>
						<td>Skin</td>
						<td>Lithium</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>698</td>
						<td>JPRN-UMIN000029403</td>
						<td>Pilot clinical study of boron neutron capture therapy on post-radiotherapy, recurrent breast cancer</td>
						<td>Breast</td>
						<td>Lithium</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>699</td>
						<td>JPRN-UMIN000018388</td>
						<td>Prospective Evaluation of the Molecular Effects of Itraconazoleas an anti-cancer agent: A Window of Opportunity Study</td>
						<td>Multiple cancer types</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>700</td>
						<td>JPRN-jRCTs011200001</td>
						<td>Multicenter Clinical Trial of Neoadjuvant Therapy for Locally Advanced Rectal Cancer by Chemoradiation Combined with Metformin</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>701</td>
						<td>ACTRN12613000520730</td>
						<td>The effect of adjuvant therapy with aspirin on relapse prevention of hepatocellular carcinoma after curative resection: A prospective randomized controlled trial</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>702</td>
						<td>CTRI/2020/03/023846</td>
						<td>To check safety and efficacy of Naltrexone in advanced esophageal cancer.</td>
						<td>Head and Neck</td>
						<td>Naltrexone</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>703</td>
						<td>CTRI/2018/02/011824</td>
						<td>Study of Pantoprazole in a Patients with Head   Neck Cancers</td>
						<td>Head and Neck</td>
						<td>Pantoprazole</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>705</td>
						<td>JPRN-C000000142</td>
						<td>PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancer</td>
						<td>Lung</td>
						<td>Meloxicam</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>706</td>
						<td>NL7496</td>
						<td>Phase II study of oral metformin for intravesical treatment of non- muscle-invasive bladder cancer (TROJAN)</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>707</td>
						<td>CTRI/2019/11/021924</td>
						<td>A trial comparing maintenance with low dose oral methotrexate and propranolol versus observation after standard chemotherapy in patients with relapsed high grade epithelial ovarian cancer.</td>
						<td>Gynaecological</td>
						<td>Propranolol</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>708</td>
						<td>CTRI/2012/03/002483</td>
						<td>To Evaluate the effect of Metformin versus Placebo as an Add-on Therapy in patients with recurrent epithelial ovarian cancer receiving chemotherapy: A double blind randomized controlled clinical trial.</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>709</td>
						<td>CTRI/2020/11/028953</td>
						<td>Assessment of nivolumab and metronomic aspalliative Treatment  in head and neck cancer patients</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>712</td>
						<td>CTRI/2012/12/003180</td>
						<td>A study to assess safety and effectiveness  of oral medicine   of  valproate in advanced brain tumors</td>
						<td>CNS</td>
						<td>Valproic Acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>713</td>
						<td>CTRI/2020/08/026992</td>
						<td>A study  of low intensity chemotherapy in relapsed and refractory lymphoma patients</td>
						<td>Lymphoma</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>715</td>
						<td>TCTR20171106001</td>
						<td>Immunomodulatory Effect of Vitamin D in Colon Cancer Patients: a Randomized Clinical Trial</td>
						<td>GI</td>
						<td>Calcipotriol; Calcitriol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>716</td>
						<td>JPRN-UMIN000002577</td>
						<td>Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients.</td>
						<td>Urological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>718</td>
						<td>JPRN-jRCTs071180031</td>
						<td>Newly diagnosed elderly symptomatic multiple myeloma: phase 2 study</td>
						<td>Other Haem-onc</td>
						<td>Plerixafor</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>719</td>
						<td>ACTRN12614000133639</td>
						<td>The STRICT pilot study - Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial</td>
						<td>GI</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>720</td>
						<td>CTRI/2019/09/021060</td>
						<td>Effect of addition of zoledronic acid to chemotherapy in improving the response of tumor before surgery, in women with breast cancer (triple negative subtype)</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>721</td>
						<td>CTRI/2017/08/009265</td>
						<td>Role of Nelfinavir during chemoradiation for Cervical Cancer</td>
						<td>Gynaecological</td>
						<td>Nelfinavir</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>722</td>
						<td>JPRN-UMIN000016438</td>
						<td>A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancers</td>
						<td>Gynaecological</td>
						<td>Celecoxib</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>723</td>
						<td>CTRI/2020/11/028826</td>
						<td>Effects of Anaesthesia On Immune Suppression, Inflammation AND Metastasis Of Breast Cancer.</td>
						<td>Breast</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>724</td>
						<td>CTRI/2017/02/007777</td>
						<td>Study of chemotherapy treatment after completion of standard treatment</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>725</td>
						<td>ACTRN12610000936022</td>
						<td>Vitamin D supplementation prior to surgery for colorectal cancer: a randomised pilot study.</td>
						<td>GI</td>
						<td>Calcipotriol; Calcitriol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>726</td>
						<td>ACTRN12612001050842</td>
						<td>Valproic acid and Metformin to treat patients with brain tumours</td>
						<td>CNS</td>
						<td>Metformin; Valproic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>727</td>
						<td>CTRI/2019/01/016837</td>
						<td>Comparision of two types of chemotherapy regimen in head and neck cancer</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>728</td>
						<td>ACTRN12614001054606</td>
						<td>Pilot study to evaluate the prognostic and metabolic effects of metformin during treatment of metastatic prostate cancer with androgen deprivation therapy</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>729</td>
						<td>JPRN-UMIN000002435</td>
						<td>Assessment of a combination therapy with Candesartan and Celecoxib for patients with advanced hepatocellular carcinoma after transhepatic arterial chemoembolization.</td>
						<td>GI</td>
						<td>Candesartan; Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>730</td>
						<td>ACTRN12616001021460</td>
						<td>Sodium Valproate/Metformin Combination therapy for prostate cancer</td>
						<td>Urological</td>
						<td>Metformin; Valproic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>731</td>
						<td>CTRI/2018/03/012274</td>
						<td>A clinical trial to study the effects of two drugs, Curcumin and Metformin in patients with history of head and neck squamous cell cancers</td>
						<td>Head and Neck</td>
						<td>Metformin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>732</td>
						<td>CTRI/2019/02/017394</td>
						<td>Pioglitazone study in Blood cancer</td>
						<td>Leukemia</td>
						<td>Pioglitazone</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>733</td>
						<td>JPRN-UMIN000027795</td>
						<td>The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer.</td>
						<td>Urological</td>
						<td>Dutasteride</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>734</td>
						<td>JPRN-UMIN000031532</td>
						<td>Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE III)</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>735</td>
						<td>JPRN-UMIN000003261</td>
						<td>Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant   treatment in patients with primary breast cancer</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>736</td>
						<td>ChiCTR2000038968</td>
						<td>A prospective, randomized controlled, multicenter clinical trial of indomethacin in the treatment of abiraterone-resistant castration-resistant prostate cancer</td>
						<td>Urological</td>
						<td>Indomethacin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>737</td>
						<td>ChiCTR2000039296</td>
						<td>Effects of intra-venous lidocaine in general anesthesia on postoperative inflammatory response and prognosis in patients with breast cancer</td>
						<td>Breast</td>
						<td>Lidocaine</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>738</td>
						<td>ChiCTR2000039651</td>
						<td>Effects of sevoflurane inhalation anesthesia on proliferation and apoptosis of colon cancer cells in vitro: a randomized controlled trial.</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>739</td>
						<td>JPRN-jRCTs031200326</td>
						<td>A phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma patients</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>740</td>
						<td>ChiCTR2000041072</td>
						<td>A Phase II Open-Label Randomized Controlled Clinical Trial of Pembrolizumab Plus Chemotherapy Combined With Cox-2 Inhibitor (Celecoxib) Versus Pembrolizumab Plus Chemotherapy In Advanced Non-small Cell Lung Cancer (NSCLC)</td>
						<td>Lung</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>741</td>
						<td>ACTRN12621000223831</td>
						<td>Efficacy of assigning treatment for participants with Chronic Myelomonocytic Leukaemia based on their individual molecular results (lenzilumab plus azacitidine versus sodium ascorbate plus azacitidine).</td>
						<td>Leukemia</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>742</td>
						<td>ChiCTR2000040604</td>
						<td>the effect of anaesthetic technique in patients undergoing NSCLC surgery- a multicenter study</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>743</td>
						<td>NCT03011671</td>
						<td>Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma</td>
						<td>CNS</td>
						<td>Acetazolamide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>745</td>
						<td>NCT04942626</td>
						<td>Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients</td>
						<td>GI</td>
						<td>Anakinra</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>747</td>
						<td>NCT04926467</td>
						<td>Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)</td>
						<td>GI</td>
						<td>Anakinra</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>749</td>
						<td>NCT04900792</td>
						<td>A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma</td>
						<td>CNS</td>
						<td>Ascorbic acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>750</td>
						<td>NCT03418038</td>
						<td>Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance</td>
						<td>Lymphoma</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>751</td>
						<td>NCT04677816</td>
						<td>Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients</td>
						<td>Breast</td>
						<td>Cholecalciferol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>752</td>
						<td>NCT03710876</td>
						<td>Efficacy   Safety of RAd-IFN Administered with Celecoxib   Gemcitabine in Patients with Malignant Pleural Mesothelioma</td>
						<td>Lung</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>753</td>
						<td>NCT04302324</td>
						<td>A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>757</td>
						<td>NCT02518555</td>
						<td>Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</td>
						<td>Leukemia; Lymphoma</td>
						<td>Diphtheria vaccine; Pertussis vaccine; Tetanus vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>760</td>
						<td>NCT03688178</td>
						<td>DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab</td>
						<td>CNS</td>
						<td>Diphtheria vaccine; Tetanus vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>763</td>
						<td>NCT04096911</td>
						<td>Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer</td>
						<td>Gynaecological</td>
						<td>HPV vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>764</td>
						<td>NCT04432597</td>
						<td>HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers</td>
						<td>Multiple cancer types</td>
						<td>HPV vaccine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>765</td>
						<td>NCT03848039</td>
						<td>Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9</td>
						<td>Gynaecological</td>
						<td>HPV vaccine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>766</td>
						<td>NCT04911816</td>
						<td>Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>767</td>
						<td>NCT03782415</td>
						<td>Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Ibudilast</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>769</td>
						<td>NCT04697576</td>
						<td>Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma</td>
						<td>Skin</td>
						<td>Influenza vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>770</td>
						<td>NCT02470299</td>
						<td>Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients</td>
						<td>Gynaecological</td>
						<td>Ketorolac</td>
						<td>Other</td>
					</tr><tr>
						<td>771</td>
						<td>NCT04539808</td>
						<td>NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>772</td>
						<td>NCT03671811</td>
						<td>Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>773</td>
						<td>NCT04926155</td>
						<td>The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>774</td>
						<td>NCT04925063</td>
						<td>The Effect of Metformin in Patients With Newly Diagnosed mHSPC</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>777</td>
						<td>NCT02294006</td>
						<td>Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs</td>
						<td>Endocrine</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>778</td>
						<td>NCT02823691</td>
						<td>The MetNET-2 Trial</td>
						<td>Endocrine</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>780</td>
						<td>NCT04930991</td>
						<td>High Dose Omeprazole in Patients With Pancreatic Cancer</td>
						<td>GI</td>
						<td>Omeprazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>782</td>
						<td>NCT03138720</td>
						<td>Pre-operative Treatment for Patients With Untreated Pancreatic Cancer</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>783</td>
						<td>NCT02754726</td>
						<td>Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma</td>
						<td>GI</td>
						<td>Paricalcitol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>784</td>
						<td>NCT03942328</td>
						<td>Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer</td>
						<td>GI</td>
						<td>Pneumococcal vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>785</td>
						<td>NCT01351896</td>
						<td>Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</td>
						<td>Lymphoma; Leukemia</td>
						<td>Pneumococcal vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>786</td>
						<td>NCT03035331</td>
						<td>Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma</td>
						<td>Lymphoma</td>
						<td>Pneumococcal vaccine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>787</td>
						<td>NCT04848519</td>
						<td>Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma</td>
						<td>Urological</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>792</td>
						<td>NCT04940299</td>
						<td>Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma</td>
						<td>Lung; Skin; Urological</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>793</td>
						<td>NCT04729959</td>
						<td>Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>794</td>
						<td>NCT01953900</td>
						<td>iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma</td>
						<td>Other; Soft Tissue Sarcoma</td>
						<td>Varicella vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>795</td>
						<td>2020-000725-27</td>
						<td>Intratumoral Influenza Vaccine for Early Colorectal Cancer</td>
						<td>GI</td>
						<td>Influenza vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>796</td>
						<td>2020-005088-30</td>
						<td>STOP-LEUKEMIA: A pilot study of metformin as a leukemia-preventive drug in patients with CCUS or LR-MDS</td>
						<td>Other Haem-onc</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>797</td>
						<td>JPRN-UMIN000003905</td>
						<td>Phase I/II study of Aurora-A kinase peptide vaccine against hematological malignancies in combination with Pertussis vaccine (Pelita III strain) as an adjuvant.</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Pertussis vaccine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>798</td>
						<td>ChiCTR2100042869</td>
						<td>The Efficacy and Safety of Sirolimus Early Conversion Protocol in Liver Transplant Patients with Hepatocellular Carcinoma: a Single-Arm, Multi-Center, Prospective Study</td>
						<td>GI</td>
						<td>Sirolimus</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>799</td>
						<td>IRCT20200313046756N2</td>
						<td>Evaluation of the Effect of deferasirox on the treatment of ??Acute myeloid leukemia</td>
						<td>Leukemia</td>
						<td>Deferoxamine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>800</td>
						<td>RPCEC00000367</td>
						<td>Doxycycline for prostate cancer</td>
						<td>Urological</td>
						<td>Doxycycline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>801</td>
						<td>CTRI/2021/05/033482</td>
						<td>it is a phase III trial where advanced pancreatic adenocarcinoma  patients will be randomised in 2 arms . 1 arm includes losartan given with folfirinox chemotherapy regime and the other arm includes fofirinox chemotherapy only .</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>802</td>
						<td>NCT04945148</td>
						<td>Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>803</td>
						<td>NCT04962672</td>
						<td>Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study</td>
						<td>CNS</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>804</td>
						<td>NCT04985201</td>
						<td>Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy</td>
						<td>Lung</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>805</td>
						<td>ACTRN12621000784819</td>
						<td>A preliminary study of the addition of prazosin to radiotherapy in men with prostate cancer</td>
						<td>Urological</td>
						<td>Prazosin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>806</td>
						<td>KCT0006304</td>
						<td>An Open Label, Single-Arm, Phase I Exploratory Trial to Assess the Safety and Preliminary Efficacy of mFOLFIRINOX with Hydroxychloroquine and Chlorphenesin carbamate in Patient with in Inoperable Locally Advanced or Metastatic Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>807</td>
						<td>ChiCTR2100044011</td>
						<td>Observational clinical study of anlotinib hydrochloride combined with gefitinib in first-line treatment of EGFR-sensitive mutations in advanced NSCLC</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Other</td>
					</tr><tr>
						<td>808</td>
						<td>NCT04997811</td>
						<td>Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes</td>
						<td>Other Haem-onc</td>
						<td>Bezafibrate; Danazol; Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>809</td>
						<td>NCT04997993</td>
						<td>Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies</td>
						<td>Multiple cancer types</td>
						<td>Leflunomide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>810</td>
						<td>2014-005508-62</td>
						<td>A phase II, randomized, non-comparative, pre-surgical study of atorvastatin or observation in Ki-67 positive, TAZ-expressing early breast cancer patients</td>
						<td>Breast</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>812</td>
						<td>NCT05016349</td>
						<td>Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.</td>
						<td>Breast</td>
						<td>Mifepristone</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>813</td>
						<td>NCT05014776</td>
						<td>Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer</td>
						<td>GI</td>
						<td>Tadalafil</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>814</td>
						<td>NCT05011058</td>
						<td>An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</td>
						<td>Lymphoma</td>
						<td>Valganciclovir</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>816</td>
						<td>2016-000871-26</td>
						<td>Studio di Fase II, randomizzato, in aperto, controllato di fattibilit iquest; dell iquest;impiego di doxiciclina nel tumore mammario in stadio precoce</td>
						<td>Breast</td>
						<td>Doxycycline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>817</td>
						<td>2016-004004-60</td>
						<td>Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient.</td>
						<td>GI</td>
						<td>Etoricoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>822</td>
						<td>NCT05036109</td>
						<td>DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid; Cholecalciferol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>823</td>
						<td>NCT05049863</td>
						<td>Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)</td>
						<td>Lung</td>
						<td>Allopurinol; Mycophenolate</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>824</td>
						<td>NCT03433781</td>
						<td>A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations</td>
						<td>Other Haem-onc</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>825</td>
						<td>NCT05036226</td>
						<td>COAST Therapy in Advanced Solid Tumors and Prostate Cancer</td>
						<td>Urological; Multiple cancer types</td>
						<td>Hydroxychloroquine; Metformin; Nelfinavir; Sirolimus</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>827</td>
						<td>NCT05023967</td>
						<td>Metformin and Nightly Fasting in Women With Early Breast Cancer</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>828</td>
						<td>NCT05055323</td>
						<td>A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer</td>
						<td>GI</td>
						<td>Pyrvinium Pamoate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>829</td>
						<td>NCT05053750</td>
						<td>TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</td>
						<td>Gynaecological</td>
						<td>Zoledronic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>830</td>
						<td>2021-001328-17</td>
						<td>Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1.</td>
						<td>Breast; GI</td>
						<td>Imipramine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>831</td>
						<td>2021-001375-16</td>
						<td>DIPGEN  ndash; Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG)</td>
						<td>CNS</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>832</td>
						<td>ISRCTN16867955</td>
						<td>A randomised phase 3 trial evaluating the role of finasteride in increasing compliance with active surveillance, in men with a new diagnosis of low and intermediate risk prostate cancer, when compared with usual care.</td>
						<td>Urological</td>
						<td>Finasteride</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>834</td>
						<td>DRKS00025207</td>
						<td>Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy</td>
						<td>CNS</td>
						<td>Meclofenamate</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>835</td>
						<td>CTRI/2021/06/034467</td>
						<td>Effect of Ketorolac of VEGF and TGF-B release in breast cancer resection surgery.</td>
						<td>Breast</td>
						<td>Ketorolac</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>838</td>
						<td>NCT05080946</td>
						<td>Using Aspirin to Improve Immunological Features of Ovarian Tumors</td>
						<td>Gynaecological</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>839</td>
						<td>NCT05103644</td>
						<td>Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients</td>
						<td>Breast</td>
						<td>Atorvastatin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>840</td>
						<td>NCT02432378</td>
						<td>Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines</td>
						<td>Gynaecological</td>
						<td>Celecoxib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>841</td>
						<td>NCT05076682</td>
						<td>Reverse Triple Negative Immune Resistant Breast Cancer</td>
						<td>Breast</td>
						<td>Cromoglicic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>842</td>
						<td>CTRI/2021/09/036296</td>
						<td>Oral Chemotherapy for advanced head and neck cancer.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>843</td>
						<td>CTRI/2021/09/036956</td>
						<td>Pioglitazone in Patients with Recurrent/ Refractory Inoperable High-Grade Osteosarcoma</td>
						<td>Bone Sarcoma</td>
						<td>Pioglitazone</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>844</td>
						<td>NCT05083780</td>
						<td>Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>845</td>
						<td>NCT05116917</td>
						<td>Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.</td>
						<td>GI</td>
						<td>Influenza vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>846</td>
						<td>NCT03299309</td>
						<td>PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma</td>
						<td>CNS</td>
						<td>Diphtheria vaccine; Tetanus vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>847</td>
						<td>NCT05077137</td>
						<td>A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy</td>
						<td>Skin</td>
						<td>Diphtheria vaccine; Tetanus vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>848</td>
						<td>NCT05096481</td>
						<td>PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma</td>
						<td>CNS</td>
						<td>Diphtheria vaccine; Tetanus vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>849</td>
						<td>NCT05097248</td>
						<td>Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received   1 Line of Chemotherapy</td>
						<td>Breast</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>850</td>
						<td>NCT05077800</td>
						<td>FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>851</td>
						<td>NCT01638676</td>
						<td>A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients</td>
						<td>Skin</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>854</td>
						<td>NCT05091424</td>
						<td>A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia</td>
						<td>Leukemia</td>
						<td>Tocilizumab</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>855</td>
						<td>NCT05080790</td>
						<td>Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Zoledronic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>856</td>
						<td>ACTRN12621001347853</td>
						<td>Clinical study assessing the anti-cancer activity of sulfasalazine in patients with advanced or metastatic pancreatic ductal adenocarcinoma whose cancer has worsened following therapy with current standard of care.</td>
						<td>GI</td>
						<td>Sulfasalazine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>857</td>
						<td>ACTRN12621001458820</td>
						<td>Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib</td>
						<td>Other Haem-onc</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>858</td>
						<td>CTRI/2021/09/037015</td>
						<td>Evaluating the Efficacy of Pioglitazone in combination with Neoadjuvant Chemotherapy in Patients with Extremity Skeletal High-Grade Osteosarcoma Treated with Curative Intent: A Multi-centre, Randomized Phase II Clinical Trial</td>
						<td>Bone Sarcoma</td>
						<td>Pioglitazone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>860</td>
						<td>NCT05141877</td>
						<td>Influences of Propofol and Sevoflurane Anesthesia in Brain Tumor</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>861</td>
						<td>NCT03107416</td>
						<td>Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells</td>
						<td>GI</td>
						<td>Bumetanide</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>862</td>
						<td>NCT03281369</td>
						<td>A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)</td>
						<td>GI</td>
						<td>Linagliptin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>864</td>
						<td>NCT03392246</td>
						<td>A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor na ve Advanced EGFR Mutant Lung Cancer</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>865</td>
						<td>NCT00463814</td>
						<td>AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies</td>
						<td>Multiple cancer types</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>867</td>
						<td>NCT02450656</td>
						<td>Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>868</td>
						<td>NCT03162627</td>
						<td>Selumetinib and Olaparib in Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>869</td>
						<td>NCT03581487</td>
						<td>Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>870</td>
						<td>NCT01364051</td>
						<td>Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies</td>
						<td>Skin; Multiple cancer types</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>872</td>
						<td>NCT03213691</td>
						<td>Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)</td>
						<td>Lymphoma; Multiple cancer types</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>873</td>
						<td>NCT02151084</td>
						<td>A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer</td>
						<td>Urological; GI</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>874</td>
						<td>NCT03326310</td>
						<td>Selumetinib and Azacitidine in High Risk Chronic Blood Cancers</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>875</td>
						<td>NCT02143466</td>
						<td>AZD9291 in Combination With Ascending Doses of Novel Therapeutics</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>876</td>
						<td>NCT03944772</td>
						<td>Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>877</td>
						<td>NCT02546661</td>
						<td>Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer</td>
						<td>Urological</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>878</td>
						<td>NCT02664935</td>
						<td>National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>880</td>
						<td>NCT02299999</td>
						<td>SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer</td>
						<td>Breast</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>883</td>
						<td>NCT04348045</td>
						<td>Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.</td>
						<td>GI</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>885</td>
						<td>NCT01089101</td>
						<td>Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma</td>
						<td>CNS</td>
						<td>Selumetinib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>886</td>
						<td>NCT04576117</td>
						<td>A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma</td>
						<td>CNS</td>
						<td>Selumetinib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>887</td>
						<td>NCT04166409</td>
						<td>A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma</td>
						<td>CNS</td>
						<td>Selumetinib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>888</td>
						<td>2018-004505-34</td>
						<td>A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10  / CBD 5 ) in patients with advanced untreatable hepatocellular carcinoma</td>
						<td>GI</td>
						<td>Cannabidiol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>892</td>
						<td>NCT01933932</td>
						<td>Assess Efficacy   Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC</td>
						<td>Lung</td>
						<td>Selumetinib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>893</td>
						<td>NCT05178628</td>
						<td>The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Tinzaparin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>894</td>
						<td>NCT05184816</td>
						<td>A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis</td>
						<td>Multiple cancer types</td>
						<td>Deferoxamine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>895</td>
						<td>NCT05183204</td>
						<td>Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>896</td>
						<td>NCT05188170</td>
						<td>Niclosamide in Pediatric Patients With Relapsed and Refractory AML</td>
						<td>Leukemia</td>
						<td>Niclosamide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>897</td>
						<td>NCT05166577</td>
						<td>Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC</td>
						<td>Head and Neck</td>
						<td>Valganciclovir</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>898</td>
						<td>ChiCTR2100046201</td>
						<td>A prospective, multicenter, randomized, controlled study on whether long-term oral antibiotics can effectively reduce the incidence of postoperative tumor recurrence and metastasis in patients with colorectal cancer</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>899</td>
						<td>NCT05164952</td>
						<td>Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole</td>
						<td>Breast</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>900</td>
						<td>NCT05190315</td>
						<td>Chlorpromazine and Standard of Care in Glioblastoma</td>
						<td>CNS</td>
						<td>Chlorpromazine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>901</td>
						<td>NCT05210374</td>
						<td>Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas</td>
						<td>Soft Tissue Sarcoma; Bone Sarcoma</td>
						<td>Disulfiram</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>903</td>
						<td>NCT05250791</td>
						<td>Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Other</td>
					</tr><tr>
						<td>904</td>
						<td>NCT05247268</td>
						<td>Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Young Women with Early Endometrial Cancer</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>905</td>
						<td>NCT05255653</td>
						<td>Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>906</td>
						<td>NCT05272462</td>
						<td>Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Minoxidil</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>907</td>
						<td>NCT05236036</td>
						<td>Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma</td>
						<td>CNS</td>
						<td>Mycophenolate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>908</td>
						<td>NCT05253131</td>
						<td>Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas</td>
						<td>Bone Sarcoma; Soft Tissue Sarcoma</td>
						<td>Selumetinib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>909</td>
						<td>NCT05207670</td>
						<td>A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies</td>
						<td>Lymphoma</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>910</td>
						<td>ACTRN12622000016730</td>
						<td>HER2Pro 1B - Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study</td>
						<td>Breast</td>
						<td>Prochlorperazine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>911</td>
						<td>IRCT20210819052230N1</td>
						<td>Study of the efficacy of memantine in metastatic colon cance</td>
						<td>GI</td>
						<td>Memantine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>912</td>
						<td>IRCT20211213053377N1</td>
						<td>The radioprotective effect of metformin against radiotherapy-induced complications</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>913</td>
						<td>IRCT20170728035349N2</td>
						<td>Evaluation of Metformin impact on the downstaging of rectal cancer patients undergoing  neo-adjuvant chemo-radiotherapy</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>914</td>
						<td>CTRI/2021/12/038966</td>
						<td>Effect of anaesthetic technique on the recurrence of breast cancer after surgery.</td>
						<td>Breast</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>915</td>
						<td>ChiCTR2100047608</td>
						<td>Clarithromycin added to pomadomide-cyclophosphamide-dexamethasone (Cla-PCd)  versus pomadomide cyclophosphamide-dexamethasone (PCd) in relapsed or refractory multiple myeloma: a prospective, multicentre, randomised, controlled clinical trial</td>
						<td>Other Haem-onc</td>
						<td>Clarithromycin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>916</td>
						<td>CTRI/2021/11/038016</td>
						<td>An Efficacy and Safety Study of Erdafitinib (JNJ42756493) in Participants with Urothelial Cancer</td>
						<td>Urological</td>
						<td>Metformin; Midazolam</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>917</td>
						<td>ChiCTR2100047864</td>
						<td>A clinical study of carrelizumab and apatinib mesylate combined with propranolol in the treatment of advanced cholangiocarcinoma</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>919</td>
						<td>NCT05281276</td>
						<td>Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>920</td>
						<td>NCT05324384</td>
						<td>Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma</td>
						<td>Other</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>921</td>
						<td>NCT05279690</td>
						<td>Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors</td>
						<td>Urological; Multiple cancer types</td>
						<td>Colchicine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>922</td>
						<td>NCT05284552</td>
						<td>Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Tinzaparin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>923</td>
						<td>NCT05300958</td>
						<td>Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Deferoxamine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>924</td>
						<td>NCT05365893</td>
						<td>PHL Treatment in Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine; Losartan; Paricalcitol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>925</td>
						<td>NCT05318469</td>
						<td>Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Ivermectin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>927</td>
						<td>NCT05316467</td>
						<td>Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>928</td>
						<td>NCT05316935</td>
						<td>GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>929</td>
						<td>NCT05326984</td>
						<td>Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia</td>
						<td>Leukemia</td>
						<td>Metformin</td>
						<td>Other</td>
					</tr><tr>
						<td>930</td>
						<td>NCT05343260</td>
						<td>Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Other</td>
					</tr><tr>
						<td>931</td>
						<td>NCT05331911</td>
						<td>Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>932</td>
						<td>NCT05291390</td>
						<td>Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)</td>
						<td>Leukemia</td>
						<td>Pyronaridine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>933</td>
						<td>NCT05326464</td>
						<td>Tofacitinib in Recurrent GBM Patients</td>
						<td>CNS</td>
						<td>Tofacitinib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>934</td>
						<td>NCT05348213</td>
						<td>Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma</td>
						<td>Lymphoma</td>
						<td>Tofacitinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>935</td>
						<td>ChiCTR2100049941</td>
						<td>Clinical project of new chemotherapy regiments for glioblastoma multiform (GBM)</td>
						<td>CNS</td>
						<td>Levetiracetam</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>936</td>
						<td>ChiCTR2100049694</td>
						<td>Effect of Lidocaine on CD4 + / CD8 + T cells and body stress in patients  undergoing gastric cancer surgery</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>937</td>
						<td>IRCT20210703051770N1</td>
						<td>Evaluation and comparison of treatment regimens in patients with acute leukemia.</td>
						<td>Leukemia</td>
						<td>Zidovudine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>938</td>
						<td>IRCT20220409054463N1</td>
						<td>Metformin as a chemotherapeutic agent</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>939</td>
						<td>ChiCTR2100050796</td>
						<td>Effects of lidocaine and dexmedetomidine on perioperative tumor metastasis markers and inflammatory markers in patients undergoing thoracoscopic lung cancer resection</td>
						<td>Lung</td>
						<td>Lidocaine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>941</td>
						<td>JPRN-UMIN000001815</td>
						<td>Prospective randomized controlled study for preventive effect of menatetrenone against the recurrence of hepatocellular carcinoma after hepatectomy</td>
						<td>GI</td>
						<td>Menatetrenone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>942</td>
						<td>JPRN-UMIN000014689</td>
						<td>Study about the efficacy of metformin to immune function in cancer patients.</td>
						<td>Multiple cancer types</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>943</td>
						<td>JPRN-UMIN000028405</td>
						<td>Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer.</td>
						<td>Multiple cancer types</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>944</td>
						<td>JPRN-UMIN000013951</td>
						<td>Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.</td>
						<td>Gynaecological</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>945</td>
						<td>JPRN-UMIN000021750</td>
						<td>A clinical trial to inspect whether varicella zoster virus vaccine inoculation induces antitumor immunity in patients with adult T-cell leukemia / lymphoma</td>
						<td>Leukemia; Lymphoma</td>
						<td>Varicella vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>946</td>
						<td>JPRN-UMIN000020856</td>
						<td>Exploratory study on the anti-proliferative effects of metformin on endometrial cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>948</td>
						<td>NCT05470283</td>
						<td>Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma</td>
						<td>Skin</td>
						<td>Acetazolamide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>949</td>
						<td>NCT05462613</td>
						<td>Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>950</td>
						<td>NCT05381597</td>
						<td>5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer</td>
						<td>Skin</td>
						<td>Calcipotriol</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>952</td>
						<td>NCT05462496</td>
						<td>Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Ciprofloxacin; Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>953</td>
						<td>NCT05450055</td>
						<td>Intraperitoneal Lidocaine in Ovarian Cancer Surgery</td>
						<td>Gynaecological</td>
						<td>Lidocaine</td>
						<td>Other</td>
					</tr><tr>
						<td>954</td>
						<td>NCT05445791</td>
						<td>Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>955</td>
						<td>NCT05451043</td>
						<td>Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>956</td>
						<td>NCT05464810</td>
						<td>Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Simvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>957</td>
						<td>NCT05391750</td>
						<td>Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Tocilizumab</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>959</td>
						<td>NCT05400603</td>
						<td>Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma</td>
						<td>Other</td>
						<td>Zoledronic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>960</td>
						<td>DRKS00028966</td>
						<td>Evaluation of the effect of total intravenous and inhalation anesthesia on tumor growth</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>961</td>
						<td>CTRI/2022/05/042576</td>
						<td>Metformin with  chemotherapy in Triple negative and Her2neu positive breastcancer - a randomisedstudy</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>962</td>
						<td>JPRN-jRCTs041220024</td>
						<td>A Phase 1 study of Fasudil with MAP targeting cancer stem cell.</td>
						<td>Bone Sarcoma</td>
						<td>Fasudil</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>963</td>
						<td>NCT04046094</td>
						<td>Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients</td>
						<td>Urological</td>
						<td>Ascorbic acid</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>964</td>
						<td>NCT05487859</td>
						<td>Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)</td>
						<td>Urological</td>
						<td>Acarbose</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>965</td>
						<td>NCT05501548</td>
						<td>Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer</td>
						<td>Urological</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>966</td>
						<td>NCT05507398</td>
						<td>The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer</td>
						<td>Breast</td>
						<td>Atorvastatin; Metformin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>967</td>
						<td>NCT05483010</td>
						<td>Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)</td>
						<td>Other Haem-onc</td>
						<td>Atorvastatin; Rosuvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>968</td>
						<td>NCT05578287</td>
						<td>RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>969</td>
						<td>NCT05563766</td>
						<td>A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer</td>
						<td>GI</td>
						<td>Itraconazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>970</td>
						<td>NCT05521984</td>
						<td>Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)</td>
						<td>CNS</td>
						<td>Dapagliflozin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>972</td>
						<td>NCT05513365</td>
						<td>Phase II Dutasteride in Combination With CAB vs CAB in SDC</td>
						<td>Head and Neck</td>
						<td>Dutasteride</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>974</td>
						<td>NCT05518110</td>
						<td>PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>975</td>
						<td>NCT05576896</td>
						<td>Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>976</td>
						<td>NCT05560035</td>
						<td>The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery</td>
						<td>Gynaecological</td>
						<td>Lidocaine</td>
						<td>Other</td>
					</tr><tr>
						<td>978</td>
						<td>NCT05564377</td>
						<td>Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial</td>
						<td>Multiple cancer types</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>979</td>
						<td>NCT05538897</td>
						<td>Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>980</td>
						<td>NCT05502900</td>
						<td>Adjuvant Melatonin for Uveal Melanoma</td>
						<td>Ocular</td>
						<td>Melatonin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>981</td>
						<td>NCT05490953</td>
						<td>Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma</td>
						<td>Lymphoma</td>
						<td>Pentoxifylline</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>982</td>
						<td>NCT05544019</td>
						<td>Study of SGR-1505 in Mature B-Cell Neoplasms</td>
						<td>Leukemia</td>
						<td>Posaconazole</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>984</td>
						<td>NCT03801369</td>
						<td>Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>985</td>
						<td>NCT05554328</td>
						<td>Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial</td>
						<td>Gynaecological</td>
						<td>Selumetinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>986</td>
						<td>NCT05550415</td>
						<td>The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer</td>
						<td>Breast</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>987</td>
						<td>NCT05580861</td>
						<td>Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment</td>
						<td>Leukemia</td>
						<td>Sulfasalazine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>988</td>
						<td>2021-006689-18</td>
						<td>An open randomized phase II clinical trial evaluating the safety and efficacy of rapamycin in the treatment of gliomas high-grade malignant gliomas in children as part of the establishment management of rare and ultra rare diseases of the central nervous system associated with mTOR pathway activation: BraimTOR- ONKO</td>
						<td>CNS</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>990</td>
						<td>ISRCTN73037722</td>
						<td>LION: lifting immune checkpoints with NSAIDs</td>
						<td>Breast; Lung; Urological</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>991</td>
						<td>ACTRN12622001201763</td>
						<td>Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial</td>
						<td>CNS</td>
						<td>Aliskiren; Celecoxib; Metformin; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>993</td>
						<td>ChiCTR2100053537</td>
						<td>An exploratory study on the synergistic effect of simultaneous hepatic arterial infusion of sodium bicarbonate injection in the treatment of hepatocellular carcinoma with anti-PD-1 monoclonal antibody</td>
						<td>GI</td>
						<td>Sodium Bicarbonate</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>994</td>
						<td>NCT05637567</td>
						<td>Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>995</td>
						<td>NCT05675787</td>
						<td>Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia</td>
						<td>Gynaecological</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>996</td>
						<td>NCT05647330</td>
						<td>Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>998</td>
						<td>NCT04887935</td>
						<td>Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer</td>
						<td>Urological</td>
						<td>Dapagliflozin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>999</td>
						<td>NCT05667415</td>
						<td>Treatment of Advance Gastric Cancer With Disulfiram</td>
						<td>GI</td>
						<td>Disulfiram</td>
						<td>Other</td>
					</tr><tr>
						<td>1002</td>
						<td>NCT05664464</td>
						<td>Glutamate Inhibitors in Glioblastoma</td>
						<td>CNS</td>
						<td>Memantine; Sulfasalazine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1003</td>
						<td>NCT05680662</td>
						<td>The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1004</td>
						<td>NCT05607407</td>
						<td>Methimazole in Patients With Progressive Glioblastoma</td>
						<td>CNS</td>
						<td>Methimazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1005</td>
						<td>NCT05720559</td>
						<td>Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1006</td>
						<td>NCT05606692</td>
						<td>Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)</td>
						<td>Gynaecological</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1007</td>
						<td>NCT05663242</td>
						<td>The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1009</td>
						<td>NCT05651594</td>
						<td>Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1010</td>
						<td>NCT05678348</td>
						<td>Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma</td>
						<td>Head and Neck</td>
						<td>Pyrimethamine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1011</td>
						<td>NCT05586360</td>
						<td>T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer</td>
						<td>Urological</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1012</td>
						<td>NCT05709574</td>
						<td>Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer</td>
						<td>GI</td>
						<td>Tadalafil</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1013</td>
						<td>NCT05626829</td>
						<td>Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma</td>
						<td>Head and Neck</td>
						<td>Tranilast</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1014</td>
						<td>NCT05694936</td>
						<td>Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1015</td>
						<td>NCT05634707</td>
						<td>Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)</td>
						<td>CNS</td>
						<td>Fluoxetine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1016</td>
						<td>RBR-76j763k</td>
						<td>Vitamin K3 treatment in Stomach Cancer patients in a public hospital</td>
						<td>GI</td>
						<td>Menadione</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1017</td>
						<td>CTRI/2022/11/046961</td>
						<td>A study to compare the effect of  different types of anaesthesia on blood inflammatory markers in gynaecological cancer patients.</td>
						<td>Gynaecological</td>
						<td>Propofol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1018</td>
						<td>ChiCTR2100054650</td>
						<td>A phase II clinical study evaluating the efficacy and safety of Fruquintinib combined with azithromycin liposome in patients with Platinum resistant ovarian cancer</td>
						<td>Gynaecological</td>
						<td>Azithromycin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1019</td>
						<td>CTRI/2023/01/049248</td>
						<td>A study to see the effectives of a parasitic drug called Mebendazole when given with chemotherapy CCNU in patients.</td>
						<td>CNS</td>
						<td>Mebendazole</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1020</td>
						<td>CTRI/2023/02/049406</td>
						<td>A study comparing two chemotherapy regimens prior to surgery for patients with technically unresectable oral cancers</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1023</td>
						<td>NCT05865548</td>
						<td>Addition of Aspirin to Standard of Care in Oral Cancer</td>
						<td>Head and Neck</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1024</td>
						<td>NCT05733000</td>
						<td>CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1025</td>
						<td>NCT05849129</td>
						<td>Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1026</td>
						<td>NCT05796973</td>
						<td>Measuring Oncological Value of Exercise and Statin</td>
						<td>Gynaecological; Breast; Urological</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1027</td>
						<td>NCT05846880</td>
						<td>VitD3 Supplementation in Patients With Multiple Myeloma</td>
						<td>Other Haem-onc</td>
						<td>Cholecalciferol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1028</td>
						<td>NCT05731726</td>
						<td>Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1029</td>
						<td>NCT05756166</td>
						<td>Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Celecoxib</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1030</td>
						<td>NCT05802992</td>
						<td>The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients</td>
						<td>Other Haem-onc</td>
						<td>Colchicine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1032</td>
						<td>NCT05799144</td>
						<td>pBI-11   TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS 1, hrHPV+ Oropharyngeal Cancer</td>
						<td>Head and Neck</td>
						<td>HPV vaccine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1033</td>
						<td>NCT05843188</td>
						<td>Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1034</td>
						<td>NCT05842174</td>
						<td>Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1035</td>
						<td>NCT05833594</td>
						<td>Whole-course Immunonutrition Combined With Chemoradiotherapy ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma</td>
						<td>Head and Neck</td>
						<td>L-Glutamine; Omega 3</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1036</td>
						<td>NCT05861336</td>
						<td>GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1037</td>
						<td>NCT03675893</td>
						<td>RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1039</td>
						<td>NCT05759312</td>
						<td>Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1040</td>
						<td>NCT05774964</td>
						<td>Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1041</td>
						<td>NCT05741164</td>
						<td>Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer</td>
						<td>Breast</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1042</td>
						<td>NCT05797662</td>
						<td>A Study of Propranolol to Treat Kaposi Sarcoma</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1045</td>
						<td>NCT05821556</td>
						<td>Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients</td>
						<td>GI</td>
						<td>Simvastatin; Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1046</td>
						<td>NCT05754684</td>
						<td>Quadruple Immunotherapy for Neuroblastoma</td>
						<td>Other</td>
						<td>Spironolactone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1047</td>
						<td>NCT05846789</td>
						<td>Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers</td>
						<td>Breast</td>
						<td>Tocilizumab</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1048</td>
						<td>NCT05866172</td>
						<td>HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC</td>
						<td>GI</td>
						<td>Zoledronic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1050</td>
						<td>ChiCTR2200057842</td>
						<td>Metformin and omeprazole induce enhanced high-dose vitamin C in the treatment of advanced malignant tumors</td>
						<td>Multiple cancer types</td>
						<td>Ascorbic acid; Metformin; Omeprazole</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1051</td>
						<td>CTRI/2023/02/049751</td>
						<td>A STUDY ON METFORMIN AND CHEMOTHERAPY COMBINATION IN NON-DIABETES MELLITUS PATIENTS FOR BREAST CANCER</td>
						<td>Breast</td>
						<td>Metformin</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1052</td>
						<td>CTRI/2023/02/049523</td>
						<td>Study of Losartan and Standard of care therapy in advanced biliary tract cancer</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1053</td>
						<td>ChiCTR2200061789</td>
						<td>Fasudil hydrochloride in the treatment of gene-specific ovarian cancer patients</td>
						<td>Gynaecological</td>
						<td>Fasudil</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1054</td>
						<td>ChiCTR2200066615</td>
						<td>The effect of intraoperative intravenous lidocaine infusion on short-term recovery and long-term prognosis of patients with lung cancer: a prospective, randomized, controlled clinical trial</td>
						<td>Lung</td>
						<td>Lidocaine</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1055</td>
						<td>ChiCTR2200065595</td>
						<td>Exploratory Clinical Study on Mifepristone for the Treatment of Recurrent Glioblastoma</td>
						<td>CNS</td>
						<td>Mifepristone</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1056</td>
						<td>ChiCTR2300068631</td>
						<td>Oral aminophylline combined with sunitinib malate capsule in the treatment of locally advanced unresectable renal clear cell carcinoma or distant metastasis: a prospective, open, single-arm, multicenter exploratory study</td>
						<td>Urological</td>
						<td>Aminophylline</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1057</td>
						<td>ChiCTR2300068563</td>
						<td>lidocaine Effects on neutrophil extracellular trapping and angiogenesis biomarkers in postoperative breast cancer patients with different  anesthesia methods</td>
						<td>Breast</td>
						<td>Lidocaine</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1058</td>
						<td>2019-001071-37</td>
						<td>Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido</td>
						<td>Gynaecological</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1059</td>
						<td>2021-004189-37</td>
						<td>Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer</td>
						<td>Head and Neck; Lung</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1061</td>
						<td>2022-001989-36</td>
						<td>Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial</td>
						<td>GI</td>
						<td>Sertraline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1062</td>
						<td>IRCT20200608047702N1</td>
						<td>The effect of finasteride in the prevention of  bladder tumor recurrence</td>
						<td>Urological</td>
						<td>Finasteride</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1063</td>
						<td>IRCT20200409047007N3</td>
						<td>The effect of concurrent administration of melatonin and neoadjuvant Chemotherapy on the pathological response in breast cancer patients</td>
						<td>Breast</td>
						<td>Melatonin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1064</td>
						<td>NCT05998135</td>
						<td>Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Atovaquone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1065</td>
						<td>NCT05903703</td>
						<td>Canagliflozin With Gemcitabine in Pancreatic Carcinoma</td>
						<td>GI</td>
						<td>Canagliflozin</td>
						<td>Other</td>
					</tr><tr>
						<td>1066</td>
						<td>NCT05933980</td>
						<td>Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer</td>
						<td>GI</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1067</td>
						<td>NCT05896839</td>
						<td>Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer</td>
						<td>Skin</td>
						<td>Sirolimus</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1068</td>
						<td>NCT05591560</td>
						<td>Itraconazole in Advanced Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Itraconazole</td>
						<td>Other</td>
					</tr><tr>
						<td>1069</td>
						<td>NCT05025735</td>
						<td>Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer</td>
						<td>Breast</td>
						<td>Dapagliflozin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1070</td>
						<td>NCT05953350</td>
						<td>A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i</td>
						<td>Multiple cancer types</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1071</td>
						<td>NCT05913427</td>
						<td>Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)</td>
						<td>Endocrine</td>
						<td>Megestrol Acetate</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1072</td>
						<td>NCT06007846</td>
						<td>A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer</td>
						<td>GI</td>
						<td>Memantine</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1074</td>
						<td>NCT05929495</td>
						<td>Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma</td>
						<td>CNS</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1075</td>
						<td>NCT05968690</td>
						<td>Naltrexone and Propranolol Combined With Immunotherapy</td>
						<td>Skin</td>
						<td>Naltrexone; Propranolol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1076</td>
						<td>NCT05926336</td>
						<td>The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action</td>
						<td>Multiple cancer types</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1077</td>
						<td>NCT06017141</td>
						<td>Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1078</td>
						<td>NCT05979818</td>
						<td>Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer</td>
						<td>Lung</td>
						<td>Propranolol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1079</td>
						<td>NCT01988831</td>
						<td>Efficacy of Propranolol Treatment to Prevent Melanoma Progression</td>
						<td>Skin</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1080</td>
						<td>NCT05961761</td>
						<td>Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1081</td>
						<td>NCT05947825</td>
						<td>Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients</td>
						<td>GI</td>
						<td>Sitagliptin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1082</td>
						<td>NCT05899465</td>
						<td>Perioperative Treatment With Tranexamic Acid in Melanoma</td>
						<td>Skin</td>
						<td>Tranexamic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1083</td>
						<td>NCT05595473</td>
						<td>A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Valganciclovir</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1084</td>
						<td>NCT04339140</td>
						<td>Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer</td>
						<td>Gynaecological</td>
						<td>Zafirlukast</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1085</td>
						<td>CTRI/2022/08/045109</td>
						<td>Clinical trial of metformin and valproic acid combination in lung cancer</td>
						<td>Lung</td>
						<td>Metformin; Valproic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1086</td>
						<td>CTRI/2022/08/044794</td>
						<td>Metformin as Chemo-sensitizer in Ovarian Malignancies</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1087</td>
						<td>CTRI/2022/10/046252</td>
						<td>Investigate the effect of Propranolol and Celecoxib combine with Receptor activator of nuclear factor kappa-  ?  ?? ligand (RANKL) blockade therapy during the perioperative period of Osteosarcoma (Bone cancer) patients.</td>
						<td>Bone Sarcoma</td>
						<td>Celecoxib; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1088</td>
						<td>CTRI/2023/05/052737</td>
						<td>effect of addition of Aspirin in oral cancer survival</td>
						<td>Head and Neck</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1090</td>
						<td>CTRI/2023/05/053195</td>
						<td>Define role of chronomodulation in Gemcitabinne chemotherapy</td>
						<td>GI</td>
						<td>Melatonin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1091</td>
						<td>IRCT20230315057722N1</td>
						<td>Effect of pentoxifylline in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (ASCT)</td>
						<td>Other Haem-onc</td>
						<td>Pentoxifylline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1092</td>
						<td>CTRI/2023/07/055019</td>
						<td>EFFECT OF INTRAVENOUS LOCAL ANAESTHETIC AND REGIONAL BLOCK ON LEVELS OF MARKERS OF RECURRENCE IN PATIENTS UNDERGOING SURGERY FOR BREAST CANCER</td>
						<td>Breast</td>
						<td>Lidocaine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1093</td>
						<td>ChiCTR2300074309</td>
						<td>To explore the safety and efficacy of atorvastatin in combination with chemotherapy versus chemotherapy in patients with extensive small-cell lung cancer resistant to first-line standard therapy: a randomized controlled Phase III trial</td>
						<td>Lung</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1094</td>
						<td>IRCT20230627058596N1</td>
						<td>Effect of Atorvastatin Usage on Patients with Oral squamous cell carcinoma</td>
						<td>Head and Neck</td>
						<td>Atorvastatin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1095</td>
						<td>ChiCTR2300074442</td>
						<td>ParecoxibNA can modulate tumor microenvironment and inhibit cell proliferation, metastasis in non-small cell lung cancer</td>
						<td>Lung</td>
						<td>Parecoxib</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1096</td>
						<td>IRCT20230221057485N1</td>
						<td>The effect of adding Desloratadine to neoadjuvant chemotherapy in patients with breast cancer</td>
						<td>Breast</td>
						<td>Desloratadine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1097</td>
						<td>KCT0008659</td>
						<td>Randomized phase II study of chemoimmunotherapy with or without metformin as a first-line treatment in patients with squamous cell lung carcinoma</td>
						<td>Lung</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1098</td>
						<td>JPRN-jRCT2080222349</td>
						<td>A Phase 1, Open-Label, Multi-center Study to Assess the Safety and Tolerability of AZD6244 (Selumetinib, ARRY142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)</td>
						<td>GI</td>
						<td>Selumetinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1099</td>
						<td>JPRN-jRCTs021230005</td>
						<td>A randomized phase 2 study assessing the efficacy and safety of levofloxacin added to the GEM/nabPTX combination therapy in patients with advanced pancreatic cancer(T-CORE2201)</td>
						<td>GI</td>
						<td>Levofloxacin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1100</td>
						<td>NCT06102863</td>
						<td>Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia</td>
						<td>Gynaecological</td>
						<td>Atorvastatin; Rosuvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1101</td>
						<td>NCT06157099</td>
						<td>Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma</td>
						<td>Skin</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1102</td>
						<td>NCT06148038</td>
						<td>CBD for Breast Cancer Primary Tumors</td>
						<td>Breast</td>
						<td>Cannabidiol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1103</td>
						<td>NCT06076837</td>
						<td>The Seven Trial: Exploiting the Unfolded Protein Response</td>
						<td>GI</td>
						<td>Celecoxib; Chloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1104</td>
						<td>NCT06126731</td>
						<td>Combination Study of Antibiotics With Enzalutamide (PROMIZE)</td>
						<td>Urological</td>
						<td>Ciprofloxacin; Metronidazole</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1105</td>
						<td>NCT06084780</td>
						<td>Intestinal   Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)</td>
						<td>Other</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1106</td>
						<td>NCT06030622</td>
						<td>Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Digoxin; Metformin; Simvastatin</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1107</td>
						<td>NCT06191133</td>
						<td>Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma</td>
						<td>Gynaecological</td>
						<td>Fenofibrate</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1108</td>
						<td>NCT06102525</td>
						<td>A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Glioblastoma</td>
						<td>CNS</td>
						<td>Valganciclovir</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1109</td>
						<td>NCT06150898</td>
						<td>Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)</td>
						<td>Breast</td>
						<td>Ketorolac</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1110</td>
						<td>NCT06044025</td>
						<td>A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy</td>
						<td>Urological</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1111</td>
						<td>NCT06162377</td>
						<td>Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A   Window of Opportunity   Pilot Study.</td>
						<td>Head and Neck</td>
						<td>Methylnaltrexone</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1112</td>
						<td>NCT06099769</td>
						<td>A Study of Enzalutamide, Enzalutamide in Combination with Mifepristone, or Chemotherapy in People with Metastatic Breast Cancer</td>
						<td>Breast</td>
						<td>Mifepristone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1113</td>
						<td>NCT06049901</td>
						<td>Nitazoxanide in Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Nitazoxanide</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1114</td>
						<td>NCT06176339</td>
						<td>Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients</td>
						<td>Breast</td>
						<td>Pentoxifylline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1115</td>
						<td>NCT06115174</td>
						<td>Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Pentoxifylline</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1116</td>
						<td>NCT06142318</td>
						<td>Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma</td>
						<td>Head and Neck</td>
						<td>Pirfenidone</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1117</td>
						<td>NCT06145074</td>
						<td>Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.</td>
						<td>GI</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1118</td>
						<td>NCT06134388</td>
						<td>Sulfasalazine in Patients With Metastatic Colorectal Cancer</td>
						<td>GI</td>
						<td>Sulfasalazine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1119</td>
						<td>NCT06168487</td>
						<td>Telmisartan in Prostate Cancer</td>
						<td>Urological</td>
						<td>Telmisartan</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1120</td>
						<td>CTIS2022-500599-79-00</td>
						<td>Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma</td>
						<td>Lymphoma</td>
						<td>Tofacitinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1121</td>
						<td>CTIS2022-500745-24-00</td>
						<td>Phase II Dutasteride in combination with CAB vs CAB in SDC (DUCT)</td>
						<td>Head and Neck</td>
						<td>Dutasteride</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1122</td>
						<td>ChiCTR2300074976</td>
						<td>A single-arm clinical trial to evaluate the efficacy and safety of Simvastatin, Orlistat, and Trimetazidine in combination with second-line treatment drugs for advanced liver cancer</td>
						<td>GI</td>
						<td>Orlistat; Simvastatin</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1123</td>
						<td>ChiCTR2300076126</td>
						<td>PET-guided high-dose vitamin C synergised with 131I, 177Lu-DOTA-TATE, 177Lu-PSMA for advanced thyroid cancer, neuroendocrine tumours, and prostate cancer</td>
						<td>Endocrine; Urological</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1124</td>
						<td>ACTRN12623001164684</td>
						<td>Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for cancer: The ReDO cancer treatment study</td>
						<td>Multiple cancer types</td>
						<td>Atorvastatin; Chloroquine; Dipyridamole; Doxycycline; Hydroxychloroquine; Ivermectin; Loratadine; Mebendazole; Melatonin; Metformin; Phenylbutyrate</td>
						<td>Other</td>
					</tr><tr>
						<td>1125</td>
						<td>CTRI/2023/11/059909</td>
						<td>Utility of Hydroxychloroquine medicine as a supportive treatment for breast cancer patients</td>
						<td>Breast</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1126</td>
						<td>CTIS2023-503938-52-00</td>
						<td>Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)</td>
						<td>CNS</td>
						<td>Perampanel</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1127</td>
						<td>NCT03170115</td>
						<td>Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1128</td>
						<td>NCT06452394</td>
						<td>NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline</td>
						<td>Breast</td>
						<td>Doxycycline</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1129</td>
						<td>NCT06480110</td>
						<td>Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer</td>
						<td>Urological</td>
						<td>Ebastine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1130</td>
						<td>NCT06424067</td>
						<td>Phase 2 Study of Fingolimod in Lung Cancers</td>
						<td>Lung</td>
						<td>Fingolimod</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1131</td>
						<td>NCT06218524</td>
						<td>The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM</td>
						<td>CNS</td>
						<td>Haloperidol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1132</td>
						<td>NCT06229340</td>
						<td>Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations</td>
						<td>Multiple cancer types</td>
						<td>Leflunomide</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1133</td>
						<td>NCT06211335</td>
						<td>Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma</td>
						<td>Head and Neck</td>
						<td>Losartan</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1134</td>
						<td>NCT06445166</td>
						<td>Propranolol for the Treatment of Kaposi Sarcoma in Adults</td>
						<td>AIDS-related; Soft Tissue Sarcoma</td>
						<td>Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1135</td>
						<td>IRCT20230903059342N2</td>
						<td>Investigating the treatment of ovarian cancer by optimized measles vaccine</td>
						<td>Gynaecological</td>
						<td>Measles vaccine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1136</td>
						<td>CTRI/2024/01/061661</td>
						<td>To Study effectiveness of oral chemotherapy with low dose immunotherapy compared with  chemotherapy in Head and Neck Cancer Patients</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1137</td>
						<td>CTRI/2024/01/061073</td>
						<td>Study of 2 different type of chemotherapy in Head and Neck Cancer Patients</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1138</td>
						<td>NL-OMON46294</td>
						<td>Immune protective anesthesia during  endoscopic colon surgery to improve long-term survival</td>
						<td>GI</td>
						<td>Propofol</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1140</td>
						<td>NL-OMON33441</td>
						<td>Phase I study of nelfinavir in combination with temsirolimus in the treatment of patients with advanced cancers, including second line renal cell cancer</td>
						<td>Multiple cancer types</td>
						<td>Nelfinavir</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1141</td>
						<td>JPRN-jRCT2031230531</td>
						<td>A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumor</td>
						<td>Breast; GI</td>
						<td>Sulfasalazine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1142</td>
						<td>CTRI/2024/03/063617</td>
						<td>A study to find new treatments for patients with blood cancers</td>
						<td>Leukemia</td>
						<td>Artesunate</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1143</td>
						<td>CTRI/2024/03/063519</td>
						<td>Effect of different modes of anaesthesia, i.e., TIVA using propofol and lignocaine with inhalational agents, on values of VEGF and Tells activity ( T helper cell CD4+ and cytotoxic T cells CD 8 +).</td>
						<td>Gynaecological</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1144</td>
						<td>CTRI/2024/04/065574</td>
						<td>Study to compare the longevity of life between using low-dose immunotherapy before surgery and only surgery alone for advanced stage oral cancer</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1145</td>
						<td>CTRI/2024/04/065470</td>
						<td>Effect of addition of aspirin in cervical cancer survival</td>
						<td>Gynaecological</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1146</td>
						<td>ChiCTR2400081288</td>
						<td>A multicenter, single-arm, phase II clinical study of the efficacy and safety of oral atorvastatin combined with temozolomide in the treatment of glioblastoma</td>
						<td>CNS</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1147</td>
						<td>ChiCTR2400082375</td>
						<td>A Phase Ib Study on the Safety and Feasibility of Combined Therapy with Sildenafil, Tirelizumab, and Platinum-Containing Double Drugs as First-Line Treatment for Advanced Lung Adenocarcinoma</td>
						<td>Lung</td>
						<td>Sildenafil</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1148</td>
						<td>ChiCTR2400082666</td>
						<td>A single-arm, multicenter prospective study of RAS inhibitors combined with bevacizumab in patients with mCRC</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1149</td>
						<td>ChiCTR2100053586</td>
						<td>Effects of different anesthesia methods on postoperative recovery and prognosis of patients with colorectal tumors</td>
						<td>GI</td>
						<td>Lidocaine</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1150</td>
						<td>NCT06442709</td>
						<td>Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients</td>
						<td>Head and Neck</td>
						<td>Tocilizumab</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1151</td>
						<td>NCT04512105</td>
						<td>Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia</td>
						<td>Leukemia</td>
						<td>Pitavastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1152</td>
						<td>CTIS2024-511452-40-00</td>
						<td>Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)</td>
						<td>CNS</td>
						<td>Riluzole</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1153</td>
						<td>CTIS2024-511626-30-00</td>
						<td>MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1154</td>
						<td>CTIS2024-518267-35-00</td>
						<td>Atorvastatinbehandling til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og pr  fibrotisk myelofibrose.</td>
						<td>Other Haem-onc</td>
						<td>Atorvastatin</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1155</td>
						<td>CTIS2024-515251-37-00</td>
						<td>Effect of obesity due to the action of aspirin and its effectiveness in therapy for the treatment of colon cancer.</td>
						<td>GI</td>
						<td>Acetylsalicylic Acid</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1156</td>
						<td>ACTRN12624000917538</td>
						<td>Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma: CetPro study</td>
						<td>Skin</td>
						<td>Prochlorperazine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1157</td>
						<td>CTRI/2024/08/072823</td>
						<td>A randomized controlled trial to evaluate if the use of a combination of chemotherapy and immunotherapy results in an increased surgical resection rate for patients with unresectable oral cavity cancers when compared to standard chemotherapy.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1158</td>
						<td>CTRI/2024/10/075166</td>
						<td>A clinical trial to compare the effect of two neoadjuvant chemotherapy drug regimens in technically unresectable head and neck cancer.</td>
						<td>Head and Neck</td>
						<td>Celecoxib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1159</td>
						<td>CTRI/2024/10/075019</td>
						<td>Effectiveness of the drug Sirolimus in treatment of vascular anomalies.</td>
						<td>Multiple cancer types</td>
						<td>Sirolimus</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1160</td>
						<td>ACTRN12624001353583</td>
						<td>Perioperative propranolol and celecoxib (ProCel) in stage III melanoma</td>
						<td>Skin</td>
						<td>Celecoxib; Propranolol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1161</td>
						<td>CTRI/2024/11/076460</td>
						<td>Sirolimus treatment to reduce size of rhabdomyoma (a tumor in the heart) in children.</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Sirolimus</td>
						<td>Phase 3/4</td>
					</tr><tr>
						<td>1162</td>
						<td>NCT06428045</td>
						<td>STARLITE for Unresectable High-Grade Gliomas</td>
						<td>CNS</td>
						<td>Ritonavir</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1163</td>
						<td>NCT06698822</td>
						<td>A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2  Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA</td>
						<td>Lymphoma</td>
						<td>Tofacitinib</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1164</td>
						<td>NCT06599762</td>
						<td>Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Tranexamic Acid</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1165</td>
						<td>NCT06644079</td>
						<td>Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma</td>
						<td>Skin</td>
						<td>Tranexamic Acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1166</td>
						<td>NCT06695026</td>
						<td>A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects with Hepatocellular Carcinoma</td>
						<td>GI</td>
						<td>Valganciclovir</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1167</td>
						<td>NCT06701812</td>
						<td>Digoxin Medulloblastoma Study</td>
						<td>CNS</td>
						<td>Digoxin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1168</td>
						<td>NCT06630221</td>
						<td>Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations</td>
						<td>Leukemia; Other Haem-onc</td>
						<td>Eltrombopag</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1169</td>
						<td>NCT06639724</td>
						<td>Perioperative Fostamatinib with Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Fostamatinib</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1170</td>
						<td>NCT06389201</td>
						<td>Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients</td>
						<td>Head and Neck</td>
						<td>Hydroxychloroquine</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1171</td>
						<td>NCT06408298</td>
						<td>HCQ in Resectable Localized Prostate Cancer</td>
						<td>Urological</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1172</td>
						<td>NCT06330038</td>
						<td>Anesthesia and Non-small Cell Lung Cancer Recurrence</td>
						<td>Lung</td>
						<td>Propofol</td>
						<td>Phase 4</td>
					</tr><tr>
						<td>1173</td>
						<td>NCT06636734</td>
						<td>Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial</td>
						<td>Head and Neck</td>
						<td>Lovastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1174</td>
						<td>NCT06549855</td>
						<td>PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1175</td>
						<td>NCT06687876</td>
						<td>Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy</td>
						<td>GI</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1176</td>
						<td>NCT06353061</td>
						<td>Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1177</td>
						<td>NCT06627270</td>
						<td>Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer</td>
						<td>Head and Neck</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1178</td>
						<td>NCT06616597</td>
						<td>Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer</td>
						<td>Urological</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1179</td>
						<td>NCT06554613</td>
						<td>Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC</td>
						<td>Lung</td>
						<td>Olanzapine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1180</td>
						<td>NCT06484153</td>
						<td>Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma</td>
						<td>GI</td>
						<td>Pirfenidone</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1181</td>
						<td>NCT06670976</td>
						<td>Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma</td>
						<td>Soft Tissue Sarcoma</td>
						<td>Propranolol</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1182</td>
						<td>2022-001284-27</td>
						<td>H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial</td>
						<td>Lung</td>
						<td>Fexofenadine</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1183</td>
						<td>ChiCTR2400087406</td>
						<td>To compare the efficacy and safety of low-dose venetoclax combined with azole and full-dose venetoclax without azole in the treatment of newly diagnosed AML patients who are intolerant to intensive chemotherapy</td>
						<td>Leukemia</td>
						<td>Itraconazole; Posaconazole</td>
						<td>Other</td>
					</tr><tr>
						<td>1184</td>
						<td>ChiCTR2400088782</td>
						<td>Rosuvastatin combined with FOLFIRI chemotherapy regimen to improve the efficacy of advanced colorectal cancer</td>
						<td>GI</td>
						<td>Rosuvastatin</td>
						<td>Other</td>
					</tr><tr>
						<td>1185</td>
						<td>ChiCTR2400089169</td>
						<td>Phase II clinical trial of lopinavir/ritonavir in patients with castration-resistant prostate cancer</td>
						<td>Urological</td>
						<td>Lopinavir; Ritonavir</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1186</td>
						<td>NCT06437574</td>
						<td>Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer</td>
						<td>Urological</td>
						<td>Simvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1187</td>
						<td>NCT04616248</td>
						<td>In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Tocilizumab</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1188</td>
						<td>NCT06391918</td>
						<td>Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors</td>
						<td>Multiple cancer types</td>
						<td>Valganciclovir</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1189</td>
						<td>NCT05013450</td>
						<td>Dupilumab_Metastatic NSCLC</td>
						<td>Lung</td>
						<td>Anakinra</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1190</td>
						<td>NCT06241352</td>
						<td>Statin Addition to Chemotherapy for Advanced Pancreatic Cancer</td>
						<td>GI</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1191</td>
						<td>NCT06327451</td>
						<td>Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma</td>
						<td>CNS</td>
						<td>Atorvastatin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1192</td>
						<td>NCT06624371</td>
						<td>Atovaquone Combined with Radiation in Children with Malignant Brain Tumors</td>
						<td>CNS</td>
						<td>Atovaquone</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1193</td>
						<td>NCT06518434</td>
						<td>A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients</td>
						<td>GI</td>
						<td>Cannabidiol</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1194</td>
						<td>NCT06328387</td>
						<td>HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer</td>
						<td>Breast</td>
						<td>Hydroxychloroquine</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1195</td>
						<td>NCT06328686</td>
						<td>Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases</td>
						<td>Multiple cancer types</td>
						<td>L-Arginine</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1196</td>
						<td>NCT06540937</td>
						<td>Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor</td>
						<td>Endocrine</td>
						<td>Leflunomide</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1197</td>
						<td>NCT06454383</td>
						<td>Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer</td>
						<td>GI</td>
						<td>Leflunomide</td>
						<td>Phase 1</td>
					</tr><tr>
						<td>1198</td>
						<td>NCT06539806</td>
						<td>Clinical Study Evaluating the Effect of Losartan</td>
						<td>GI</td>
						<td>Losartan</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1199</td>
						<td>NCT06500234</td>
						<td>Nutrition Impact on Immunotherapy of Cancer</td>
						<td>Multiple cancer types</td>
						<td>Megestrol Acetate; Olanzapine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1200</td>
						<td>NCT06417736</td>
						<td>Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women</td>
						<td>Gynaecological</td>
						<td>Megestrol Acetate</td>
						<td>Not available/Missing</td>
					</tr><tr>
						<td>1201</td>
						<td>NCT06686043</td>
						<td>HPV Vaccine, Imiquimod, and Metformin Combination Trial</td>
						<td>Gynaecological</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1202</td>
						<td>NCT06537843</td>
						<td>Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia</td>
						<td>Leukemia</td>
						<td>Metformin</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1203</td>
						<td>NCT06569368</td>
						<td>A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1204</td>
						<td>NCT06356597</td>
						<td>Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial</td>
						<td>GI</td>
						<td>Metronidazole</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1205</td>
						<td>NCT06338683</td>
						<td>Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer</td>
						<td>Multiple cancer types</td>
						<td>Olanzapine</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1206</td>
						<td>ChiCTR2400085250</td>
						<td>A single-center, dose-escalation, and cohort-expanding single-arm, open-label Phase I/IIa clinical study evaluating the safety, tolerability, and initial efficacy of doxycycline in patients with intrahepatic cholangiocarcinoma that progresses after standard treatment</td>
						<td>GI</td>
						<td>Doxycycline</td>
						<td>Phase 1/2</td>
					</tr><tr>
						<td>1207</td>
						<td>CTIS2022-502633-26-00</td>
						<td>Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial</td>
						<td>Skin</td>
						<td>Tranexamic Acid</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1208</td>
						<td>CTIS2022-500307-49-00</td>
						<td>AMUM trial -Adjuvant Melatonin for Uveal Melanoma: A randomized open Phase III Study</td>
						<td>Ocular</td>
						<td>Melatonin</td>
						<td>Phase 3</td>
					</tr><tr>
						<td>1209</td>
						<td>CTIS2023-504191-26-00</td>
						<td>DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial</td>
						<td>Skin</td>
						<td>Diclofenac</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1210</td>
						<td>CTIS2022-502524-41-00</td>
						<td>A window-of-opportunity trial with high-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colorectal cancer: the ALFEO pilot study</td>
						<td>GI</td>
						<td>Ascorbic acid</td>
						<td>Phase 2</td>
					</tr><tr>
						<td>1211</td>
						<td>IRCT20240923063132N1</td>
						<td>Efficacy and safety of sodium valproate in treatment of Acute myeloid leukemia</td>
						<td>Leukemia</td>
						<td>Valproic Acid</td>
						<td>Phase 2/3</td>
					</tr><tr>
						<td>1212</td>
						<td>NCT04705909</td>
						<td>Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer</td>
						<td>Breast</td>
						<td>Pitavastatin</td>
						<td>Phase 2/3</td>
					</tr></tbody>
				<fthfoot style="display: table-footer-group; border-spacing: 0px; height: 0px; border-collapse: collapse; visibility: hidden;"><fthtr style="display: table-row; border-spacing: 0px; height: 0px; border-collapse: collapse;"><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd><fthtd style="display: table-cell; height: 0px; width: auto;"></fthtd></fthtr></fthfoot></table></div>

				<br>
				
<script type="text/javascript">

	fetchTable("%","%","%");
	document.getElementById("redo_body").addEventListener("click", selectTableRow);
	document.getElementById("lastUpdate").innerHTML=document.getElementById('Last_Import').innerHTML;
	
	$(document).ready(function(){
		$("#redo").tablesorter();		
	});	
		
	function selectTableRow(){
		var td=event.target;
		var tr=td.parentNode;
		var NCT=tr.getElementsByTagName("td")[1].textContent;
		fetchRecord(NCT);
	}
	
	function setCheckbox(checkbox){
		if(checkbox.checked){
			checkbox.value="Y";
		} else {
			checkbox.value="%";
		}
		var cg=document.getElementById("Cancer_Group").value;
		fetchTable(cg,controlled.value,pediatric.value);
	}
	
</script>
<!-- modal box for NCT record -->
<div id="myModal" class="modal">
  <!-- Modal content -->
  <div id="modal-content" class="modal-content">
    <span class="close">Ã</span>
    <div id="NCT_record">
		<table class="redo" id="NCT_Record" style="width:98%;">
		<thead>
		</thead>
		<tbody>
		<tr>
		<td id="Title" colspan="3">Title</td>
		</tr>
		<tr>
		<td id="NCT_Number">ID</td>
		<td id="Acronym">AKA</td>
		<td id="Status">Status</td>
		</tr>
		<tr>
		<td id="Phase">Phase</td>
		<td id="Drug_INN" colspan="2">Drug</td>
		</tr>
		<tr>
		<td id="Controlled">Controlled</td>
		<td id="Multi-Arm">Multi-Arm</td>
		<td id="Pediatric">Pediatric</td>
		</tr>
		<tr>
		<td id="Cancer_Group" colspan="3">Cancer Group</td>
		</tr>
		<tr>
		<td id="Cancer_Type" colspan="3">Cancer Type</td>
		</tr>
		<tr>
		<td id="Age">Age</td>
		<td id="Gender">Gender</td>
		<td id="Enrollment">Enrollment</td>
		</tr>
		<tr>
		<td id="Country_PI">Country PI</td>
		<td id="Start_Date">Start Date</td>
		<td id="Completion_Date">Completion Date</td>
		</tr>
		<tr>
		<td id="Other_IDs" colspan="2">Other IDs</td>
		<td id="Sponsor_Type">Sponsor</td>
		</tr>
		<tr>
		<td id="Sponsors" colspan="3">Sponsors</td>
		</tr>
		<tr>
		<td id="Funders" colspan="3">Funders</td>
		</tr>
		<tr>
		<td id="URL" colspan="2">URL</td>
		<td id="Last_Update_Posted">Last Update Posted</td>
		</tr>
		</tbody>
		</table>
	</div>
  </div>
</div>

						
  </div>
</div>
  </div>
</div>
</div></article>
</div>


          </div>
  </div>

          </section>
        </div>
    </main>
      <footer id="site-footer" class="site-footer" role="contentinfo">                  <section class="footer-top">
              <div class="region region--footer-top">
    <div class="region__inner">
                  
<div id="block-acf-footer-info" class="block block--acf-general block--acf-footer-info"><div class="footer--info">
  <div class="footer--info-address">
    <div class="footer--info-logo">
      <img src="/themes/custom/entityone/logo.png" style="max-height: 60px;" alt="Logo">
    </div>
              <p>
                  <span>Brusselsesteenweg 11</span>
                                  <span>1860 Meise</span>
                          <span><a href="tel:+32 (0)2 268 48 16">+32 (0)2 268 48 16</a></span>
              </p>
      </div>
  <div class="footer--info-contact">
                      <p class="contact-title">Happy to hear from you</p>
                    <p class="contact-text">Please contact us about anything related to our foundation or work.</p>
                    <p><a href="/contact-us" class="btn btn--invert btn--small">Contact us</a></p>
            </div>
  <div class="footer--info-newsletter">
                  <p class="newsletter-title">Sign up for updates</p>
                          <p><a href="http://eepurl.com/dsphoT" target="_blank" class="btn btn--small ext" data-extlink="" rel="noreferrer">Subscribe</a></p>
            </div>
</div>
</div>


          </div>
  </div>

          </section>
                                  <div class="region region--footer-bottom">
    <div class="region__inner">
                <nav id="menu--footer" aria-label="Footer" class="block block-menu navigation menu--footer">
      
              <ul class="menu">
                    <li class="menu-item">
        <a href="/en/disclaimer" data-drupal-link-system-path="node/369">Disclaimer</a>
              </li>
                <li class="menu-item">
        <a href="https://www.anticancerfund.org/sitemap.xml">Sitemap</a>
              </li>
                <li class="menu-item">
        <a href="/en/privacy-and-liability-policy" title="Privacy and Liability Policy" data-drupal-link-system-path="node/365">Privacy Policy</a>
              </li>
                <li class="menu-item">
        <span>Copyright Anticancer Fund 2024</span>
              </li>
        </ul>
  


  </nav>
<div id="block-acf-footer-social-media" class="block block--acf-general block--acf-footer-social-media">

<div class="footer--social-media">
  <span>Follow us:</span>
  <div class="social-icons">
          <a href="https://www.facebook.com/anticancerfund" class="social-icon" rel="noreferrer">
        <svg class="icon icon--facebook">
          <use xlink:href="#icon--facebook"></use>
        </svg>
      </a>
          <a href="https://www.instagram.com/anticancer.fund/" class="social-icon" rel="noreferrer">
        <svg class="icon icon--instagram">
          <use xlink:href="#icon--instagram"></use>
        </svg>
      </a>
          <a href="https://www.youtube.com/channel/UCwx4jZiNnCFAvsczUep-h4g" class="social-icon" rel="noreferrer">
        <svg class="icon icon--youtube">
          <use xlink:href="#icon--youtube"></use>
        </svg>
      </a>
          <a href="https://x.com/Anticancerfund" class="social-icon" rel="noreferrer">
        <svg class="icon icon--twitter">
          <use xlink:href="#icon--twitter"></use>
        </svg>
      </a>
          <a href="https://www.linkedin.com/company/anticancer-fund" class="social-icon" rel="noreferrer">
        <svg class="icon icon--linkedin">
          <use xlink:href="#icon--linkedin"></use>
        </svg>
      </a>
      </div>
</div>
</div>


          </div>
  </div>

                      <section class="doormat">
          
        </section>
      </footer>
  </div>




    
    <script src="/sites/default/files/js/js_CZXNbvf1c4qQo2-QsI9U6NrOQBOjk1AueTj-URQysd0.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=entityone&amp;include=eJxtjksOwyAMRC9EwpHQxDUuxbFRAlJ6-2ZRqd_FaPTebCaDYgbNZ1LTIcVCfqnA1ku_u3EU9QUa-OharMbLNhp0fmLgkci9Fj5rbVpgxPGfDOIuyqlDovT1EyHfPOOG4-3Fok51mhQmA8L7z7QzNro-AF8uUjc"></script>
<script src="/modules/contrib/eu_cookie_compliance/js/eu_cookie_compliance.min.js?v=10.3.10" defer=""></script>
<script src="/sites/default/files/js/js_rXCkJ6LxqnrtTudXhJoMDjcKb2899U2bb4itOalf0WY.js?scope=footer&amp;delta=2&amp;language=en&amp;theme=entityone&amp;include=eJxtjksOwyAMRC9EwpHQxDUuxbFRAlJ6-2ZRqd_FaPTebCaDYgbNZ1LTIcVCfqnA1ku_u3EU9QUa-OharMbLNhp0fmLgkci9Fj5rbVpgxPGfDOIuyqlDovT1EyHfPOOG4-3Fok51mhQmA8L7z7QzNro-AF8uUjc"></script>

  

<div id="drupal-live-announce" class="visually-hidden" aria-live="polite" aria-busy="false"></div><div id="sliding-popup" role="alertdialog" aria-describedby="popup-text" style="height: auto; width: 100%; bottom: 0px;" class="sliding-popup-bottom"><div class="eu-cookie-compliance-banner eu-cookie-compliance-banner-info" aria-hidden="false">
  <div class="popup-content info eu-cookie-compliance-content">
    <div id="popup-text" class="eu-cookie-compliance-message">
      <h2><span>We use cookies on this site to enhance your user experience.</span></h2><p><span>By clicking âAcceptâ, you agree to us doing so.</span></p>
              <button type="button" class="find-more-button eu-cookie-compliance-more-button find-more-button-processed" tabindex="0"><span>More info</span></button>
            <a href="https://anticancerfund.org/disclaimer" class="eu-cookie-compliance-disclaimer" tabindex="0">disclaimer</a>
    </div>
    <div id="popup-buttons" class="eu-cookie-compliance-buttons">
      <button type="button" class="agree-button eu-cookie-compliance-secondary-button button button--small" tabindex="0"><span>Accept<svg xmlns="http://www.w3.org/2000/svg" width="17" height="12" viewBox="0 0 17 12">
        <polyline fill="none" stroke="#3F474C" stroke-linecap="round" stroke-linejoin="round" stroke-width="2" points="584 61.762 588.837 66.6 598.437 57" transform="translate(-583 -56)"></polyline>
      </svg></span>
</button>
              <button type="button" class="decline-button eu-cookie-compliance-default-button button button--small button--primary" tabindex="0"><span>No, thanks</span></button>
          </div>
  </div>
</div></div><app-weava-root id="weava-root" class="weava" ng-version="15.2.1"></app-weava-root></body><grammarly-desktop-integration data-grammarly-shadow-root="true"></grammarly-desktop-integration></html>